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Long non-coding RNAs (lncRNAs), that are not translated into protein, comprise a 
large proportion of transcripts produced by the eukaryotic genome. While many 
lncRNAs have now been identified, functional characterisation of these transcripts is 
still limited. However, as more lncRNAs are being studied, they are being recognised 
as important regulators of key cellular and developmental programmes. With that, 
dysregulated activity of lncRNAs is also now connected to numerous types of disease, 
including cancers. 
 
Melanoma is a particularly aggressive form of skin cancer which is associated with a 
high death rate. With currently limited effective therapeutic options, lncRNAs may 
represent a new class of therapeutic targets. Two well-characterised proteins in 
melanocyte and melanoma development are MITF and SOX10. These transcription 
factors regulate the expression of genes important for melanoma cell proliferation, 
invasion, and metastasis. While protein-coding genes within the MITF-SOX10 
transcriptional programmes are well studied, lncRNAs are not. By understanding the 
role of lncRNAs in such processes, our knowledge of melanoma development and 
progression can be enhanced, and possible methods of treatment may be revealed.  
 
For this study, a group of 12 candidate MITF-regulated lncRNAs expressed in 
melanocytes and/or melanoma cells were initially selected. The nuclear-expressed 
intergenic lncRNA Disrupted In Renal Carcinoma (DIRC3) was prioritised for further 
investigation, as a representative lncRNA involved in the MITF-SOX10 transcriptional 
response in melanoma. Melanoma patients classified as expressing low levels of 
DIRC3 were found to have decreased survival. Knockdown analysis then led to the 
identification of DIRC3 as a MITF-SOX10 regulated tumour suppressor in melanoma 
that inhibits anchorage-independent growth. DIRC3 appears to perform this function 
by activating expression of its neighbouring tumour suppressive gene IGFBP5. DIRC3 
regulates IGFBP5 expression through modulating the chromatin structure across its 
own locus so that it suppresses the ability of SOX10 to bind to putative regulatory 
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elements. Such regulation of IGFPB5 also goes on to impact expression of numerous 
genes involved in cancer-associated processes. 
 
This project highlights the role of DIRC3 as a tumour suppressive lncRNA in 
melanoma. Through participating in the regulation of the MITF-SOX10 transcriptional 
programme, DIRC3 inhibits anchorage-independent growth, a key hallmark of 
malignant transformation. This activity demonstrates the potential important roles 
lncRNAs may play within such regulatory networks as well as implicate them as 
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Chapter 1: Introduction 
 
1.1 Non-coding portion of the genome 
 
Traditionally RNA has been viewed as a mediator between genetic information 
encoded in DNA and functional proteins. However, using deep sequencing methods, 
the transcriptome has been revealed to be increasingly complex. Roughly 75-90% of 
the human genome is now estimated to be transcribed, but only 2% is translated into 
proteins, leaving the majority of transcription occurring in non-protein-coding 
regions (Djebali et al. 2012, Dunham et al. 2012). This transcription suggests the 
transcribed RNAs may have roles beyond being an intermediate between DNA and 
proteins. 
 
Advances in transcriptome profiling have enabled the identification of a vast 
repertoire of RNA molecules in the human transcriptome (Djebali et al. 2012, Iyer et 
al. 2015, Liao et al. 2017). As well as being far more prevalent than protein-coding 
transcripts, non-protein coding transcripts or non-coding RNAs (ncRNAs) are far more 
diverse and complex than originally anticipated (Birney et al. 2007). Previously, such 
ncRNAs have been viewed as ‘junk’ or transcriptional noise from functional DNA 
elements. However, functional roles for ncRNAs are now being revealed. ncRNAs 
form a heterogenous group of RNAs, allowing them to encompass a broad range of 
roles. Some of the most well-known ncRNAs behave as housekeeping genes, such as 
ribosomal RNAs and transfer RNAs, which are constitutively expressed in cells to help 
maintain regular cellular activity (Dykes and Emanueli 2017). The remaining 
regulatory ncRNAs are divided arbitrarily based on their size. Short/small noncoding 
RNAs (sncRNAs) are less than 200 nucleotides in length and include microRNAs 
(miRNAs), small interfering RNAs (siRNAs), PIWI-interacting RNAs (piRNAs), and small 
nucleolar RNAs (snoRNA) (Briggs et al. 2015, Deniz and Erman 2016, Jandura and 
Krause 2017, Richtig et al. 2017). Correspondingly, those equal to or greater than 200 
nucleotides in length are recognised as long non-coding RNAs (lncRNAs) (Derrien et 
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al. 2012). Whilst most focus has previously been on sncRNAs, lncRNAs are now 
recognised as a highly heterogenous group of RNAs that regulate key developmental 
processes via a range of mechanisms and so are receiving increased attention.  
 
1.2 Long non-coding RNAs 
 
1.2.1 LncRNA transcript and genomic features 
 
LncRNAs are generated via pathways similar to protein-coding genes and harbour a 
number of similar features. The majority of lncRNAs are transcribed by RNA 
polymerase II (RNAPII). LncRNA transcripts are also spliced, 5’-capped and 
polyadenylated (Cheetham et al. 2013, Bach and Lee 2018, Camacho et al. 2018). 
However, they also have key features that differ from protein-coding genes. One is 
the lack of functional open reading frame (ORF) leading to their absence of protein-
coding potential (Derrien et al. 2012). However, it should be noted that short 
functional ORFs that generate small peptides have been identified within some 
functional lncRNAs (Choi et al. 2018). Compared to mRNAs, lncRNAs are also usually 
shorter and contain fewer exons (typically 1-3) (Derrien et al. 2012, Melé et al. 2017). 
Recent work has also identified differences in chromatin features between lncRNAs 
and protein-coding genes, including histone marks. Active lncRNA promoters have 
been found to encompass open chromatin organisation with histone modification 
profiles distinct from protein-coding genes. Such modifications include increased 
H3K27me3, H3K9me3, and H3K36me3 marks in lncRNA promoters relative to 
protein-coding genes expressed to a similar level (Alam et al. 2014, Melé et al. 2017). 
Such modifications associated with these actively transcribed lncRNAs typically 
represent transcriptionally poised or repressed regions, as well as transcriptional 
elongation respectively (Alam et al. 2014). The unexpected increase in H3K9me3 has 
also been associated with lncRNA with more tissue-specific expression patterns 
(Melé et al. 2017). 
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Although lncRNAs were originally viewed as transcriptional noise, functional loci have 
now been identified. However, the overall proportion of functional lncRNAs is still 
unknown with the majority of lncRNAs currently uncharacterised (Quek et al. 2015, 
Uszczynska-Ratajczak et al. 2018). The level of lncRNA conservation between 
organisms has been key in the debate concerning lncRNA functionality. Overall, 
lncRNA transcripts are typically less conserved than protein-coding genes across their 
gene bodies, with 5% of lncRNAs sequenced being under selective constraint in 
vertebrates (Vance and Ponting 2014); however, their promoters show conservation 
comparable to protein-coding genes (Derrien et al. 2012). Also, lncRNAs experience 
greater conservation than neutrally evolving ancestral repeat sequences (which are 
proposed to be under neutral selection) and harbour short stretches of highly 
conserved sequences (Derrien et al. 2012, Guttman and Rinn 2012). Although the 
majority are typically species-specific (Washietl et al. 2014, Hezroni et al. 2015), in 
one study 8,953 lncRNAs were identified in both humans and other species 
(Sarropoulos et al. 2019). Thousands have also been annotated in a range of species 
and tissues in other studies (Hezroni et al. 2015, Melé and Rinn 2016). Conservation 
in multiple species is currently one of the key indicators for functionality. 
Consequently, such genomic comparisons between species can be used when 
identifying putatively functional lncRNAs (Necsulea and Kaessmann 2014). However, 
conservation of lncRNA sequences not being as constrained as that of protein-coding 
genes allows them to be more tolerant of mutations, and so more likely to experience 
quicker evolutionary change. It is also important to consider conservation of lncRNA 
function through their structure or short regions that interact with binding partners. 
Such features allow for lncRNA conservation to be held in their folded secondary 
structures (Johnsson et al. 2014). A lack of primary sequence conservation does not 
hinder the preservation of function. This has been demonstrated by rescue 
experiments using several human lncRNAs which phenotypically rescued depletion 
of their homologs in zebrafish (Ulitsky et al. 2011). However, forming predictions for 
which lncRNAs are functional based on structure rather than sequence can currently 
make identification of candidates more challenging. 
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Another key feature of lncRNAs is their specificity of expression. RNA-seq analysis has 
previously found lncRNAs to have more precise expression patterns in several cell 
and tissue types than protein-coding genes (Fatica and Bozzoni 2014). This specificity 
of expression may help explain why the level of lncRNA transcript expression is so 
low (Hezroni et al. 2015). Earlier studies looking into the spatial distribution of lncRNA 
transcription in mouse brains(Mercer et al. 2008) and the transcriptional profiles of 
cells from the developing human neocortex found that while lncRNAs are identified 
in lower abundance in pooled tissues, they have high levels of expression in specific 
cell types (Mercer et al. 2008, Liu, Nowakowski, et al. 2016). Consequently, the 
process of homogenisation of different tissues combined with precise patterns of 
expression was proposed to lead to the low level of expression detected (Derrien et 
al. 2012). However, this has been debated with lncRNA abundance being found to 
not differ greatly from protein-coding genes expressed at a similar level when cell-to-
cell variability was explored using fluorescent in situ hybridisation (FISH) (Cabili et al. 
2015), ultimately arguing against the presence of specific cells expressing particularly 
high levels of the lncRNAs. Nonetheless, overall, tightly controlled expression 
patterns make lncRNAs interesting candidates in control of developmental processes. 
Their functional transcripts are also energetically less costly and quicker to produce 
than protein regulatory factors which require additional processes, including 
translation (Marchese et al. 2017). Without the need to be translated, lncRNAs may 
be rapidly up- or down-regulated in response to stimuli so may be useful molecules 
for rapid regulation of target genes (Geisler and Coller 2013). In addition, such 
specificity of expression is likely very cost-effective as lncRNAs may interact with 
generic protein machinery while regulating targets in cell- or tissue-specific manners 
(Marchese et al. 2017). Consequently, fewer protein regulatory factors, which 
require translation, would be required in addition to the transcription of lncRNAs at 





1.2.2 LncRNA classification  
 
LncRNAs are primarily categorized based on their genomic location relative to 
protein-coding genes (Derrien et al. 2012). The largest group are intergenic lncRNAs 
which are present between (and not intersecting) genes. This form differs from the 
remaining lncRNA classes which typically overlap coding loci. The next most common 
form are antisense lncRNAs which overlap and are transcribed in the opposite 
direction relative to their closest gene. Sense-overlapping are transcribed within the 
exons and introns of genes on the sense strand of the DNA. Sense intronic are present 
within the introns of protein-coding genes. Bidirectional lncRNAs are located within 
close proximity to the transcript but on the opposite DNA strand and are often 
transcribed from a shared promoter (Derrien et al. 2012, Bhan et al. 2017, Ransohoff 
et al. 2017). 
 
 
Figure 1.1 Classification of lncRNAs according to their proximity to protein-coding genes. 
LncRNAs are broadly classified as Antisense, Intergenic, Sense-overlapping, Sense-intronic, 
and Bidirectional based on the genomic location relative to protein-coding genes. Genes 
encoding lncRNAs are represented in orange while protein-coding genes are in blue. Figure 
based on Zhao and Lin 2015. 
 
Such broad classifications have formed due to the discovery and annotation of 
lncRNAs taking place faster than the understanding of their functions. However, more 
detailed analyses of lncRNAs has allowed some to also be defined based on structure, 
and mechanism of action, function, or interaction with protein-coding genes or other 
known DNA elements  as well as their metabolism profiles (St.Laurent et al. 2015, 











1.2.3 LncRNAs – a new class of gene expression regulators  
 
LncRNAs have been identified in both the nucleus and cytoplasm where they carry 
out a diverse range of mechanisms to regulate the activity of their targets. The 
heterogenous nature of lncRNAs allows them to act at multiple levels of control from 
epigenetic regulation to mRNA decay (Derrien et al. 2012, Cheetham et al. 2013). As 
has been described for protein regulatory factors, lncRNAs may either activate or 
repress expression of their targets (Kino et al. 2010, Goding 2016). They may also 
regulate broad transcriptional programmes by affecting the activity of key master 
regulators (Yu et al. 2008, Kajino et al. 2019). Overall, functional lncRNAs may be 
broadly categorised based on whether they operate in a transcript-dependent or -
independent manner (Kopp and Mendell 2018).  
 
1.2.3.1 Transcript-dependent activity 
 
Functional lncRNA transcripts interact with a range of regulatory factors to execute 
their function. The tertiary structure of lncRNAs allows the formation of multiple 
modular recognition domains that specifically interact with different factors including 
DNA, RNA, and proteins (Chu et al. 2011, Briggs et al. 2015). This versatility allows 
lncRNAs to bind a wide plethora of regulatory factors, including transcription and 
chromatin-modifying factors, as well as mRNAs and miRNAs (Cao et al. 2018).  These 
functional lncRNA transcripts may also act local to or distal from their site of synthesis 
and can be categorised based on their mode of action – scaffolds, guides, decoys, and 
signals (Wang and Chang 2011). An overview of their functions is described in Figure 
1.2. 
 
Scaffold: Using their modular recognition domains lncRNAs can interact with multiple 
regulatory factors so that they are brought together in a spatiotemporal manner into 
one functional unit (Briggs et al. 2015, Kaikkonen and Adelman 2018). This may occur 
for protein units which are unable to form direct interactions themselves so rely on 
lncRNA binding to promote protein complex formation. Such an activity has been 
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described for KCNQ1OT1 (KCNQ1-overlapping transcript 1) with PRC2 and G9a, as 
well as HOTAIR (HOX Transcript Antisense RNA) with PRC2 and LSD1 (Rinn et al. 2007, 
Pandey et al. 2008). LncRNAs may also interact with enzyme subunits to induce 
conformational changes that alter their enzymatic activity, such as in the case of LINK-
A which promotes hyperactivation of AKT by inducing association between its PIP3 
and PH domains (Lin et al. 2017, Lin and Yang 2018). LncRNAs may also nucleate inter-
chromosomal interactions orchestrating chromatin changes so that nuclear structure 
is regulated (Sun et al. 2018).  
 
Guide: LncRNAs may direct targets to specific locations within the cell. In some cases, 
protein DNA binding domains do not suitably recognise target genes, so they utilise 
the binding specificity of lncRNAs. Consequently, lncRNAs may modulate protein-
DNA binding to regulate the activity of transcription factors or chromatin modifiers 
(Guttman and Rinn 2012). As a group, the precise activity of lncRNAs would 
subsequently allow a relatively small number of regulatory proteins to act on a large 
number of genes (Davidovich et al. 2013, Hendrickson et al. 2016). This has been 
suggested to be a reason for the exponential increase in the number of lncRNAs 
identified in higher eukaryotes as the lncRNAs allow more precise targeting of widely-
expressed regulatory proteins (Jandura and Krause 2017). Such activity has previously 
been described for HOTTIP (HOXA Distal Transcript Antisense RNA) which activates, 
expression of HOXA genes by recruiting the WRD5/MLL histone methyltransferase 
(HMT) complex (methylation complex) to facilitate H3K4 trimethylation and 
activation of the HOXA promoter (Wang et al. 2011). In the case of SAMMSON 
(survival associated mitochondrial melanoma-specific oncogenic non-coding RNA), 
the lncRNA re-localises the mitochondria surface protein p32 from the nucleus to the 
mitochondria to enhance mitochondrial metabolism (Leucci, Vendramin, et al. 2016), 
demonstrating the ability of a lncRNA to regulate cellular activities by relaying 
communication between the nucleus and mitochondria. The lncRNA NEAT1 (Nuclear 
Enriched Abundant Transcript 1) is also able to interact with a range of paraspeckle 
proteins, including p54nrb, PSPC1, and PSF, for the creation and maintenance of 
paraspeckles (Clemson et al. 2009, Sasaki et al. 2009) as well as regulating 
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paraspeckle positioning so that actively transcribed genes are positioned where they 
may be easily spliced or near appropriate transcription factors. LncRNAs may also 
regulate the three-dimensional arrangement of the genome so that sections are in 
distinct activating or repressive compartments. For example, FIRRE (functional 
intergenic repeating RNA element) promotes chromatin loop formation to organise 
chromosomal interactions within the nucleus by binding to cohesion and CTCF. This 
way FIRRE guides portions of the X chromosome into distinct repressive 
compartments during X chromosome inactivation (XCI) (Hacisuleyman et al. 2014). 
 
During the process of transcription, nascent transcripts, which have not been 
released from their locus, may act as tethers, recruiting regulatory factors 
(transcription and chromatin regulators) to their locus which may encompass 
regulatory elements such as enhancers (Bach and Lee 2018). Such an interaction has 
been explored for the transcription factor Yin-Yang 1 (YY1) which interacts with both 
DNA and RNA in regions proximal to promoters and enhancers (Sigova et al. 2015). 
Sigova et al (2015) hypothesised that by binding to both DNA and RNA, the 
association of transcription factors with their targets may be reinforced. Using an 
RNA sequence based on the YY1 target gene promoter increased occupancy and local 
concentration of YY1 within the enhancer/promoter domain in a positive feedback 
loop. However, it should be noted this model is limited to YY1 (Sigova et al. 2015).  
 
Decoy: LncRNAs may inhibit the activity of other regulatory factors by sequestering 
them away or competitively binding with their targets. By preventing otherwise 
inhibitory or stimulatory factors identifying their targets, activities such as post-
translational modifications or changes mRNA stability can be prevented (Guttman 
and Rinn 2012). For example, GAS5 (Growth arrest specific 5) binds to the DNA 
binding domain of the glucocorticoid receptor to prevent it interacting with its targets 
via a DNA recognition sequence and PANDA (P21 associated ncRNA DNA damage 
activated) sequesters NF-YA following DNA damage to limit the expression of pro-
apoptotic genes (Kino et al. 2010, Hung et al. 2011). MALAT1 (Metastasis associated 
lung adenocarcinoma transcript 1) is also known to sequester splicing regulatory 
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factors, including SRSF1 and serine/arginine (SR) and so regulates alternative splicing 
(Tripathi et al. 2010). This mechanism of action may also occur in the cytoplasm. For 
example, NORAD (Noncoding RNA activated by DNA damage) binds to PUM1 and 
PUM2 to prevent them initiating mRNA decay of their targets (Lee et al. 2016). 
LncRNAs that interact with shared miRNAs are also known as competing endogenous 
RNAs (ceRNAs) (Wang et al. 2016). ceRNAs prevent degradation of their target 
mRNAs by preventing binding of miRNAs. H19 binds to mRNA targets of MiR-17-5p 
to prevent their degradation (Imig et al. 2015). Another recognised ceRNA is PTENP1 
(Phosphatase And Tensin Homolog Pseudogene 1) which interacts with miRNAs 
which would otherwise target the PTEN-coding transcript in melanoma cells (Poliseno 
et al. 2010). 
 
Signal: As lncRNAs only require transcription to produce a functional molecule, they 
can respond quickly to diverse stimuli. Combined with their spatiotemporal 
specificity of expression in cells and tissues, lncRNAs may act as signals (Guttman and 
Rinn 2012). Following induction by such a range of unique stimuli, lncRNAs can 
regulate the activity of a variety of targets. LncRNAs within this group are well 
associated with key developmental stages or the occurrence of disease (Richtig et al. 
2017). Some signal-acting lncRNAs regulate allele specificity such as XIST (X-inactive 
specific transcript) which mediates transcriptional silencing of the X chromosome in 
female cells (reviewed by Pontier and Gribnau, 2011). They may also specify 
anatomical formation such as positional cell identity and limb patterning, as 
demonstrated by HOTAIR and HOTTIP which are particularly expressed in posterior 
cell types (Kumar and Krumlauf 2016). In other cases, lncRNAs may be induced 
following DNA damage, such as DINO (Damage induced noncoding) which binds to 
and stabilises p53 during the DNA-damage-induced response (Schmitt et al. 2016). In 
these ways, lncRNAs may act as regulators of signalling pathways as well as offer a 
means of tracking the occurrence of such processes. 
 
LncRNAs frequently use a combination of the mechanisms described to perform their 
functions. For example, XIST is a signal for XCI but in the process acts as a scaffold 
 26 
and a guide to key regulatory proteins to induce repression (Tian et al. 2010, Pontier 
and Gribnau 2011). In the case of PANDA as well as acting as a decoy for NF-YA, its 
induction by p53 following DNA damage contributes to its role as a signal as well 
(Hung et al. 2011).  
 
For functional lncRNA transcripts, care must be taken when interpreting lncRNA-
protein interaction data. In the case of HOTAIR, while it was proposed that the 
lncRNA recruits chromatin modifiers PRC2 and LSD1 to repress activity at the HOXD 
locus (Rinn et al. 2007, Tsai et al. 2010), tethering the HOTAIR transcript to its target 
site independent of the chromatin-modifying proteins also repressed activity at the 
locus. Consequently, it may be the HOTAIR transcript that is sufficient to induce 
transcriptional repression independent of the chromatin-modifying proteins (Chu et 
al. 2011). In line with that, PRC2 has been found to bind non-specifically in a size-
dependent manner to lncRNAs (Davidovich et al. 2015). 
 
 
Figure 1.2 Schematic illustration for four mechanisms of transcript-dependent lncRNA 
regulation. Functional lncRNAs transcripts can interact with DNA, RNA, and/or proteins. (A) 
Scaffolds bring together effector molecules to form a functional unit. As well as interacting 
with proteins and forming functional ribonucleoprotein complexes, lncRNAs may manipulate 
nuclear structures. (B) Guides bind and direct regulatory factors to precise genomic locations. 
(C) Decoys bind and titrate target proteins or miRNAs away from their targets. (D) LncRNAs 
act as signals due to the specificity of their location and timing of expression. As this is in 
(A) Scaffold (B) Guide 
(C) Decoy (D) Signal 
LncRNA Proteins Gene 
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response to precise stimuli, expression of such lncRNAs can represent key biological events 
Figure based on Wang and Chang 2011.  
 
1.2.3.2 Transcript-independent activity 
 
LncRNAs can also function independently of their transcript, making the RNA 
transcript itself a non-functional by-product (Kopp and Mendell 2018). In some cases, 
they may utilise machinery used to process the transcript to regulate their targets 
(Kornienko et al. 2013). In this case production of the lncRNA from its locus is 
important for function and not the mature transcript or sequence. Processes such as 
splicing may mediate the function of such lncRNAs. In the case of BLUSTR (Bivalent 
locus Sfmbt2), regulation of expression of its neighbouring gene Sfmbt2 was found to 
be dependent upon transcription and splicing of the lncRNA (Engreitz et al. 2016). 
 
Regulatory elements, such as promoters and enhancers within lncRNA loci may 
mediate function independently of a functional transcript. For example, UPH 
(Upperhand) positively regulates transcription of neighbouring gene Hand2 through 
its own transcription across a super-enhancer for the protein-coding gene (Anderson 
et al. 2016). In the case of AIRN (Antisense Igf2r RNA non-coding), the lncRNA is 
transcribed across the promoter of Igfr2, leading to silencing of the gene (Latos et al. 
2012). In other cases, nucleosome density may be altered due to their disassembly 
and reformation following transcription elongation – repositioning them so they 
occlude promoters or binding sites. Or the RNA polymerase II itself may act to 
displace transcription, or other regulatory factors, bound to DNA (Latos et al. 2012, 
Anderson et al. 2016, Kaikkonen and Adelman 2018). In the case of antisense lncRNA 
transcription, the RNAPII may collide with an RNAPII for its neighbouring gene, 
resulting in inhibition of the expression of that gene, a process recognised as 
transcriptional interference (Hobson et al. 2012). The process of lncRNA transcription 
may also enable deposition of active histone modifications such as through histone-
modifying enzymes interacting with RNAPII (Ng et al. 2003, Lennox and Behlke 2016). 
Transcription may also promote gene expression by displacing negative regulators 
(PcG transcriptional repressors) or removing inhibitory nucleosomes making, 
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regulatory elements such as promoters more accessible (Kaikkonen and Adelman 
2018).  
 
A broad range of mechanisms for lncRNAs are being identified that may or may not 
rely on the presence of a functional transcript. Manipulating expression of functional 
transcripts has already been explored in detail as similar methods may be used for 
protein-coding genes – including the use of siRNAs and CRISPR (Gilbert et al. 2014, 
Biswas et al. 2018). However, lncRNA loci overlapping regulatory factors can make it 
difficult to distinguish functional lncRNAs from the DNA elements they encompass 
(Richard and Eichhorn 2018). 
 
1.2.4 LncRNAs have emerged as important regulators of cancer 
 
Cancer is a complex disease associated with uncontrolled growth and invasion of 
abnormal cells. Over the multi-step process of tumorigenesis, somatic mutations 
accumulate, allowing cells to develop so they can eventually metastasise, decreasing 
the likelihood of patient survival (Hanahan et al. 2000, Siegel et al. 2019). The causes 
of cancers are not fully understood, but there are known risk factors that increase an 
individual’s likelihood of developing the disease. Such factors include those which 
may be modified by the individual (including excess body weight and use of tobacco) 
as well as those that cannot (including inherited genetic mutations or immune 
conditions) (Siegel et al. 2019). Despite medicinal advances, cancer is a growing 
global issue as it is now the second leading cause of death worldwide, surpassing 
infectious disease (Lozano et al. 2012).  
 
The hallmarks of cancer are biological activities that enable tumour growth and 
progression. These include deregulation of energy metabolism, sustained 
proliferative signalling, avoidance of growth suppressors, replicative immortality, 
resistance of cell death, evasion of the immune system, induction of angiogenesis, 
activation of cell invasion, and metastasis (Hanahan and Weinberg 2011). As these 
hallmarks are acquired, tumours progress towards becoming metastatic and so more 
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lethal. Tumours may also recruit host cells, secreted proteins and extracellular matrix 
factors to the tumour microenvironment, forming complex interactions important to 
tumour development (Hanahan and Weinberg 2011, Ungefroren et al. 2011).  
 
At the molecular level, cancer is associated with a broad range of genetic mutations, 
chromosomal translocations, and epigenetic reprogramming (Suvà et al. 2013). Such 
changes can result in the activation of cancer-causing oncogenes or suppression of 
tumour suppressors (Bach and Lee 2018). For cancer cells to continue to develop, 
they can bypass mechanisms typically used to protect the body against such genetic 
alterations. The chromosomal instability allows cancer cells to continue to evolve by 
acquiring new mutations and increasing their genetic diversity, enabling them to 
grow, metastasise, and survive external therapies (Hanahan and Weinberg 2011).  
 
Increasing evidence is pointing towards the non-coding portion of the genome being 
important in cancer initiation and progression. Recently, reports showed that over 
80% of putative cancer-associated single nucleotide polymorphisms 
(SNPs)(Freedman et al. 2011) as well as 122 out of 158 recurrent somatic copy 
number alterations (SCNAs) (Beroukhim et al. 2010), were located outside of protein-
coding genes, many of which overlap lncRNA loci  (Beroukhim et al. 2010, Freedman 
et al. 2011, Iyer et al. 2015).  
 
Mutations close to lncRNA loci can influence the expression of lncRNAs. Alterations 
to promoters or enhancers may lead to dysregulated lncRNA expression (Guo et al. 
2016, Camacho et al. 2018).  In addition, epigenetic changes may alter lncRNA 
expression. It has been recognised that DNA methylation patterns of promoters for 
lncRNAs are distinct between tumour and healthy samples (Yan et al. 2015). In other 
cases, critical cancer regulatory proteins such as MYC and p53 have been reported to 
control the expression of cancer-associated lncRNAs (Hart et al. 2014, Huarte 2015, 
Grossi et al. 2016). Using comparisons between tumours and normal tissues, highly 
tumour-specific alterations to lncRNA expression have been identified demonstrating 
the commonality of lncRNA dysregulation in cancer (Iyer et al. 2015, Yan et al. 2015). 
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Mutations may also lead to structural changes which influence lncRNA function. For 
example, by either disrupting or generating new lncRNA binding sites. This can then 
influence the ability of lncRNAs to associate with DNA regulatory elements, miRNAs, 
or regulatory proteins (Wan et al. 2014, Zheng et al. 2016). LncRNAs may also be 
unable to form RNA-RNA interactions required for the correct formation of their 
secondary structure (Wan et al. 2014). 
 
Some lncRNAs participate in cancer development and progression as a consequence 
of their dysregulated activity. As found with protein-coding genes, lncRNAs have 
been identified that behave both as oncogenes and tumour suppressors. Well-
characterised oncogenes include MALAT1 which regulates proliferation, invasion, 
and metastasis in non-small cell lung cancer, as well as SChLAP1 (Second 
chromosome locus associated with prostate-1) which promotes invasion and 
metastasis in prostate cancer (Gutschner et al. 2013, Prensner et al. 2013). Numerous 
tumour suppressors have also been characterised, including MEG3 (Maternally 
expressed 3) in glioma, and Linc-p21 in head and neck squamous cell carcinoma 
(HNSCC) which both regulate proliferation and cell-cycle arrest (Gong and Huang 
2017, Jin et al. 2019). Of lncRNAs characterised so far, dozens have been identified 
that participate in a range of cancers, including MALAT1, H19 and HOTAIR (Gupta et 
al. 2010, Luan et al. 2016, Xu et al. 2017). In some cases, lncRNA candidates have 
been recognised that regulate resistance to currently available therapies. HOTAIR 
promotes chemoresistance in colorectal cancer by suppressing miR-218 and so 
activating NF-kB/TS signalling while GAS5 antagonises chemoresistance in pancreatic 
cancer by down-regulating miR-181c-5p (Li et al. 2017, Gao et al. 2018). 
Consequently, lncRNAs stand as important factors for improving our understanding 










Numerous lncRNAs have been identified with altered expression and functional roles 
in melanoma (Hulstaert et al. 2017, Sun et al. 2019). These could represent novel 
therapeutic targets as current therapies used to treat metastatic melanoma 
frequently succumb to the development of resistance or have a low number of 
patients that effectively respond (Kozar et al. 2019). Cutaneous melanoma is the 
leading cause of skin cancer-related deaths despite accounting for roughly 1% of 
cases (Yu et al. 2018, Siegel et al. 2019). The high lethality is a result of melanoma 
metastasis (Balch et al. 2009). The incidence of melanoma is also increasing globally, 
while it remains typically higher in fair-skinned individuals (Garbe et al. 2016, Yu et 
al. 2018). A major risk of melanoma is excessive exposure to ultraviolet (UV) 
radiation, such as sunlight (Siegel 2019). The risk may also be increased if skin cancer 
is common in a family, if an individual has a large number (> 50) of moles, a paler 
complexion, or if they have a weakened immune system (Garbe et al. 2016, Siegel et 
al. 2019).  
 
Melanoma is typically known to be derived from the malignant transformation of 
melanocytes (Mort et al. 2015). However, neural crest stem cells or melanoblasts 
may also play an important role in part due to them being undifferentiated or less 
differentiated than melanocytes as well as more invasive (White et al. 2011, Marie et 
al. 2019). Melanocytes are pigment-producing dendritic cells that originate in the 
neural crest during embryonic development prior to migration to the skin (Mort et 
al. 2015). The primary function of epidermal melanocytes is to produce melanin 
through melanogenesis and transfer the melanin pigment in melanosomes to 
neighbouring keratinocytes via numerous contacts (Mort et al. 2015, Shain and 
Bastian 2016). There, they construct a layer covering the keratinocyte nuclei to 
protect their DNA from UV radiation damage  by scattering and absorbing the UV 
radiation (Shain and Bastian 2016).  
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Following increased proliferation, melanocytes form benign naevi (moles). Typically, 
the cells undergo senescence so that they do not continue to grow uncontrollably 
(Larue and Beermann 2007). However, cells that bypass senescence continue to 
proliferate and can pass through a series of phenotypically and transcriptionally 
distinct phases of growth via the process of melanomagenesis (Larue and Beermann 
2007, Braeuer et al. 2011) and lead to metastatic melanoma. The key steps are 
described in Figure 1.3. Following metastasis, secondary melanoma tumours are 
typically identified in the liver, lung, and brain (Mobley et al. 2012).   
  
 
Figure 1.3. Progression of melanocytes to metastatic melanoma. (A) Atypical moles are 
recognised as dysplastic naevi. These irregularly shaped moles have a greater chance of 
developing into melanoma. Following genetic and epigenetic alterations, melanocytes are 
transformed into benign naevi. The nevus is formed as melanocytes proliferate at the basal 
layer of the epidermis and lose contact with keratinocytes. (B) Cells that bypass senescence 
spread horizontally through the epidermis in the pre-malignant radial growth phase (RGP). 
(C) A proportion of cells experience a reduction in adhesive molecules and increased 
extracellular matrix-degrading enzymes, allowing the cells to cross the basement membrane, 
invade into through the dermis and into subcutaneous tissue, in the vertical growth phase 
(VGP) (D) Finally cells are able to metastasise as the tumour cells are able to enter the 
lymphatic and vascular vessels. (Larue and Beermann 2007, Braeuer et al. 2011, Mobley et 
al. 2012). 
 
Melanoma primarily occurs following somatic mutations, while a small proportion 
are the result of inherited mutations. Both lead to aberrant cell proliferation, 













(A) Dysplastic Nevus 
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individuals with inherited genetic defects that increase their susceptibility to 
melanoma, roughly 25-40% inherit the mutated CDKN2A (Levy et al. 2006, Soura et 
al. 2016). This gene plays an important role in cell cycle control with its mutation 
being associated with atypical cell proliferation and avoidance of cellular senescence 
(Potrony et al. 2015). Somatic mutations occur through the lifetime of an individual. 
A range of candidate genes have been identified that are affected by such mutations. 
Activation of BRAF in the Mitogen-activated protein kinase (MAPK) signalling 
pathway is the most common mutation in melanoma with it present in 50-60% of 
cases – 90% of which contain the BRAFV600E protein (Davies et al. 2002, Hulstaert et 
al. 2017). Cells containing this mutation typically exhibit increased cell growth and 
survival (Sullivan and Flaherty 2011). Another member of the MAPK signalling 
pathway, NRAS, has been identified as mutated in ~25% of melanoma cases, 
including cells without the BRAF mutation (Tudrej et al. 2017). Two other melanoma 
regulatory factors of interest in melanoma are the transcription factors MITF 
(Microphthalmia-associated transcription factor) and SOX10 (SRY (sex-determining 
region Y)-box 10). Both are critical regulators of melanoma cell survival, proliferation, 
and invasion, as well as have been associated with patient response to therapeutics 
(Cronin et al. 2013, Ploper et al. 2015, Tudrej et al. 2017). In addition to these 
oncogenic mutations, IGFBP5 (Insulin-like growth factor binding protein) has been 
identified as an important tumour suppressor which is repressed in melanoma (Wang 




IGFBP5 belongs to a family of six insulin-like growth factor (IGF) binding proteins 
which act through both IGF-dependent and -independent mechanisms (Baxter 2014, 
Bach 2018). IGFBPs participate in a range of processes including regulation of DNA 
damage, transcription, and apoptosis (Grimberg et al. 2005, Beattie et al. 2006, Azar 
et al. 2014, Baxter 2014). 
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Dysregulated expression of IGFBP5 has been identified in a variety of human cancers. 
The protein was found to influence development and progression of cancers as well 
as resistance to therapies (Su et al. 2011, Sureshbabu et al. 2012, Baxter 2014, Wang 
et al. 2015, Hwang et al. 2016). Numerous preclinical studies in a range of tissues 
have found IGFBP5 to suppress growth and metastasis of tumours through inhibiting 
processes including cell adhesion, survival, and angiogenesis (Su et al. 2011, 
Sureshbabu et al. 2012, Hwang et al. 2016).  
 
The role of IGFBP5 as a tumour suppressor has also been studied in melanoma. It was 
found to negatively regulate melanoma growth and metastatic properties in vitro and 
in vivo (Wang et al. 2015). The team found IGFBP5 to function through negatively 
regulating expression of E-cadherin and stem cell markers including SOX2, NANOG, 
and OCT4. The protein was also found to inhibit the MEK-ERK and p38-MAPK 
signalling pathways. It was proposed that through such actions, IGFBP5 is able to 
regulate a range of cellular activities in melanoma, including suppression of cell 
proliferation and invasion, as well as EMT, metastasis, and stem cell features (Wang 




MITF-M is a key transcription factor involved in the regulation of melanocyte and 
melanoma development (Hemesath et al. 1994, Garraway et al. 2005). The MITF 
protein contains a basic helix-loop-helix leucine zipper (bHLH-Zip) DNA-binding 
domain that binds to a canonical E-box, as well as two transactivation domains (Levy 
et al. 2006, Seberg et al. 2017). Several isoforms of MITF exist, which have either 
broad or specific expression in different tissue types. These isoforms use alternative 
promoters and so vary based on their unique 5’ ends. MITF-M is the shortest isoform 
and is expressed almost exclusively in melanocytes and melanomas (Mobley et al. 
2012, Hartman and Czyz 2015, Kawakami and Fisher 2017).  
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Known as the ‘master regulator of melanocytes’, MITF holds a prominent role in the 
regulation of melanocyte development and differentiation (Hemesath et al. 1994, 
Garraway et al. 2005, Kawakami and Fisher 2017). MITF targets genes important for 
cellular processes including, invasion (GMPR, DIAPH1), pigmentation (TYR, DCT), cell 
cycle (CDK2), survival (BCL2, BCL2A1) and cell adhesion (CAECAM) (Goding and 
Arnheiter 2019). The importance of MITF in melanocyte development was first 
recognised in mice with mutated MITF who experienced defects in pigmentation of 
the skin, eye, and hair follicles, as well as affected cells in the inner ear. Other affected 
cells included pigmented epithelial cells, mast cells, and osteoclasts (Hodgkinson et 
al. 1993, Steingrimsson et al. 1994). In humans, germline mutation of MITF has been 
associated with Waardenburg syndrome II (WS2) and Tietz syndrome, which express 
altered skin and hair pigmentation as well as deafness as a consequence of fewer 
melanocytes present in the inner ear (Tassabehji et al. 1995, Pingault et al. 2010). 
 
Expression of MITF is controlled by an interplay of activators and repressors. SOX10, 
PAX6, as well as ß-catenin of the Wnt signalling pathway, have been found to activate 
expression of MITF in melanocyte development (Lang et al. 2005, Ploper et al. 2015). 
Recognised repressors of MITF include FOXD3 (Forkhead box D) which prevents PAX3 
(Paired box 3) binding the MITF promoter, and ATF4 (Activating Transcription Factor 
4) which represses expression of MITF mRNA (Thomas and Erickson 2009, Falletta et 
al. 2017). MITF also interacts with a range of co-factors which contribute to its ability 
to regulate expression of target genes. These include the histone acetyltransferases 
p300 and CBP (CREB-binding protein), as well as BRG1 (Brahma-related gene 1), a key 
component of the SWI/SNF complexes BAF and PBAF  (Sato et al. 1997, Laurette et 
al. 2015). 
 
Aberrant expression of MITF in melanoma is frequently the result of dysregulated 
expression of key regulatory pathways. The Wnt-ß-catenin (canonical), PI3K-AKT, and 
MAPK pathways become constitutively activated in melanoma, leading to aberrant 
activation or repression of target genes (Larue and Delmas 2006, Kwong and Davies 
2013, Dantonio et al. 2018). An overview of how these pathways can become 
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dysregulated, leading to increased expression of MITF, is given in Figure 1.4. Genetic 
and epigenetic mutations lead to activation or suppression of the activity of different 
components of these pathways resulting in their altered activity. In the case of BRAF, 
the BRAFV600E point mutation results in constitutive activation of the protein and so 
increased activity of the MAPK pathway (Pollock et al. 2003, Dankort et al. 2009). In 
some cases, dysregulation of individual proteins can impact the activity of multiple 
pathways. For example, activating point mutations in NRAS lead to activation of both 
the MAPK and PI3-AKT pathways (Dankort et al. 2009, Kwong and Davies 2013). 
Following increased activity of each of these pathways, there is increased expression 
of MITF. It should also be noted that in some cases MITF expression is inhibited, such 
as through activation of Wnt5A in the non-canonical Wnt signalling pathway. In this 
case, suppression of MITF by Wnt5A activity was found to increase melanoma cell 











































































































































































































































































































































































































































































































































































































































































Evidence of MITF oncogenic behaviour arose following the identification of a gain in 
copy number at the MITF locus in melanoma cell lines. MITF was then found to be 
amplified in 10 and 21% of primary cutaneous and metastatic melanomas 
respectively relative to melanocytic naevi, showing a correlation between MITF 
activity and cancer aggressiveness (Garraway et al. 2005, Hoek and Goding 2010, 
Verfaillie et al. 2015). With its vital role in melanoma cell survival, differentiation, 
proliferation and migration MITF has been suggested to behave as a ‘lineage 
addiction’ oncogene (Garraway et al. 2005, Hartman and Czyz 2015). Expression of 
MITF is also associated with a reduction in 5-year survival rate for melanoma patients, 
again implicating MITF in progression and lethality of a proportion of melanomas 
(Garraway et al. 2005). Activation of MAPK signalling by BRAFV600E typically represses 
MITF protein and mRNA expression, however, increased MITF expression is detected 
in a proportion of BRAFV600E mutated melanoma cells through mechanisms including 
amplification of MITF gene or activation of Wnt signalling (Garraway et al. 2005, 
Wellbrock et al. 2008). It has also been proposed that the mutation across the 
consensus sequence for SUMOylation of BRAFV600E prevents typical degradation of 
MITF (Miller et al. 2005).  
 
Primary tumours contain distinct subpopulations of cells with MITF-high and -low 
expression signatures (Ennen et al. 2017). Clusters of low MITF expressing cells have 
been identified at the edge of primary lesions where melanoma invasion is triggered, 
eventually allowing the cells to metastasise (Caramel et al. 2013). High MITF has also 
been identified at distal sites where proliferating cells have metastasised, 
demonstrating an ability of the cells to switch their transcriptional state (Verfaillie et 
al. 2015). The level of MITF expression has been proposed to influence cancer 
phenotype in a dosage-dependent manner. High MITF promoting differentiation, 
intermediate proliferation, low invasion (and so metastasis), and absence of MITF 
resulting in senescence (Carreira et al. 2006, Hoek et al. 2008, Goding 2011, Verfaillie 
et al. 2015), summarised in Figure 1.4. Consequently, active MITF levels determine 
phenotype switching of melanoma cells in response to environmental triggers or 




Figure 1.5. Rheostat model for the effect of level of MITF activity on the behaviour of 
melanoma cells. Melanoma cells with very low levels of MITF activity undergo senescence. 
If MITF activity is enough that senescence is not induced, cells develop more invasive 
behaviour. Cells expressing higher MITF activity become more proliferative, while those with 
the highest levels begin to differentiate. Consequently, this model demonstrates the 
connection between the level of MITF activity and melanoma cell behaviour, which is 




SOX10 plays a vital role in melanocyte and melanoma development (Harris et al. 
2010, Graf et al. 2014). SOX10 belongs to the subgroup SOXE of SOX transcription 
factors which are characterized by a conserved high-mobility group (HMG) DNA-
binding domain that recognises the sequence motif 5′-T/AT/ACAAAG-3′ (Haldin and 
LaBonne 2010). SOX10 participates in regulating neural crest cell proliferation, 
survival, and multipotency, as well as melanocyte differentiation (Haldin and 
LaBonne 2010, Harris et al. 2010). With that, SOX10 plays a major role throughout 
melanocyte development (Shakhova et al. 2012). 
 
SOX10 regulates melanocyte-specific genes  including MITF, MIA, DCT, TYR, and 
TYRP1 which participate in regulation of cellular processes including proliferation, 
invasion, differentiation survival and melanogenesis (Harris et al. 2010, Fufa et al. 
2015, Seberg et al. 2017, Cronin et al. 2018). SOX10 also interacts with coactivators 
including PAX3 and BRG1  to help facilitate SOX10 regulation of its target genes 
(Potterf et al. 2000, Marathe et al. 2017, Cronin et al. 2018). The importance of SOX10 
in development is demonstrated by embryonic lethality following homozygous 
deletion of SOX10 in mice (Herbarth et al. 1998), while overexpression was found to 






induce the formation of giant congenital naevi in mice (Shakhova et al. 2012). 
Humans with SOX10 haploinsufficiency experience pigmentation defects and 
diseases including Waardenburg syndrome (WS2 and WS4) (Pingault et al. 2010). 
 
SOX10 has upregulated expression in both primary and metastatic melanomas 
(Shakhova et al. 2012, Cronin et al. 2013, Huang et al. 2015). Accordingly, studies 
have implicated SOX10 in melanoma initiation and maintenance (Shakhova et al. 
2012), with increased expression being associated with worse prognosis (Civenni et 
al. 2011, Graf et al. 2014). SOX10 is not typically mutated in melanoma, and its lack 
of expression or inhibition lead to cell death in melanoma cells, both of which 
demonstrate the importance of SOX10 function in melanoma (Shakhova et al. 2012, 
Cronin et al. 2013, Graf et al. 2014). In addition, when studied in melanoma mouse 
models, SOX10 haploinsufficiency prevented or significantly delayed malignant 
tumours developing (Shakhova et al. 2012, Cronin et al. 2013). Roles for SOX10 have 
been identified in regulating survival, cell cycle, proliferation, and invasion of 
melanoma cells (Shakhova et al. 2012, Cronin et al. 2013, Graf et al. 2014). It should 
also be noted that SOX10 has also been related to positively regulating expression of 
the oncogenic lncRNA SAMMSON which is expressed in 90% of human melanomas 
(Leucci, Vendramin, et al. 2016).  
 
1.3.1.4 MITF-SOX10 pathway 
 
The MITF and SOX10 transcription factors participate together to regulate a wide 
range of processes in neural crest stem cell, melanocyte, and melanoma 
development (Seberg et al. 2017, Tudrej et al. 2017).  Studies have identified 
enrichment of MITF and SOX10 at shared regulatory elements for target genes, 
suggesting that they co-occupy these regions (Fufa et al. 2015, Laurette et al. 2015, 
Verfaillie et al. 2015) – these include the genes DCT, TYR, and TRP1 (Marathe et al. 
2017). In addition to jointly regulating melanocyte- and melanoma-specific genes, 
MITF and SOX10 interact with similar regulatory factors. These include BRG1 and 
PAX3 which aid in controlling chromatin accessibility (Marathe et al. 2017).  
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As well as SOX10 inducing MITF expression, MITF binding sites have been identified 
upstream of the SOX10 gene, suggesting direct cross-activation between MITF and 
SOX10. Accordingly, it has also been proposed that these transcription factors form 
feed-forward loops, promoting one another’s expression (Verfaillie et al. 2015). It 
should also be noted that as well as functioning via regulating MITF activity, SOX10 
can function independent of MITF, demonstrated by ectopic expression of MITF in 
cells not fully rescuing expression of melanocyte-specific SOX10 target genes 
following SOX10 depletion (Marathe et al. 2017). Work in mice also demonstrated 
that heterozygous loss of both MITF and SOX10 had more severe loss of pigmentation 
than those with loss of only one (Potterf et al. 2000). The cooperative regulation of 
target genes by MITF and SOX10 demonstrate a higher level of transcriptional 
organisation.  
 
MITF and SOX10 have also been identified as ‘master regulators’ of proliferative gene 
networks in melanoma. Dynamic transcriptional changes in the activity of MITF and 
SOX10 allow reversible transitions between the proliferative and invasive states 
(Hoek et al. 2008, Verfaillie et al. 2015). The proliferative gene expression signature 
is associated with high levels of MITF and SOX10, while low MITF-SOX10 is identified 
in cells with an invasive melanoma gene signature (Carreira et al. 2006, Hoek et al. 
2008, Verfaillie et al. 2015). These distinct proliferative and invasive transcriptional 
states also influence the acquisition of resistance to MAPK pathway inhibitors 
(Konieczkowski et al. 2014, Sun et al. 2014, Verfaillie et al. 2015). For example, 
reduced SOX10 in melanoma has been reported to lead to activation of TGF-ß 
signalling and upregulation of epidermal growth factor receptor (EGFR) and platelet-
derived growth factor receptor-b (PDGFRB) which promoted resistance to BRAF and 





1.4.1 Characterised lncRNAs in melanoma  
 
While protein-coding genes are well-characterised regulators of melanoma, lncRNAs 
are less well understood. RNA-sequencing projects have identified large numbers of 
lncRNAs with dysregulated expression in melanoma. For example, the 
MiTranscriptome compendium identified 339 melanoma-associated lncRNA 
transcripts whose expression is restricted to melanoma, of which 24 were proposed 
to have putative functional roles based on their levels of conservation across 46 
vertebrate species (Iyer et al. 2015).  
 
Both oncogenic and tumour suppressive lncRNAs have been identified that can 
regulate a range of cellular processes in melanoma. The lncRNA BANCR (BRAF-
activated noncoding RNA) is connected to the MAPK signalling pathway and is 
induced by BRAFV600E. BANCR influences melanoma cell migration and proliferation 
by activating the ERK1/2 and JNK components of the MAPK pathway (Flockhart et al. 
2012, Li et al. 2014). Another well characterised melanoma-expressed lncRNA is 
SLNCR (SRA-like non-coding RNA). This oncogenic lncRNA promotes proliferation and 
invasion in melanoma cells by repressing the activity of the tumour suppressor 
p21Waf1/Cip1 as well as matrix metalloproteinase 9 (MMP9) (Schmidt et al. 2016, 
2019). SLNCR does this by recruiting the androgen receptor (AR) to Early growth 
response protein 1 (EGR1)-bound genomic loci and switching transcriptional 
activation by EGR1 to a repressive activity (Schmidt et al. 2019). The lncRNA SPRY4-
IT1 (Sprouty4-Intron 1) also acts as a melanoma oncogene by binding to lipin2 and 
promoting lipid metabolism through avoiding lipotoxicity. This leads to an inhibition 
of apoptosis as well as increased proliferation and invasion (Mazar et al. 2014). As 
oncogenes, expression of these lncRNAs is associated with worse prognosis and 
lower survival rate in melanoma patients (Li et al. 2014, Liu, Shen, et al. 2016, Schmidt 
et al. 2019). 
 
Fewer tumour suppressive lncRNAs in melanoma have so far been characterised. The 
lncRNA GAS5 is downregulated in melanoma and suppresses melanoma cell 
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migration and invasion, at least in part, by inhibiting expression of MMP2 (Chen et al. 
2016). PTENP1, which was found to be deleted in 20.9% of melanoma tissues, has 
also been recognised as a tumour suppressor in melanoma. PTENP1 acts as a decoy 
against miRNAs targeting the melanoma tumour suppressor gene PTEN. Deletion of 
PTENP1 was also found to be associated with complete or partial deletion of the 
melanoma-associated CDKN2A in human melanoma cell lines, although this was not 
found in human melanoma tissues (Poliseno et al. 2011). PTENP1 may also act 
independently of PTEN, acting as a decoy for miRNAs that have alternative or 
additional targets to PTEN. Correspondingly, deletion of PTENP1 led to a reduction in 
the mRNA levels of tumour suppressive genes including the pro-apoptotic factor BIM 
(BH3-only protein Bim), the cyclin-dependent kinase (CDK) inhibitor p21, and the 
BRAF inhibitor Sprouty2 (Yusoff et al. 2002, Tarek and Dutta 2009, Gogada et al. 
2013). It should be noted that each of these genes act as antagonists to the MAPK 
signalling pathway, leading to the hypothesis that PTENP1 deletion may promote 
activation of MAPK signalling (Tsavachidou et al. 2004, Akiyama et al. 2009, Poliseno 
et al. 2011).  
 
As well as understanding more about causes and development of melanoma, 
identifying the roles, mechanisms of action, and regulation of expression of 
oncogenic and tumour suppressive lncRNAs expressed in melanoma will enable the 
development of novel biomarkers and therapies for treating individuals with the 
disease. 
 
1.4.2 LncRNAs as biomarkers and therapeutics 
 
For patients diagnosed with melanoma, survival depends greatly on how far the 
disease has progressed. Individuals with stage I and II melanoma typically have 
surgery to remove the tumour. This is highly effective with a five-year survival rate of 
roughly 90% and 70% for stage I and II respectively (Balch et al. 2004, Yu et al. 2018, 
Siegel et al. 2019). Once the primary tumour thickness passes 2mm the prognosis 
reduces dramatically as the tumours are more likely to metastasise. Once melanomas 
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reach the lymph nodes (stage III), the five-year survival drops to 45%, with the 
prognosis worse if the tumour metastases reach multiple lymph nodes. If metastases 
have reached distant organs, the five-year survival rate then drastically drops to 10% 
(Balch et al. 2004). For patients with metastatic melanoma, generic cancer 
treatments such as chemotherapy or radiation therapy are often used (Siegel et al. 
2019).  
 
The inefficiency of chemotherapy and radiation therapy have led to the development 
of newer methods to treat metastatic melanoma (Singh and Salama 2016, Pérez-
Guijarro et al. 2017). Such therapies have begun to focus on the tumours’ mutational 
status, allowing the development of more personalised medicine. This was done in 
the case of vemurafenib (PLX4032) which targets activity of the BRAFV600E, and so 
reduces MAPK pathway signalling in patients with metastatic melanoma. The BRIM3 
clinical trial was the first time a clear clinical response was observed when treating 
late-stage melanoma, with a response rate of 48% compared to just 5% when using 
dacarbazine (chemotherapy) (Chapman et al. 2011). While vemurafenib is initially 
effective, resistance to the drug can occur. Consequently, combination therapies are 
now being increasingly explored, such as targeting BRAFV600E and MEK using a 
combination of dabrafenib and trametinib to increase efficiency when targeting 
melanomas (Chapman et al. 2014, Brugnara et al. 2018). In more recent cases 
immunotherapies are being explored, including targeting immune checkpoint 
inhibitors PD-1 and CTLA-41–8 in order to enhance the T-cell-mediated response to 
tumours. While these have led to great advances in melanoma treatment, they can 
also cause adverse immune-related effects, leaving only a selection of patients 
responding positively to the treatment (Grywalska et al. 2018, Khair et al. 2019). 
 
LncRNAs represent new molecular targets for the diagnosis and treatment of 
melanoma. Their specificity of expression in tissues and cell types, and at specific 
points in disease development, makes them ideal candidates for the generation of 
novel biomarkers and therapeutic molecules (Bolha et al. 2017). Using unique 
signatures based on lncRNA expression, generation of patient diagnosis, prognosis 
 45 
and identification of the most suitable treatment, as well as monitoring patient 
progression are all possible (Rapisuwon et al. 2016). The specificity of expression is 
also useful for the generation of novel highly selective therapies to target lncRNA 
expression to prevent cancer and hopefully minimise off-target effects (Amit and 
Hochberg 2013). In addition, with lncRNAs greatly outnumbering protein-coding 
genes, they greatly increase in the number of possible targets. Current methods for 
targeting lncRNAs is predominantly focused on inhibiting oncogenic lncRNAs using 
methods such as antisense oligonucleotides (ASOs) and siRNAs (Leucci, Coe, et al. 
2016). 
 
One lncRNA that demonstrates potential therapeutic targetability in melanoma is 
SAMMSON. This oncogenic lineage-specific lncRNA is detected in greater than 90% 
of human melanomas and is co-amplified with MITF as well as positively regulated by 
SOX10. The lncRNA regulates mitochondrial homeostasis and metabolism through 
promoting the activity of p32, a master regulator of mitochondrial metabolism 
(Leucci, Vendramin, et al. 2016). Invasive melanoma cells which were resistant to 
MAPK inhibitors (Verfaillie et al. 2015) were sensitive to depletion of SAMMSON, with 
the cells experiencing reduced growth. The ability to therapeutically target 
SAMMSON was also assessed in vivo using patient-derived xenograft (PDX) 
melanoma models Mel006 and Mel010. When treated intravenously with GapmeRs 
targeting SAMMSON, tumour growth was inhibited, including a reduction in 
proliferation and increase in apoptosis. The treatment also showed no adverse 
effects on the mice used. In addition, although the BRAFV600E inhibitor dabrafenib was 
able to inhibit tumour growth, when treatment was combined with GapmeR3 the 
tumour regressed and there was a significant increase in apoptosis. Overall, 
SAMMSON represents a potential lncRNA therapeutic target that may be used in 
combination with other therapies (Leucci, Vendramin, et al. 2016). 
 
By exploring the role of more lncRNAs in melanoma there will be new candidates that 
may be exploited as biomarkers or therapeutically, be that on their own or in 
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combination with currently used methods. This way lncRNAs offer a new avenue in 
the development of agents in the treatment of melanoma. 
 
1.5 Aims of the thesis 
 
The overall objective of this project was to begin to explore the role of novel 
melanoma-expressed intergenic lncRNAs that participate in the MITF-SOX10 
transcriptional pathway. Focus is traditionally placed on the role of protein-coding 
genes in key regulatory pathways, leaving characterisation of lncRNAs in such 
processes largely unexplored. DIRC3 is used as a model intergenic lncRNA to 
investigate the role of lncRNAs in MITF-SOX10-mediated control of melanoma 
progression.  
 
The primary objectives for this project were to; 
• Identify MITF- and SOX10-regulated lncRNAs expressed in melanocyte and/or 
melanoma cell lines 
• Reveal whether DIRC3 regulates its neighbouring cancer-associated genes  
• Identify DIRC3 regulation of gene expression programmes important to 
melanoma development 
• Identify whether DIRC3 expression regulates any of the key hallmarks of 
cancer using in vitro assays 
• Begin to explore DIRC3 mechanism by measuring the levels of SOX10 binding 
and histone modifications across the DIRC3 locus upon its knockdown 
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Chapter 2: Materials and Methods 
 
2.1. Cell manipulation 
 
2.1.1 Cell culture 
 
Human immortalised melanocytes (Hermes) cells were grown in Dulbecco’s Modified 
Eagle Serum (DMEM) (ThermoFisher) which was supplemented with 10% Fetal 
Bovine Serum (FBS; (ThermoFisher)) human stem cell factor (hSCF)(ThermoFisher) 
and endothelin-1 (ET-1) (BaChem). They were kept in a humid environment at 37 °C 
and 5% CO2 and passaged every two-to-three days when they reached roughly 90% 
confluency. 
 
Human melanoma (501mel, SKmel28, A375) cell lines were grown in RPMI-1640 
(ThermoFisher) with 10% Fetal Bovine Serum (FBS). They were kept in a humid 
environment at 37 °C and 5% CO2 and passaged every two-to-three days when they 
reached roughly 90% confluency. 
 
Table 2.1 Melanoma cell types used and where they were sourced. 
Cell Type Source 
Hermes1 – human immortalised melanocyte cell line Wellcome Trust Functional 
Genomic Cell Bank 
501mel – human immortalised melanoma cell line, 
BRAFV600E mutant, expresses high level of MITF 
Colin Goding, Ludwig Institute, 
Oxford 
Skmel-28 – human immortalised highly invasive 
melanoma cell line, BRAFV600E mutant, expresses low 
level of MITF  
Colin Goding, Ludwig Institute, 
Oxford 
A375 – human immortalised malignant melanoma cell 
line, BRAFV600E mutant  
ATCC 
IGR-37 – human immortalised malignant melanoma 
cell line, BRAFV600E mutant 
Colin Goding, Ludwig Institute, 
Oxford 
IGR-39 – human immortalised primary melanoma cell 
line, BRAFV600E mutant 






For siRNA (Sigma-Aldrich) and MISSION® esiRNA (Sigma-Aldrich) knockdown, 
SKmel28 and 501mel melanoma cells were seeded at a density of 5x104 cell/ml into 
the wells of a 6-well plate containing 2 mL of medium. After 24 hours the cells were 
transiently transfected using 4 µl Lipofectamine (ThermoFisher) in 150 µl of OPTI-
MEM (ThermoFisher) which was added to 100 pmol of siRNA or 1.5µg of esiRNA in 
150 µl of OPTI-MEM medium. Following a 25-minute incubation at room 
temperature, the mixtures were applied to the prepared cells while gently rocking 
the plate to allow even distribution. The cells were harvested 72 hours later for 
analysis. 
 
Table 2.2 siRNA oligos.  








For ASO LNA GapmeR (Exiqon) knockdown, SKmel28 melanoma cells were seeded at 
a density of 6x104 cell/ml into the wells of a 6-well plate containing 2 mL of medium. 
After 24 hours the cells were transiently transfected using 5 µl Lipofectamine in 150 
µl of OPTI-MEM which was added to 150 pmol of ASO in 150 µl of OPTI-MEM 
medium. Following a 25-minute incubation at room temperature, the mixtures were 
applied to the prepared cells while gently rocking the plate to allow even distribution. 
The cells were then harvested 72 hours later for analysis. 
 
Table 2.3 Antisense LNA GapmeR oligos. 
Oligo name Oligo sequence (5’-3’) 
DIRC3 ASO1 ACAAATAAGTAGACGT 
DIRC3 ASO2 AACGGAAGGGACGTGT 




For CRISPRi knockdown, SKmel28 melanoma cells were seeded at a density of 8x104 
cell/ml into the wells of a 6-well plate containing 2 mL of medium. After 24 hours the 
cells were transiently transfected using 4 µl Lipofectamine in 100 µl of OPTI-MEM 
which was added to 2 µg of vector in 100 µl of OPTI-MEM medium. Following a 25-
minute incubation at room temperature, the mixtures were applied to the prepared 
cells while gently rocking the plate to allow even distribution. After 72 hours, the cells 
were trypsinised, resuspended in media containing puromycin (0.7 µg/ml), and 
transferred to a 6-cm dish (ThermoFisher). The cells were harvested as a pool seven 
days later for analysis. 
 
2.1.3 Establishment of stable clonal cell line  
 
For the generation of CRISPRi knockdown clonal cells, SKmel28, 501mel, and A375 
were seeded at a density of 8x104 cell/ml, 1.5x104 cell/ml, and 8x104 cell/ml, 
respectively, into the wells of a 6-well plate containing 2 mL of medium. After 24 
hours the cells were transiently transfected using 4 µl Lipofectamine in 100 µl of OPTI-
MEM which was added to 2 µg of vector in 100 µl of OPTI-MEM medium. Following 
a 25-minute incubation at room temperature, the mixtures were applied to the 
prepared cells while gently rocking the plate to allow even distribution. After 72 
hours, the cells were trypsinised, resuspended in media containing 1 mg/ml 
(Skmel28), 1.3 mg/ml (501mel), or 1.5 mg/ml (A375) of puromycin, and transferred 
to a 10-cm dish (ThermoFisher). This was maintained until colonies of resistant cells 
began to form (roughly two weeks following the beginning of drug selection). The 
individual colonies were isolated using cloning cylinders (Sigma). The selected clones 
were expanded in media containing a 0.5 µg/ml of puromycin. 
 
2.1.4 Cell fractionation  
 
Roughly 1 x 106 cells were harvested and centrifuged at 1000 rpm for five minutes at 
4 °C. The pellet was washed in an equal volume of ice-cold PBS and re-centrifuged. 
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The pellet was then re-suspended in 200 µl of Lysis Buffer (15 mM HEPES, pH 7.5, 10 
mM KCl, 5 mM MgCl2, 0.1 mM EDTA pH 8, 0.5 mM EGTA pH 8, 250 mM Sucrose, 0.4% 
Igepal, 1 mM DTT, 0.5 mM, protease inhibitor cocktail (Roche), 100 U/ml RNAsin, and 
incubated at 4 °C for 20 minutes with rotation. The mixture was pipetted up and 
down 14 times to lyse the cells, and nuclei pelleted at 2000 g for 10 minutes at 4 °C. 
The supernatant was collected containing the cytoplasmic fraction. RNA was then 
extracted from the two fractions using the QIAGEN RNeasy Mini Kit (Section 2.3.1).  
 
2.1.5 Proliferation assay 
 
Roughly 1.5x104 SKmel28 clonal CRISPRi knockdown cells were seeded in a 6-well 
plate. The cells were maintained in media containing 0.5 µg/ml of puromycin and 
grown in 5% CO2 at 37°C. The number of cells were counted using a haemocytometer 
at days 0, 2, and 4.  
 
2.1.6 Invasion assay 
 
SKmel28 cells were serum starved in FBS-free medium for 24 hours prior to setting 
up the assay. The QCMTM 24-Well Cell Invasion Assay (Millipore) was used. 300 µl of 
FBS-free media was pipetted into the interior of the inserts (upper chamber). After 
15-30 minutes, 250 µl of medium was removed from the inserts and replaced with 
250 µl of FBS-free medium containing 8x105 cells. The lower chamber then had 500 
µl of media containing 20% FBS added. The cells were incubated in 5% CO2 at 37°C 
for 52 hours. To detach the cells that had invaded through the membrane, the upper 
chambers were placed in a well of a clean 24-well plate containing 225 µl pre-warmed 
Cell Detachment Solution and incubated at 37°C for 30 minutes. The cells were fully 
dislodged from the underside of the membrane by gently tilting the plate back and 
forth at several points during the incubation. The inserts were then removed from 
the wells. The cells were lysed and dyed by adding 75 µl of the kit’s dye solution-lysis 
buffer mix (1:75) to the cell-containing lysis solution. This was covered with tin foil 
and incubated at room temperature for 15 minutes. Finally, 200 µl of the mix was 
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transferred to a 96-well plate and fluorescence was measured with a fluorescence 
plate reader (SoftMax Pro) using a 480/520 nm filter set.  
 
2.1.7 Soft agar colony formation assay 
 
Roughly 5x103 clonal CRISPRi knockdown cells were suspended in 1.5ml growth 
medium containing 0.3% noble agar, on top of 1.5ml growth medium with 0.5% noble 
agar in a six-well plate. Cells were grown for 21 days in 5% CO2 at 37°C and 
supplemented with 100 μl of growth medium every three-to-four days. The cells were 
then fixed in fixing solution (1% Formaldehyde, 0.01% methanol, PBS) for 20-30 
minutes, stained using 0.01% crystal violet for 30-60 minutes, and then washed with 
distilled water to remove excess stain. Images were taken using a UVP Gel Doc-It2 
Imager. The number of colonies was quantified using ImageJ (Section 2.5.1). 
 
2.1.8 Transformation of competent bacterial cells 
 
DH5α chemically competent cells (ThermoFisher) were used to increase yield of 
plasmid DNA. The cells were thawed on ice and used in 25 µl aliquots. Typically, 1 µl 
of plasmid DNA or 2 µl of ligated oligo-vector was added to the cells and incubated 
on ice for 25 minutes. They were then heat-shocked by incubating at 42 °C for 30 
seconds and then on ice for two minutes. Next, 100 µl of room temperature Super 
Optimal broth with Catabolic repression (SOC) (ThermoFisher) was added to the cells, 
and they were kept at 37 °C and 220 rpm for one hour. The cells were then spread on 
Luria-Bertani (LB)-agar plates (Sigma) containing 100 µg/ml of carbenicillin. The 
plates were kept at 37 °C overnight.  
 
2.1.9 Glycerol stocks 
 
Following growth overnight in LB broth at 37 °C and 220 rpm, 500 µl of transformed 
DH5α was mixed with 500 µl of 40% Glycerol stock. The cells were flash-frozen and 
stored at -80°C. 
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2.2 DNA manipulation 
 
2.2.1 5’ Rapid amplification of cDNA ends (RACE) 
 
LncRNA 5’ and 3’ ends were identified using the GeneRacerTM Core kit (ThermoFisher) 
in SKmel28 cells according to the manufacturer’s protocol. 
 
In brief, for identification of the 5’ end of the target RNA the 5’ phosphates were 
removed using calf intestinal phosphatase (CIP) so that the GeneRacerTM RNA oligo 
could ligate only to full-length transcripts which are capped. The 5’cap structure was 
then removed from the de-phosphorylated transcripts using tobacco acid 
pyrophosphatase (TAP), leaving a 5’ phosphate for the GeneRacerTM oligo to anneal 
to. Using T4 RNA ligase, the GeneRacerTM RNA oligo was then ligated to the 5’ end of 
the RNA. The prepared mRNA was reverse transcribed using SuperScriptTM III RT 
Module (ThermoFisher) and GeneRacerTM random primers. The resultant first-strand 
cDNA was amplified using a GeneRacerTM 5’ Primer with a sequence homologous to 
the GeneRacerTM RNA oligo and reverse Gene Specific Primer. An additional round of 
PCR could be performed using nested primers.  
 
To identify the 3’ ends, purified mRNA was reverse transcribed using SuperScriptTM 
III RT Module and GeneRaceTM Oligo dT primer. The resultant first-strand cDNA was 
then amplified using a GeneRacerTM 3’ Primer with a sequence homologous to the 
GeneRacerTM Oligo dT primer. An additional round of PCR could be performed using 
nested primers. 
 
For both 5’ and 3’ RACE, PCR products were run on a 2 % agarose gel and bands of 
interest were purified using a QIAGEN PCR purification kit (Section 2.2.3) and cloned 




Table 2.4 RACE oligos.  
Oligo name Oligo sequence (5’-3’) 
5’RACE (1° PCR)  
   Dirc3 5’RACE1 GCACAGCTCAGCACCCAGACTCCTTCCA 
5’RACE (2° PCR)  
   Dirc3 5’RACE2 CCTCTTGCCTCTCCCTGCCTGTGCTCAT 
3’RACE (1° PCR)  
   Dirc3 3’RACE1 CCAGATTGTGGGCGCTTCTACTG 
3’RACE (2° PCR)  
   Dirc3 3’RACE2 ATGTGTTGGGTGTGGAACAGGGTCTCT 
 
2.2.2 pGEM-T-Easy cloning  
 
Fragments of DNA were cloned into the pGEM-T-Easy (ThermoFisher) vector 
according to the manufacturer’s instructions. Features of vector in Appendix Section 
8.1. Briefly, the reaction mix was composed of 5 µl Ligation Buffer, 1 µl pGEM-T-Easy 
vector, 2µl PCR product, and 1 µl T4 DNA ligase, as well as DEPC-treated water, 
making a total volume of 10 µl. This was left at room temperature for one hour before 
being used to transform chemically competent DH5α cells, as described in Section 
2.2.8.  
 
2.2.3 On column DNA purification 
 
PCR products and digeted vectors were purified using a QIAquick® PCR Purification 
kit (QIAGEN). The procedure was carried out according to the manufacturer’s 
protocol. In brief, the high salt Buffer PB was added to the sample, which was then 
passed through a QIAquickTM spin column, binding the DNA to the membrane. The 
DNA was then washed, to remove impurities. Following a final dry spin, the purified 
DNA was eluted in 50 µl of Elution buffer. The concentration of the eluted DNA could 
be determined using a NanoDrop. 
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2.2.4 CRISPRi plasmid construction 
The CRISPRi plasmids pX-dCas9-mod and pX-dCas9-mod-KRAB were donated by 
Andrew Bassett, Sanger Institute, Cambridge. Both vectors contain a CBh promoter 
and include resistance to ampicillin and puromycin. Vector map is presented in 
Appendix Section 8.2. The sgRNAs were designed to target a genomic region -50 and 
+150 bp of the target transcription start site using the Zhang Lab CRISPR Design Tool 
(https://zlab.bio/guide-design-resources). 
Table 2.5 CRISPRi vectors.  
Oligo name Key Features 
pX-dCas9-mod Contains a CBh promoter and resistance to ampicillin and 
puromycin.  
pX-dCas9-mod-KRAB Contains a CBh promoter and resistance to ampicillin and 
puromycin. Has the addition of a Krüppel-associated box 
(KRAB) protein 
Table 2.6 CRISPRi sgRNA oligos.  
Oligo name Oligo sequence (5’-3’) 
CASC11sg1 F CACCGCCGAAGAAAGAGGAGTTAC 
CASC11sg1 R AAACGTAACTCCTCTTTCTTCGGC 
CASC11sg2 F CACCGGCAGAAGGTCCGAAGAAAG 
CASC11sg2 R AAACCTTTCTTCGGACCTTCTGCC 
DIRC3sg1 F CACCGTTCGGGAAGCTTTTACTCA 
DIRC3sg1 R AAACTGAGTAAAAGCTTCCCGAAC 
DIRC3sg2 F CACCGTTGGTCCTGCAGGCTGTAC 
DIRC3sg2 R AAACGTACAGCCTGCAGGACCAAC 
RefSeq DIRC3sg1 F CACCGTGCACACGCATATGTGTCC 
RefSeq DIRC3sg1 R AAACGGACACATATGCGTGTGCAC 
RefSeq DIRC3sg2 F CACCGGGCAAGTCGCTCCGTCATG 
RefSeq DIRC3sg2 R AAACCATGACGGAGCGACTTGCCC 
NEGsg1 F CACCGCGCCAAACGTGCCCTGACGG 
NEGsg1 R AAACCCGTCAGGGCACGTTTGGCGC 
NEGsg2 F CACCGTGCGATGGGGGGGTGGGTAGC 




2.2.5 Oligonucleotide annealing and phosphorylation for the generation of sgRNAs 
for CRISPRi 
 
5 µl of the 100 µM Forward and Reverse oligonucleotides (Table 2.3) were mixed with 
10 µl of 2x Annealing Buffer (20mM Tris, 2mM EDTA, 100 mM NaCl) and incubated at 
94 °C for five minutes followed by room temperature for one hour. Samples were 
then phosphorylated by mixing together 1 µl of the annealed oligo, 1 µl T4 PNK (New 
England Biolabs), and 1 µl Roche T4 DNA ligase Buffer in a total volume of 10 µl. These 
were incubated at 37 °C for 30 minutes, and then 65 °C for 20 minutes to inactivate 
the enzyme. Samples were then diluted 1:10.  
 
2.2.6 Restriction enzyme digestion of CRISPRi vectors 
 
The CRISPRi vectors (pX-dCas9-mod and pX-dCas9-mod-KRAB) were digested using 
BpiI Fast Digest enzyme (ThermoFisher). For this 1 µg of vector was digested using 2 
units of enzyme and 1x restriction buffer in a total volume of 20 µl. The mix was kept 
at 37 °C for 20 minutes and heat inactivated at 65 °C for 10 minutes.  
 
2.2.7 Dephosphorylation of linearised plasmid 
 
Re-ligation of the digested vector was prevented by dephosphorylating the 5’ end of 
the linearised plasmid. This was performed using 1 µl of CIP (Calf Intestinal Alkaline 
Phosphatase (New England Biolabs) in 20 µl of the digested vector. The mix was kept 
at 37 °C for one hour and separated on a gel. The plasmid DNA was purified using a 
QIAGEN QIAquick® Gel Extraction Kit, as described in Section 2.2.8. 
 
2.2.8 DNA gel extraction 
 
Following gel electrophoresis, DNA was purified from the agarose gel using a QIAGEN 
QIAquick® Gel Extraction Kit (QIAGEN) according to the manufacturer’s protocol. In 
brief, the fragment of interest was excised from the gel and the surrounding gel 
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dissolved at 50 °C. The DNA was then bound to a membrane, washed, and eluted in 
30 µl of Elution Buffer.  
 
2.2.9 DNA ligation  
 
Dephosphorylated linearised plasmids and phosphorylated oligos were annealed 
together using vector to insert ratios of 1:2, 1:4, or 1:7, using up to 100 ng of vector. 
In a mixture made up to 10 µl, the vectors and oligos were added to 1 µl T4 DNA 
ligase (New England Biolabs) and 1 µl T4 DNA ligase buffer. These were incubated 
overnight at 16 °C.  
 
2.2.10 Colony PCR 
 
Individual colonies were screened for cloned inserts using an AmpliTaq reaction kit 
(ThermoFisher). Individual colonies were picked and mixed with a reaction mix 
containing 0.8µl of forward primer targeting the vector, 0.8 µl reverse oligo (Table 
2.4), 0.25 µl Taq polymerase (ThermoFisher), 2 µl 10X Taq polymerase buffer, 2 µl 
Magnesium chloride, and 0.5 µl 10 mM dNTP, made up to 20 µl. The mixes were 
amplified using PCR and separated using agarose gel electrophoresis (Section 2.2.13) 
to check the sizes of the bands.  
 
The primers used are given in Table 2.7. For identification of the presence of CRISPRi 
sgRNAs, the reverse oligos used for generation of the sgRNAs were used as reverse 
primers. 
 
Table 2.7 Colony PCR oligos. 
 Oligo name Oligo sequence (5’-3’) 
p-GEM-T-Easy M13 Forward GTAAAACGACGGCCAG 
 M13 Reverse CAGGAAACAGCTATGAC 
CRISPRi CRISPRi Fwd  GGCCTATTTCCCATGATTCCT 
 CRISPRi Rev TTTCTTGGGTAGTTTGCAGTTTT 
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2.2.11 Isolation of plasmid DNA 
 
Single bacterial colonies were isolated from a LB-agar plate. The colonies were 
individually inoculated in 3-5 ml of LB medium (Sigma) containing 100 µg/ml 
carbenicillin (ThermoFisher) for small-scale and 50 ml for large-scale purification. 
These were incubated at 37 °C overnight with shaking (220 rpm). Plasmid DNA was 
isolated using a QIAprep Spin Miniprep kit (QIAGEN) or QIAprep Spin Midiprep kit 
(QIAGEN) according to the manufacturer’s instructions. In brief, cells are pelleted and 
then lysed in an alkaline solution. Plasmid DNA was then bound to a silica membrane 
using a high salt buffer. Unbound material was washed off and the DNA eluted in 
Elution buffer. The concentration of the eluted plasmid DNA was measured using a 
NanoPhotometerTM Implen. 
 
2.2.12 DNA sequencing 
 
Sanger Sequencing was performed by Eurofins Scientific. Plasmids were sent at a 
concentration of 50-100 ng in 17 µl each and 5µl of forward vector primer (10 mM) 
per sequencing sample. 
 
2.2.13 Agarose gel electrophoresis 
 
Agarose gels (0.5-2%), for horizontal gel electrophoresis, were made by dissolving 
agarose (Fisher Scientific) in 100 ml of TAE (ThermoFisher) in a microwave. For later 
visualisation, 1x Gel Red Nucleic Acid Stain (Biotium) was added to the gel. The 
solidified gels were placed into a gel electrophoresis tank containing 1x TAE buffer. 
The DNA samples were loaded with 1x loading dye (New England Biolabs) into the 
wells, alongside a DNA ladder marker (2.2.2.13). The DNA fragments were separated 
in the electrophoretic tank at 80-120 V (constant voltage). The DNA was visualised 
using a transilluminator (Gel Doc-It2 Imager UVP).  
 
 58 
2.2.14 DNA ladder marker 
 
A 1kb DNA ladder marker for gel electrophoresis was made by mixing 500 µg/ml of 1 
kb DNA ladder (New England Biosciences) with 200 µl of loading buffer (New England 
Biosciences) and diluted 1:10. 
 
2.2.15 Gel extraction 
 
DNA fragments of interest were visualised using a transilluminator and excised from 
the agarose gel using a blade. DNA was extracted from the gel using a QIAquick Gel 
Extraction Kit (QIAGEN) according to the manufacturer’s instructions. In brief, the 
excised region of DNA was dissolved in a solubilising buffer at 50 °C. The solubilised 
gel was passed through a spin column. DNA was bound to the membrane while 
unbound material was removed when washed. The DNA was then eluted in Elution 
buffer and concentration measured using a NanoPhotometerTM Implen. 
 
2.2.16 Chromatin Immunoprecipitation (ChIP) 
 
Roughly 1x107 clonal SKmel28 CRISPRi cells per assay were crosslinked in 1% 
formaldehyde.  Cells were lysed by douncing in hypotonic buffer (10 mM Tris-HCl pH 
7.2, 10 mM KCl, 1.5 mM MgCl2, 1% NP40, 1x Protease Inhibitor Cocktail) and then 
centrifuged to separate the nuclear pellet. The pellet was resuspended in sonication 
buffer (50 mM Hepes KOH pH 7.9, 10 mM EDTA pH8, 1% SDS, 1x Protease Inhibitor 
Cocktail) and sonicated to roughly 500 bp in a Bioruptor Pico Diagenode. Debris was 
separated using centrifugation, and suspended chromatin diluted 1:10 in IP dilution 
buffer (10 mM Hepes KOH pH 7.9, 1% Triton X-100, 150 mM NaCl, 1mM EDTA pH8, 
0.1% SDS, 1x Protease Inhibitor Cocktail). Samples were immunoprecipitated at 4°C 
overnight using 5 µg of antibody and non-specific Immunoglobin G (IgG) isotype 
control antibody. Magnetic Pierce™ Protein G Magnetic Beads (ThermoFisher) were 
also blocked in 1ml of blocking solution (BSA 0.2mg/ml, tRNA 0.1 mg/ml) overnight 
at 4 °C while rotating. Antibody-bound samples were mixed with Dynabeads 
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(ThermoFisher) on a rotating wheel at 4°C for four hours. Non-bound proteins were 
removed by washing beads on a magnetic stand using a series of wash buffers (Wash 
Buffer I – 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, 150 mM 
NaCl; Wash Buffer II – 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 
8.1, 500 mM NaCl; Wash Buffer III – 0.25 M LiCl, 1% NP-40, 1% Sodium Deoxycholate, 
1 mM EDTA, 10 mM Tris-HCl pH u8.1). The antibody-bound proteins were then eluted 
from the beads by suspending the sample in 250 µl Elution Buffer (1% SDS, 0.1 M 
NaHCO3) and were rotated at room temperature for 15 mins. Beads were isolated 
using a magnetic stand and supernatant collected. Crosslinking was reversed by 
adding RNase (0.5mg/ml) and NaCl (0.25M) and incubating at 65°C. The samples were 
precipitated by adding 2.5 volumes of 100% ethanol and kept at -20°C for 72 hours. 
The samples were centrifuged to pellet DNA and resuspended in 100 µl of water. The 
samples were then incubated with Proteinase K buffer (50 mM Tris pH 7.5, 25 mM 
EDTA, 1.25% SDS, 0.02 mg/ml Proteinase K - ThermoFisher) at 42°C for 1-2 hours to 
remove the proteins. The DNA fragments were purified using a QIAquick PCR 
purification kit (Qiagen)(2.2.3) and binding confirmed using RT-qPCR. 
 
Table 2.8 Antibodies used for ChIP-qPCR. 
Antibody Source 
Anti-SOX10 (rabbit monoclonal antibody)  Abcam – ab155279  
Anti-Histone H3K27ac (rabbit polyclonal) Active Motif – 39133  
Anti-rabbit IgG  Merck – PP64 
 
Table 2.9. qPCR primers used to amplify SOX10-bound genomic sequences. 
Oligo Name Oligo sequence (5’-3’) 
Control 1 F CTGCTTTCTCTCCTTGCCCA 
Control 1 R CGGCTGAGCCATATGCTGTA 
Control 2F TCAGATGCATTGTCACGCCT 
Control 2R AGACCCAGTGAGAGAGACCC 
Peak 1 F CCTCTCCCAGGCCATTACAA 
Peak 1 R TAATTCCCCTCAGCTTCCAGC 
Peak 2 F CCCCTCACAGAAGAAAAGCCT 
Peak 2 R GGAGTCTGCATGAAAGGGGC 
Peak 3 F GACAGACAACAGTCATGTGGTT 
Peak 3 R GCTCCTTCCTCTTTTTCCCAGA 
Peak 4 F GAGAGTCCGTGAAGGAGTGG 
Peak 4 R CCTCCGCCAGCAATAGATAA 
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2.3 RNA manipulation 
 
2.3.1 RNA isolation and removal of DNA contamination 
 
For RNA purification, cells were harvested, washed twice with PBS, and centrifuged 
at full speed in a microcentrifuge for 10 seconds. RNA was then extracted using a 
RNeasy Mini Kit (QIAGEN) according to the manufacturer’s instructions. In brief, cells 
were lysed and homogenised by passing them through a QIAshredder (QIAGEN) in a 
lysis buffer. After adding ethanol to the RNA-containing eluate, the RNA was bound 
to a spin column membrane. Through a series of washes, contaminants were 
removed from the RNA. DNA contamination was removed using a RNase-Free DNase 
kit (as described in Section 2.3.2). Following a final series of washes to remove the 
DNase, the RNA was eluted using Elution buffer, and concentration measured using 
a nanodrop. 
 
2.3.2 On column removal of DNA contamination from RNA sample  
 
When RNA was bound to a RNeasy Mini Kit spin column, the contaminant DNA was 
removed using a RNase-Free DNase Set (QIAGEN). A mixture of 10 µl of DNase and 
70 µl of Buffer RDD were added to the RNA and left at room temperature for 15 
minutes, after which the enzyme and buffer were washed off in the following steps 
of the RNeasy Mini Kit protocol.  
 
2.3.3 First strand cDNA synthesis 
 
Extracted RNA was reverse transcribed using a QuantiTect Reverse Transcription Kit 
(QIAGEN) according to the manufacturer’s instructions. In brief, 1 µg of RNA had any 
remaining genomic DNA removed following the addition of gDNA Wipeout Buffer at 
42 °C for three minutes. A mixture containing Quantiscript Reverse Transcriptase, 
Quantiscript RT buffer, and RT primer mix, making a final volume of 20 µl, was added 
and incubated at 42 °C for 28 minutes, followed by a three-minute incubation at 95°C 
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to inactivate the Quantiscript Reverse Transcriptase.  The cDNA was then typically 
diluted 1:4 for RT-qPCR (Section 2.3.4).  
 
2.3.4 Quantitative PCR analysis of RNA expression (RT-qPCR) 
 
Transcripts of interest had primers designed for qPCR analysis using NCBI Primer 
Blast. Real-time quantitative PCR (RT-qPCR) was performed using Fast SYBR GreenTM 
Master Mix (ThermoFisher) and a StepOneTM Plus Real-Time PCR system (Applied 
Biosystem). Relative expression levels of the genes were assessed in technical 
triplicates for each run. Control non-reverse transcribed RNA were included to check 
for genomic DNA contamination. Expression levels of target transcripts were 
normalised against housekeeping gene(s) not known to be influenced by altered 
experimental conditions. Fold changes in target expression were calculated relative 
to control conditions using the ddCt method.  
 
Table 2.10 LncRNA and transcription factor qPCR oligos. 
Oligo name Oligo sequence (5’-3’) 
LncRNA  
MelncRNA1 Fwd ATATCGGCTTGCGGTTCACT 
MelncRNA1 Rev GCCTTGCTGGAGAAGGAACA 
MelncRNA4 Fwd AGGGAATCCTGCCTAAAACCT 
MelncRNA4 Rev GCTGGACCTTTGTGCTGTAG 
MelncRNA7 Fwd AATCTGTTGCCAGGTCCCAC 
MelncRNA7 Rev ACCAAGCCGAAGCCTTAGAG 
MelncRNA9 Fwd TGCCCAGAAACAGCACATTC 
MelncRNA9 Rev TCAAGCTACCAGTCAGCACA 
MelncRNA11 Fwd AGATCCGCAGAGTGGTCTGA 
MelncRNA11 Rev ATGGCCAGGGAAACAGATCC 
MelncRNA13 Fwd ATTCCACTAGCCAAAGCCCC 
MelncRNA13 Rev CAGGCCTTAAGGGCAGTTCA 
MelncRNA17 Fwd ACTCTCGCTATGTGACCCGA 
MelncRNA17 Rev CTTGTCTGCTTTTGGAGCCG 
CASC11 Fwd GCTGCAGAAGGTCCGAAGAA 
CASC11 Rev TGCGGTTGAATAGTCACCTCTG 
DANCR Fwd AATGCAGCTGACCCTTACCC   
DANCR Rev GGCTTCGGTGTAGCAAGTCT 
DIRC3 Fwd CCCACCCCACCACTATTCAC 
DIRC3 Rev CCACTGGGACAACCATCTCC 
NEAT1Fwd CTGGTCATCTGGTAAGCCCG 
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NEAT1 Rev ACATTCACTCCCCACCCTCT 
STK4AS Fwd CAGCCATGGGTGTGTAACCT 
STK4AS Rev GGTAGTGGCATTCGGAAGCA 
Transcription factor  
MITF1 Fwd TGGCAAATACGTTGCCTG 
MITF1 Rev ACGCTGTGAGCTCCCTTT 
SOX10 Fwd ACAAGAAAGACCACCCGGAC 
SOX10 Rev AAGTGGGCGCTCTTGTAGTG 
Neighbouring Genes  
Igfbp5 Fwd ACAAGAGAAAGCAGTGCAAACC 
Igfbp5 Rev CGTCAACGTACTCCATGCCT 
Tns1 Fwd GCGTTCCTCCATCCAACCAT 
Tns1 Rev GCTCCTTCTCCCTTGTCCAC 
Myc Fwd GTAGTGGAAAACCAGCAGCC 
Myc Rev AGAAATACGGCTGCACC 
Reference Genes  
hPolII Fwd TTGTGCAGGACACACTCACA 
hPolII Rev CAGGAGGTTCATCACTTCACC 
 
2.4 Protein manipulation 
 
2.4.1 Bradford assay 
 
Roughly 6x105 cells were harvested for Western Blot analysis. Cells were pelleted by 
centrifugation and lysed in 50µl of RIPA (Radioimmunoprecipitation assay) buffer 
(150 mM NaCl, 1% NP40, 0.5% EDTA, 0.1% SDS, 50 mM Tris pH 8, 0.5 mM protease 
inhibitor cocktail (Roche)), while rotating in a cold room for 10 minutes. 
 
The concentration of extracted protein was identified using a Bradford assay, so that 
equal amounts of protein could be loaded onto a gel for Western blotting. The 
concentration of the extracted proteins were measured using the PierceTM BCA 
Protein Assay Kit (ThermoFisher) following the manufacturer’s instructions. In brief, 
Albumin Standard (bovine serum albumin – BSA) was diluted using a diluent supplied 
in the kit to make up a series of protein standards (0-1.4 mg/ml). The standards and 
unknown samples were each pipetted into microplate wells in 5 µl volumes, with 250 
µl of Working Reagent added. The expression was read on a BioRad iMark microplate 
reader between 5 and 45 minutes after adding the working reagent.  
 63 
 
2.4.2 SDS-PAGE and Western Blotting 
 
SDS-PAGE and Western blotting were performed using a Mini-PROTEAN Tetra cell 
system (BioRad). Proteins were loaded with 1x sample buffer (Sigma) on a 10 % 
acrylamide gel and were separated according to size using gel electrophoresis in 
Running Buffer (2.5 mM Trizma, 2 mM Glycine)(130 V, constant voltage, 50 minutes). 
The gel, PVDF membrane (GE Healthcare Life Sciences), and sponges were soaked in 
transfer buffer. The PVDF membrane was activated by soaking in methanol for 10 
seconds. The proteins were transferred to the membrane in a wet electroblotting 
tank for 1-1.5 hours at a constant voltage (150 mA) in Transfer Buffer (20% Propanol, 
25 mM Tris, 192 mM Glycine). The membrane was then blocked by rotating for one 
hour at 4 °C in Blocking Buffer (5% milk, PBS-TWEEN (0.1%)) and then washed three 
times with Washing Buffer (PBS-TWEEN 0.1%). Specific proteins were targeted by 
incubating the membrane with blocking buffer containing the primary antibody 
overnight. The membrane was then washed three times for five minutes each with 
Washing Buffer. The membrane was incubated with blocking buffer containing the 
secondary antibody by rocking at 4 °C for one hour, followed by three washes. The 
bound antibodies were then detected using ECLTM Western Blotting Detection 
Reagents (Sigma) according to the manufacturer’s instructions. The signal was 
detected using a Vilber Fusion-SL.  
 
Table 2.11 Western blotting antibodies. 
Antibody (Primary) Source Dilution 
Anti-MITF (Rabbit polyclonal) MERCK – HPA003259 1:250 
Anti-SOX10 (Mouse monoclonal) Santa Cruz – (A-2) sc-365692 1:1000 
ß-actin (Mouse monoclonal) Santa Cruz – (C4) sc-47778 1:200 
Antibody (Secondary)   
Goat anti-rabbit IgG-HRP (Goat 
polyclonal) 
Santa Cruz – (SC-2004) 1:5000 
Goat anti-mouse (Goat 
polyclonal) 








The number of colonies grown in the soft agar assays were quantified using ImageJ 
2.0. Initially, contrast between colonies and background was increased and 
background removed using GIMP image editor. The file of interest was then imported 
into ImageJ and converted to 32-Bit. The ‘Threshold’ was set to the same level for 
each replicate. Colonies counted were selected based on settings for ‘Analyse 
Particles’ at a Size of 3-Infinity, Circularity of 0.80-1.00, and selected to show the 
Overlay masks so that any debris or background was not counted. Any colonies 




Total RNA was prepared in triplicate from DIRC3 ASO-GapmeR and CRISPRi 
knockdown, as well as IGFBP5 ASO-GapmeR knockdown, SKmel28 cells using the 
GeneJET RNA purification Kit (ThermoFisher Scientific)(Section 2.3.1). The Illumina 
HiSeq4000 (Novogene) was used to perform PolyA selected 150-bp paired-end RNA 
sequencing with a minimum depth of 30M mapped reads generated per sample. 
Computational analysis of gene expression analysis was performed by Michael 
Shapiro (University of Bath) for ASO-GapmeR knockdown and Yihong Jennifer Tan 
(University of Lausanne) for CRISPRi knockdown.  Using trim_galore version 0.4.4, 
data was cleaned for adapters and low-quality sequence ends. The cleaned data was 
then aligned using FLASH v1.2.11 and mapped to the hg19 genome using bowtie 
version 1.1.2. The human gene annotation file was acquired from Gencode (v19, 
genome assembly hg19) and data was aligned to these annotations using the 
Bioconductor package GenomicAlignments version 1.34.0 function. Using the 
Bioconductor package DESeq2 (R version 3.5.0, DESeq version 1.22.2) data was 
statistically analysed using default settings. Differential expression of genes was 
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analysed between the knockdown and control groups. P-values were adjusted by the 
Benjamini-Hochberg method, controlling for false discovery rate (FDR). 
 
2.5.3 GO analysis 
 
The Bioconductor package GOstats function hyperGtest was used for Gene Ontology 
analysis of RNA-seq data. A background dataset was generated from a list of all the 
genes expressed in SKmel28 cells. The resulting p-values were used to generate FDR 
cut-offs using the brainweaver package function. 
 
2.5.4 Gene expression analysis of TCGA melanoma RNA-seq data 
 
Analysis of RNA-seq data from The Cancer Genome Atlas (TCGA) melanoma (SKCM) 
data was performed by Pakavarin Louphrasitthiphol (Ludwig Institute Oxford). The 
data was accessed via the cBioportal for Cancer Genomics 
(http://www.cbioportal.org) and retrieved using the CGDS-R package 
(project.org/web/packages/cgdsr/index.html). Gene expression values were 
recovered as RPKM (reads per kilobase of transcript per million mapped reads) 
normalised read counts. Samples were ranked based on increasing expression value 
of the gene of interest, or mean expression for genes from a response signature, (x-
axis) and then plotted as a black line representing relative expression. The relative 
expression of DIRC3 (y-axis) in each sample was plotted as a bar graph, shown in light 
grey, with a moving average line based on a sample window of 20. The Spearman 
correlation coefficient and P-value for the correlation between genes of interact were 





Chapter 3: Selection of DIRC3 as an MITF-SOX10 regulated 
intergenic lncRNA dysregulated in cutaneous melanoma  
 
3.1 Introduction  
 
Thousands of lncRNAs have dysregulated expression in various cancers, a subset of 
which have been found to hold functional roles. Using genome-wide approaches, 
such as RNA-seq and ChIP-seq, it is possible to identify lncRNAs that have altered 
transcription between healthy and diseased tissues of the same organ (Iyer et al. 
2015, Yan et al. 2015). While the number of annotated lncRNAs has continued to 
increase, functional annotation is still very limited. It is likely that not all identified 
lncRNAs are functional and instead are a result of spurious transcription. However, 
with thousands of novel lncRNAs being identified, there are potentially large 
numbers which have important roles in regulating cellular processes (Palazzo and Lee 
2015). Due to the vast number of lncRNAs present in the human genome, 
bioinformatic pipelines allow prioritisation of a subset for further study based on 
specific criteria. By integrating a range of datasets, such as RNA-seq and ChIP-seq, the 
likelihood of identifying functionally relevant lncRNAs is increased. When at a more 
manageable number, selected candidates can be functionally validated using 
experimental techniques.  
 
LncRNAs are often categorised based on their proximity to nearby protein-coding 
genes. The largest of these categories are intergenic lncRNAs whose loci do not 
overlap protein-coding genes (Derrien et al. 2012). An advantage of studying 
intergenic lncRNAs is they are easier to specifically knockdown or amplify without the 
risk of indirectly targeting neighbouring protein-coding genes due to them not 
overlapping other genes. Of this category, some are known as enhancer- or 
promoter-associated transcripts based on them overlapping such regulatory 
elements and having precise patterns of H3 lysine 4 mono- and trimethylation (Ørom 
et al. 2010, Fufa et al. 2015, Hon et al. 2017). Such lncRNAs function through 
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controlling the activity of these elements. Enhancer-associated lncRNAs have been 
identified that function through multiple proposed mechanisms including 
manipulating chromosomal configuration and bringing regulatory elements together 
(Lam et al. 2014). Aberrant increase or reduction in the expression of lncRNAs due to 
disrupted regulation (such as by oncogenes), or mutations by copy number alteration 
or small nucleotide polymorphism, can lead to the occurrence of diseases including 
cancer (Yan et al. 2015, Chaudhary and Lal 2017, Fernando et al. 2017). Numerous 
intergenic lncRNAs have already been studied in different cancers, including 
melanoma. Such lncRNAs include BANCR, MALAT1, and SAMMSON, each of which 
have been found to participate in key melanoma functions, including cell migration, 
survival and metastasis (Flockhart et al. 2012, Tian et al. 2014, Leucci, Vendramin, et 
al. 2016).  
 
Many cancer-associated lncRNAs expression is regulated by tumour suppressors and 
oncogenes, such as p53 and MYC (Chaudhary and Lal 2017, Iaccarino 2017). MITF is 
a key transcription factor involved in the regulation of melanocyte development and 
melanoma. Acting as a lineage addiction oncogene, MITF is amplified in roughly 10-
30% of melanoma cases. This number is larger for individuals with metastatic disease, 
leading to an association between MITF and worse patient survival (Garraway et al. 
2005). MITF positively regulates expression of genes important in cell differentiation 
and proliferation, while repressing those with roles in invasion and motility (Carreira 
et al. 2006, Strub et al. 2011, Verfaillie et al. 2015). Its expression is also activated by 
SOX10 which has previously been identified in all primary and the majority of 
metastatic melanomas (Shakhova et al. 2012, Graf et al. 2014) where it can regulate 
genes important in cell survival proliferation and invasion (Cronin et al. 2013, 
Verfaillie et al. 2015). Several thousand binding sites are co-occupied by MITF and 
SOX10, resulting in their joint control of gene programmes involved in melanocyte 
development and melanoma (Laurette et al. 2015). A number of key features for their 
joint roles in melanoma have already been identified. A rheostat model for MITF 
function has previously been proposed in which low MITF expression is identified in 
proliferative cells and elevated MITF in invasive cells, while cells in which MITF is 
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almost absent undergo senescence (Hoek and Goding 2010). High SOX10 was later 
identified as another feature of proliferative cells (Verfaillie et al. 2015). 
Consequently, melanoma cells are able to phenotypically switch between these 
states under the control of MITF and SOX10, likely in response to environmental 
signals (Verfaillie et al. 2015, Kawakami and Fisher 2017). These distinct cell states, 
characterised by variations in MITF and SOX10 levels of expression, may also 
influence resistance of melanoma cells to MAPK pathway inhibitors (Konieczkowski 
et al. 2014, Sun et al. 2014). Little is currently known about the role of lncRNAs within 
the MITF-SOX10 transcriptional programmes.  
 
3.1.1 Chapter Summary 
 
This chapter focusses on identifying and beginning to characterise candidate 
melanoma-expressed intergenic lncRNAs that may have a functional role in 
melanoma. A key feature for candidate melanocyte- or melanoma-expressed 
lncRNAs is that they are bound and regulated by the melanoma oncogene MITF. 
Dysregulated in renal carcinoma 3 (DIRC3) was prioritised for further 
characterisation. Upon exploration of the DIRC3 locus, the lncRNA was found to be 
surrounded by two genes, IGFBP5 and TNS1, with known tumour suppressive roles. 
DIRC3 was also discovered to be regulated by the melanoma factor SOX10 and its 
locus was shown to harbour a number of MITF-SOX10 co-occupied binding sites. 
Using a combination of data from The Cancer Genome Atlas, and analysis of cancer 
cell lines, DIRC3 was identified as a potential tumour suppressor in melanoma that is 





3.2.1 Identification of intergenic lncRNAs bound by MITF and expressed in 
melanoma and/or melanocyte cell lines  
 
In order to identify novel melanoma-expressed lncRNAs, a pipeline was devised to 
classify lncRNAs that are located between protein-coding genes (intergenic), 
expressed in melanoma and/or melanocyte cell lines, and contain binding sites for 
the oncogene MITF. It was hypothesised that lncRNA holding these features may act 
as novel drivers or inhibitors of melanoma development and progression.  
 
RNA-sequencing (RNA-seq) analysis was used to identify and catalogue intergenic 
lncRNAs that are expressed in melanoma and/or melanocyte cell lines. Intergenic 
lncRNAs were selected solely based on their sequences not overlapping protein 
coding sequences, independent of distances between them. Two BRAFV600E mutated 
melanoma cell lines (IGR37 and IGR39) from the same patient and a melanocyte cell 
line (Hermes) were investigated. IGR37 cells are MITF-high and non-invasive (Luis et 
al. 1989) while IGR39 cells are MITF-low, de-differentiated and invasive 
(Konieczkowski et al. 2014). These cells were used as they represent different stages 
of the disease. Also, with them being derived from the same individual, any changes 
in expression observed could be associated with disease stage rather than patient 
sample. LncRNAs with altered expression in at least one of the melanoma or 
melanocyte cell lines were selected. Using this method, a catalogue of 11881 
intergenic lncRNAs was assembled. A selection of these would later be further 
characterised in human melanoma cell lines sourced from other patients to confirm 
broad expression of the lncRNAs in melanoma.  
 
Once lncRNAs expressed in melanoma and melanocyte cells were identified, those 
that are likely to be regulated by MITF were selected based on the presence of MITF 
binding sites within their promoters or loci. To do this, the RNA-seq data was 
combined with ChIP-sequencing (ChIP-seq) data mapping HA-tagged MITF binding 
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sites genome-wide in the melanoma cell line 501mel (Laurette et al. 2015). The ChIP-
seq peaks were ranked in order of decreasing strength. Peaks that were less than 
those identified for experimentally characterised functional MITF binding sites within 
promoter regions were removed to decrease the likelihood of including false 
positives for MITF binding. Subsequently, strong binding sites for MITF were 
identified in 1196 melanoma-expressed lncRNAs. A subset of lncRNAs were 
prioritised based on the proximity of their loci to key melanoma transcriptional 
regulators. Such guilt-by-association analyses is based on the prediction that the 
function of a lncRNA can be proposed based on the function of a local, or co-
expressed, known protein-coding gene (Guttman et al. 2009, Huarte et al. 2010). 
 
Following these selection steps (summarised in Figure 3.1), 12 candidate intergenic 
lncRNAs were prioritised that were predicted to play an important role in mediating 
the MITF transcriptional response in melanoma (Table 3.1). These experiments were 
























Figure 3.1 Pipeline for identification of candidate intergenic lncRNAs whose genomic loci 
are bound by MITF in melanoma. RNA-seq of melanoma (IGR39 and IGR37) and melanocyte 
(Hermes) cell lines were used to identify expressed lncRNAs. Using ChIP-seq, lncRNAs with 
MITF binding sites across their loci were identified. Final candidates were selected based on 
their location within cancer susceptibility regions or proximity to oncogenes/tumour 
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Table 3.1 Prioritised 12 MITF-bound melanoma-expressed lncRNA candidates. A list of 
intergenic lncRNAs with proposed MITF binding sites, their neighbouring genes and cancer-




Closest protein-coding gene Cancer-associated copy number 
alteration 5’ 3’ 
MelncRNA1 DENND6A SLMAP - 
MelncRNA4 LRRC37B SUZ12 - 
MelncRNA7 JUNB HOOK2 19p13.2 amplification (AML) 
MelncRNA9 HES1 OPA1 - 
MelncRNA11 EN2 INSIG1 - 
MelncRNA13 POU2F2 DEDD2 - 
MelncRNA17 PTPN1 CEBPB - 
CASC11 MYC POU5F1B 8q24.21 amplification (SKCM) 
DANCR USP46 ERVMER34-1 - 
DIRC3 IGFBP5 TNS1 2q37.1 deletion  
(COAD, HNSC, LUSC, LUAD) 
NEAT1 FRMD8 MALAT1 11p11.2 deletion (SKCM) 
STK4AS STK4 TOMM34 - 
 
3.2.2 MITF represses CASC11, DANCR, DIRC3, and NEAT1 lncRNAs in 501mel 
melanoma cells  
 
By using cell lines generated from a single melanoma patient (IGR37, IGR39) to 
identify expressed lncRNAs, it is not clear whether the proposed candidates are 
restricted to that individual. Using Real-time quantitative PCR (RT-qPCR), lncRNA 
expression profiling was performed in additional melanoma (501mel, SKmel28) and 
melanocyte (Hermes1) cell lines to identify lncRNAs that are more widely expressed 
in melanoma. The SKmel28 and 501mel immortalised cutaneous melanoma cell lines 
were derived from metastatic sites (lymph nodes) of a male and female patient 
respectively and both contain the BRAFV600E mutation. The Hermes1 cell line is a 
telomerase immortalised melanocyte cell line.  
 
Each of the candidates shows expression in at least one of the cell lines in addition to 
those used for RNA-seq (Figure 3.2). Their expression varies by seven orders of 
magnitude, making it possible to group according to low, medium, and high levels of 
expression. LncRNAs CASC11, DIRC3, STK4AS, MelncRNA7, MelncRNA9, and DANCR 
show increased expression in both melanoma cell lines compared to Hermes1. 
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Consequently, the pipeline successfully identified lncRNAs that are expressed in 
multiple cell lines. These lncRNAs may play a general role in the regulation of 
melanoma initiation and/or progression.  
 
Figure 3.2 Profiling expression of candidate intergenic lncRNAs for melanocyte and 
melanoma cell lines. RNA was extracted from melanocyte (Hermes1) and melanoma 
(501mel and SKmel28) cell lines and expression of candidate lncRNAs measured using RT-
qPCR. Based on relative expression levels, the lncRNAs are grouped as Low, Medium, or High. 
Data is presented relative to POLII expression. Mean  SE N=3 Biological Replicates. One-
















































































































Another key feature of these prioritised candidate lncRNAs is that they are targeted 
by MITF. While they contain MITF binding sites within the loci, identified using ChIP-
seq, this does not mean they are regulated by the transcription factor. It has 
previously been recognised that transcription factor binding to DNA is frequently 
insufficient to influence transcription (Zhou and O’Shea 2011). By knocking down 
MITF expression it is possible to identify which of the prioritised lncRNAs are 
regulated by MITF and so are downstream components of the MITF gene expression 
network.  
 
To identify direct transcriptional targets of MITF, knockdown of the transcription 
factor was performed using siRNAs. Western blotting and RT-qPCR were utilised to 
confirm knockdowns and determine changes in expression of candidate lncRNAs 
relative to a non-targeting control (siCtrl). Two siRNAs targeting MITF (siMitf1, 
siMitf2) were used to account for off-target effects. In accordance with the ChIP-seq 
data, 501mel cells were used. 
 
Following siRNA knockdown, expression of MITF mRNA and protein were significantly 
reduced (Figure 3.3a,b). Greater than a two-fold increase in expression with at least 
one siRNA was observed for CASC11, DANCR, DIRC3, and NEAT1 following MITF 
knockdown (Figure 3.3c). Consequently, these were predicted to be the most strongly 
regulated by MITF. The different efficiencies at which the siRNAs worked, resulting in 
a 45% and 58% knockdown in mRNA, also meant dosage responses could be 
observed. Generally, there is a greater increase in lncRNA expression following the 
larger knockdown of MITF. It should be noted that lncRNA expression typically only 
showed a significant change for siMitf1, suggesting changes could be the result of off-
target effects. However, the general pattern of expression still suggests MITF 
negatively regulates expression of the lncRNAs. In addition, expression of linc00152 
was measured as a control lncRNA whose expression should not be regulated by 
MITF. Accordingly, this lncRNA showed little change following MITF depletion. 
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Figure 3.3 MITF negatively regulates the expression of multiple candidate lncRNAs. 501mel 
cells were transfected with siRNAs targeting MITF (siMitf1 or siMitf2) or a non-targeting 
control (siCtrl). Three days following transfection, the efficiency of MITF knockdown and 
corresponding changes in lncRNA expression were measured. (A) MITF mRNA levels were 
measured using RT-qPCR. (B) MITF protein expression was measured using Western Blotting. 
Equal concentrations of extracted protein were confirmed using ACTIN as a loading control. 
Representative figure given. (C) Intergenic lncRNA expression was measured using RT-qPCR. 
Results were normalised to POLII and presented relative to expression in the siCtrl. Mean  
SE N=3 Biological Replicates. One-tailed Student’s t-test p<0.05 = * P<0.01 = **  
 
While the majority of lncRNAs showed a slight increase following reduced MITF 
expression, four candidates showed a robust increase suggestive of direct repressive 
regulation by the oncogene. This confirms that the pipeline is able to identify 


































































have previously had roles identified in cancer, melanoma, or skin development (Table 
3.2). 
 
Table 3.2 Previously identified roles in cancer for candidate intergenic lncRNAs regulated 
by MITF in 501mel. Of the 12 melanoma-expressed lncRNAs, only those with equal to or 
greater than two-fold increase in expression following MITF depletion were categorised as 
experiencing strong repression by MITF.  
Candidate Features 
CASC11 Expression positively correlates with MYC and is an identified oncogene in 
cancers including colorectal and bladder cancer (Zhang 2019; Amir 2019) 
DANCR Oncogenic lncRNA that is overexpressed in a wide range of cancers regulating 
cell proliferation, invasion and metastasis. (Zar Thin 2018)  
DIRC3 Locus is deleted in renal cell cancer (Bodmer 2003).  
NEAT1 Is an oncogenic target of p53 and is found to promote skin tumorigenesis 
(Adriaens et al., 2016) 
 
NEAT1 has previously been identified as a regulator of skin cancer by preventing 
excessive DNA damage by inducing paraspeckle formation (Adriaens et al. 2016). 
Consequently, the 2.2-fold increase in NEAT1 expression following reduced MITF, as 
well as increased expression in SKmel28 compared to Hermes1, validate the use of 
this pipeline to identify candidate lncRNAs involved in melanoma.  
 
DIRC3 was selected for further study because it is a previously uncharacterised 
lncRNA whose locus is positioned close to two genes implicated with tumour 
suppressive roles. DIRC3 was the most strongly repressed candidate by MITF, 
experiencing a 2.5-2.7-fold increase in expression upon MITF depletion. The lncRNA 
also showed high expression in both 501mel and SKmel28 melanoma cell lines 
compared to the Hermes1 melanocyte cell line.  
 
3.2.3 Initial characterisation of DIRC3 in melanoma 
 
The DIRC3 transcript and locus were further characterised to begin to investigate 
DIRC3 in melanoma. The eight-exon intergenic lncRNA DIRC3 (Dysregulated in Renal 
Carcinoma) (ENSG00000231672) is found on chromosome 2, spanning a region of 
~500 Kb. DIRC3 is also located between genes implicated in tumorigenesis (Figure 
3.4). IGFB5 (insulin-like growth factor-binding protein 5) is located roughly 600 kb 
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downstream of DIRC3 and is a melanoma tumour suppressor able to regulate cell 
migration, invasion, and anchorage-independent growth (Wang et al. 2015). 
Expression of IGFBP5 has also been associated with increased survival in patients with 
breast cancer, osteosarcoma (Ahn et al. 2010, Su et al. 2011). TNS1 (Tensin1) is 
located roughly 40 kb upstream of DIRC3. The protein is known to localise in and 
regulate focal adhesions where it participates in the control of cell migration (Chen 
et al. 2002). TNP1 (Transition protein-1) is also located within close proximity to 
DIRC3. However, this gene is important in sperm development and is only expressed 
in cells containing a haploid genome resulting in it not being of interest in this study 
(Luerssen et al. 1990). 
 
The DIRC3 transcript was mapped in SKmel28 using Rapid Amplification of cDNA Ends 
(RACE) coupled with RT-qPCR. Using this method, the precise 5’ and 3’ ends and most 
prevalent isoform of DIRC3 were identified. The SKmel28-expressed isoform is 3384 
nucleotides long and still contains eight exons but is expressed from an alternative 
transcription start site (TSS) (Figure 3.4a). This TSS is located within the first intron of 
the previously annotated DIRC3 (RefSeq gene NR_026597) resulting in a novel shorter 
isoform of DIRC3. The remainder of the transcript is the same. The validation of 5’ 
and 3’ ends also confirms DIRC3 is truly intergenic as it does not overlap with its 
neighbouring genes. 
 
Located between the IGFBP5 and TNS1 protein-coding genes in the mouse genome, 
there is a positionally equivalent gene for DIRC3 (Figure 3.4b). The positional 
conservation of DIRC3 and its neighbouring genes in mice suggest they may play an 








Figure 3.4 Schematic representation of human and mouse DIRC3 loci and neighbouring 
genes in human SKmel28 and mice. (A) DIRC3 is located on the reverse strand of 
chromosome 2 (GRCh37/hg19). The transcript lies between the protein-coding genes IGFBP5 
(600 kb downstream) and TNS1 (40 kb upstream). Using RACE, the precise 5’ and 3’ ends of 
the DIRC3 sequence were identified. 5’RACE revealed a novel TSS within the first intron of a 
previously annotated DIRC3. 3’RACE remained the same as previously annotated DIRC3 
isoforms. Novel isoform – Black. Previously identified DIRC3 (RefSeq gene NR_026597) – 
Purple. (B) DIRC3 is located on the reverse strand of chromosome 1 (GRCm38/mm10). The 
transcript lies between the protein-coding genes IGFBP5 and TNS1. 
(https://genome.ucsc.edu). 
 
The importance of the DIRC3 locus in cancer was initially explored by observing the 
frequency with which the locus is perturbed in cancer. Alterations to gene expression 
caused by small changes such as single nucleotide polymorphisms (SNPs) and 
deletions can result or participate in the occurrence of numerous diseases, including 
cancer (Yan et al. 2015). Using The Cancer LncRNome Atlas (TCLA), the DIRC3 locus 
was identified within the cancer susceptibility region (2q37), which is deleted 
multiple cancer types (Table 3.1) (tcla.fcgportal.org). This region is also a known 
chromosomal breakpoint for a family prone to renal carcinoma (Bodmer et al. 2003). 
Since tumour suppressive loci are typically lost in cancers, the deletion of DIRC3 locus 
suggests that it could act as a putative tumour suppressor in cancer.  
 
Table 3.3 DIRC3 locus is deleted in multiple cancers. Deletion of the DIRC3 locus was 
identified using the Cancer LncRNome Atlas (TCLA) (tcla.fcgportal.org) 
Cancer Type DIRC3 locus 
Colon Adenocarcinoma (COAD) Deleted 2q37.2(chr2:214015746-243199373) 
Head and Neck Squamous Cell Carcinoma 
(HNSC) 
Deleted 2q37.2(chr2:214015746-243199373) 
Lung Adenocarcinoma (LUAD) Deleted 2q37.2(chr2:214015746-243199373) 





The expression correlations of lncRNAs with different classes of protein-coding genes 
have been used to predict lncRNA function. Analysis of RNA-seq for cutaneous 
melanoma patient from the Cancer Genome Atlas (TCGA) was performed by 
Pakavarin Louphrasitthiphol at the Ludwig Institute Oxford, identified the top 10 
positively and negatively correlated genes with DIRC3. Several of the genes positively 
correlated with DIRC3 expression behave as tumour suppressors, including IGFBP5, 
PLAGL1, and NDRG4 (Valleley et al. 2007, Melotte et al. 2009, Wang et al. 2015). The 
genes negatively correlated with DIRC3 expression include the melanoma factor 
SOX10 as well as the oncogene VEGFB (Silvestre et al. 2003, Tudrej et al. 2017). DIRC3 
is also inversely correlated with TYR and MLPH, both of which participate in pigment 
production (Iozumi et al. 1993, Matesic et al. 2001). 
 
The identification of genes whose expression correlates either positively or 
negatively with DIRC3 suggests they may regulate, or be regulated by, DIRC3. Of 
those genes, the presence of regulatory factors involved in melanoma, such as 
IGFBP5 and SOX10 respectively, support the suggestion that DIRC3 may also 
participate in regulating melanoma. Finding that DIRC3 positively correlates with 
known tumour suppressors and negatively with oncogenes, are consistent with the 
proposed role of DIRC3 as a tumour suppressor.  
 
Table 3.4 Top 10 positively and negatively correlated genes with DIRC3 expression in 
melanoma. Using data from TCGA based on patients with cutaneous melanoma, expression 
of most highly positively and negatively correlated genes with DIRC3 were selected. Analysis 
performed by Pakavarin Louphrasitthiphol (Ludwig Institute Oxford). 
 













3.2.4 Increased DIRC3 expression associates with improved patient survival 
 
Although the DIRC3 locus is disrupted in multiple cancers and its expression 
correlates with genes important to melanoma, a direct link between DIRC3 and 
melanoma has not yet been discovered. By looking at the relationship between DIRC3 
expression and patient survival it is possible to observe whether changes in 
expression of the lncRNA can be used to classify how aggressive or advanced the 
cancer is. Using OncoLnc, melanoma patients were separated based on DIRC3 
expression (using the top 33% showing high DIRC3 expression versus the bottom 33% 
showing lowest DIRC3 expression). The curve was created based on clinical RNA-seq 
data of human skin cutaneous melanoma patients from TCGA (Anaya 2016). 
Associated clinical data was then used to generate a survival curve. Melanoma 
patients expressing higher levels of DIRC3 showed a significant increase in survival 
compared to those expressing low DIRC3 (Figure 3.5). The increased expression of 
DIRC3 in longer surviving patients suggests DIRC3 may have a role as a tumour 
suppressor. However, it is not possible to tell from this figure whether DIRC3 plays a 
functional role in promoting survival or is a bystander effect. If DIRC3 is found to be 
functional, there may be future options to promote expression of DIRC3 in melanoma 
patients as a new therapy. However, if no functional role is identified for DIRC3, the 
lncRNA could still be used as a biomarker to predict survival of a patient or be used 





Figure 3.5 Melanoma patients expressing higher DIRC3 survive longer. OncoLnc generated 
a Kaplan-Meier plot for SKCM patients. Patients were sorted based on DIRC3 expression and 
percent survival compared between DIRC3 high (Red - top third) and DIRC3 low (Blue - 
bottom third) groups. Low DIRC3 expression was found to correlates with statistically 
significant decreased survival in melanoma patients based on Cox regression analysis 
(logrank p-value=0.0263) (Anaya 2016). 
 
3.2.5 DIRC3 is expressed in additional cancer cells 
 
 
LncRNAs are known for typically having more restricted expression than protein-
coding genes (Fatica and Bozzoni 2014). This is a feature that makes them promising 
therapeutic targets and biomarkers. To see whether DIRC3 expression is restricted to 
melanoma, the presence of this lncRNA in different tumours types, as well as their 
healthy counterparts, was explored.  
 
Using Gene Expression Profiling Interactive Analysis 2 (GEPIA 2), expression of DIRC3 
was explored. The programme used RNA-seq expression data from 9736 tumours and 
8587 normal samples which were collated from TCGA and GTEx projects (Tang et al. 
2019). The expression profile of DIRC3 was given as a bar plot for 33 tumour and 
equivalent healthy tissue samples (Figure 3.6). DIRC3 expression is detected in the 
majority of normal and tumour samples, suggesting the lncRNA could have a more 
general role in regulation of cancers. In addition, the majority of tumours showed a 
clear reduction in DIRC3, suggesting reduced DIRC3 expression is associated with the 
Logrank p-value = 0.0263 
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occurrence of cancer, as would be observed for a tumour suppressor. This is observed 
in the case of skin cutaneous melanoma (SKCM) as well as a range of other cancers 
including uterine carcinosarcoma (UCS), rectum adenocarcinoma (READ), and 
adrenocortical carcinoma (ACC). 
 
Figure 3.6 DIRC3 is expressed in a broad range of tissues and is typically reduced in tumours. 
GEPIA 2-generated bar chart representing RNA-seq data for DIRC3 expression in tumour and 
matched normal samples from a range of human tissue types. Expression measured as 
Transcripts Per Million (TPM) (Tang et al 2019).  
 
3.2.6 DIRC3 is transcriptionally regulated by MITF and SOX10 in melanoma.  
 
The role of lncRNAs within MITF-SOX10 regulated transcriptional programmes is 
poorly understood. Both MITF and SOX10 play vital roles in regulating transcriptional 
programmes important in melanoma proliferation, invasion, and metastasis 
(Garraway et al. 2005, Graf et al. 2014, Verfaillie et al. 2015). While the identification 
of MITF-targeted lncRNAs was a key component during the initial selection of 
lncRNAs of interest, binding of DIRC3 by SOX10 as well as MITF would be a strong 
indicator of DIRC3 having a functional role in melanoma. MITF-SOX10 co-occupancy 
may define active regulatory elements, such as enhancers, important to melanoma 
(Fufa et al. 2015).  
 
By integrating melanoma ChIP-seq data for HA-tagged MITF and SOX10 in 501mel 
(Laurette et al., 2015), 279 lncRNA, including DIRC3, were found to harbour putative 
co-occupied binding sites of the two transcription factors within their loci. Of these, 
34 were promoter bound and 245 identified within the gene bodies. The melanoma-
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expressed SKmel28 DIRC3 isoform contains three sites of MITF-SOX10 co-occupancy 
(Figure 3.7). One of these sites is present upstream of the promoter and the 
remaining two are within the gene body. There are also three additional MITF, and 
one SOX10, individual binding sites. 
 
The presence of SOX10 binding alongside MITF within the promoter region of DIRC3 
suggest that the lncRNA may also be regulated by SOX10. Since only a small 
proportion of lncRNAs bound by MITF and SOX10 hold sites of co-occupancy, it was 
proposed that these may more likely possess functional roles. Binding sites across the 
DIRC3 locus also suggest the presence of regulatory elements that DIRC3 may 
subsequently be able to regulate binding to. Consequently, DIRC3 may not only be 
targeted by MITF and SOX10 but may also regulate their transcriptional response 
through regulating accessibility for their binding to sites across its locus.  
 
 
Figure 3.7 Three sites of MITF-SOX10 co-occupancy are located across the DIRC3 locus. 
UCSC Genome Browser (GRCh37/hg19) view of ChIP-seq-identified binding sites for MITF and 
SOX10 across the DIRC3 locus in 501mel (Laurette, Strub 2015). There are three sites of co-
occupancy (highlighted in blue). One binding site is upstream of the TSS, while the other two 
are within introns of the gene body. MITF and SOX10 also have three and one additional 
individual binding sites respectively (Laurette et al. 2015) (Figure generated from UCSC 
Genome Browser - https://genome.ucsc.edu).   
 
Although MITF inhibits DIRC3 expression in 501mel (Figure 3.3), it does not mean this 
mechanism is shared between melanoma cells. Knockdown of MITF using siRNAs was 
performed in SKmel28 cells to confirm commonality of the regulatory interaction. 
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Observation of the behaviour in multiple cancer cell lines or patient samples would 
suggest that DIRC3 participates in melanoma as part of the MITF response pathway.  
 
The MITF-DIRC3 expression correlation was first explored in cutaneous melanoma 
patients using RNA-seq data from TCGA (data generated by Pakavarin 
Louphrasitthiphol, Ludwig Institute Oxford). Using this method, it is possible to 
propose whether the MITF repression of DIRC3 is observed in melanoma patients. A 
negative correlation between MITF and DIRC3 is shown (Figure 3.8a), supporting the 
identified inhibitory effect MITF has on DIRC3 in 501mel. Knockdown of MITF using 
siRNAs was also performed in SKmel28. Knockdown of MITF in SKmel28 resulted in 
an 11-18% reduction in mRNA and a clear reduction in protein (Figure 3.8b,c). This 
reduction in MITF was enough to cause a 39-48% increase in DIRC3 expression (Figure 
3.8b) suggesting an inhibitory effect of MITF on DIRC3. Together, this data informs 











Figure 3.8 MITF represses DIRC3 expression. (A) TCGA RNA-seq data for 471 melanoma 
patients were ordered based on increasing levels of MITF expression. The bold lines 
represent the moving averages and vertical grey bars show absolute DIRC3 expression for 
each melanoma sample. Expression correlation data generated by Pakavarin 
Louphrasitthiphol, Ludwig Institute Oxford (B, C) SKmel28 cells were transfected with siRNAs 
targeting MITF (siMitf1 or siMitf2) or a non-targeting control (siCtrl). Three days following 
transfection, the efficiency of knockdown and corresponding level of DIRC3 expression were 
measured. (B) Level of MITF and DIRC3 expression were measured using RT-qPCR. Results 
were normalised to POLII and presented relative to expression in the siCtrl. Mean  SE N=3 
Biological Replicates. One-tailed Student’s t-test p<0.05 = * P<0.01 ** (C) Level of MITF 
protein expression was measured using Western Blotting. Equal concentrations of extracted 
protein were confirmed using ACTIN as a control. A representative figure is given. 
 
The presence of SOX10 binding sites within the promoter region of DIRC3 suggest 
that it may also be regulated by SOX10. Using data from TCGA for cutaneous 
melanoma patients (data generated by Pakavarin Louphrasitthiphol, Ludwig Institute 
Oxford), SOX10 was found to be amongst the top 10 negatively correlated genes with 































DIRC3 expression (Figure 3.9a). Together this data suggests SOX10 may play an 
important role in negatively regulating expression of DIRC3. 
 
To test whether SOX10 directly regulates expression of DIRC3, knockdown of SOX10 
was performed in the melanoma cell lines 501mel and SKmel28 (as for MITF) using 
esiRNAs. esiRNAs contain a heterogeneous mixture of siRNAs targeting the same 
mRNA sequence so only one sample of esiRNAs is required for knockdown as fewer 
off-target effects occur than when using single siRNAs (Theis and Buchholz 2010). The 
knockdowns were compared against cells transfected with esiRNA targeting 
Luciferase (esiLuc) so that any changes that occur due to the transfection of the 
esiRNAs alone were accounted for. Knockdown of SOX10 in 501mel resulted in a 71% 
in mRNA and clear reduction in protein. This also led to a reduction in expression of 
DIRC3 by 71% (Figure 3.9b,c). Knockdown of SOX10 in SKmel28 was not as efficient, 
reaching a 24% reduction for mRNA and slight reduction for protein. In this case, 
there was a 2.4-fold increase in DIRC3 expression (Figure 3.9d,e). This supports the 
inverse relationship identified using TCGA RNA-seq data.  
 
The reduction in DIRC3 following SOX10 knockdown in 501mel could be the result of 
the different expression programmes in different cell types resulting in SOX10 
activating rather than repressing DIRC3 expression. Also, the far greater knockdown 
than observed for SKmel28 could have initiated a compensatory transcriptional 
response allowing induction of other pathways which would suppress DIRC3 
expression when SOX10 is not present. With the combination of TCGA and SKmel28 
knockdown data, there is still strong evidence that DIRC3 is a direct transcriptional 
target of both SOX10 in melanoma.  
 
Overall, MITF and SOX10 regulate expression of DIRC3 in melanoma. This suggests 




Figure 3.9 SOX10 typically represses DIRC3 expression in melanoma cells. (A) TCGA RNA-
seq data for 471 melanoma patients were ordered based on an increasing level of SOX10 
expression against DIRC3. The bold lines represent the moving averages and vertical grey 
bars show absolute expression for each melanoma sample. Expression correlation data 
generated by Pakavarin Louphrasitthiphol, Ludwig Institute Oxford (B, C, D, E) 501mel and 
SKmel28 cells were transfected with an esiRNA targeting SOX10 (esiSOX10) or non-targeting 
control (esiLuc). Three days following transfection, the efficiency of knockdown and 
corresponding level of DIRC3 expression were measured. For 501mel levels of RNA (B) and 


















































Level of SOX10 and DIRC3 expression were measured using RT-qPCR. Results were 
normalised to POLII and presented relative to esiLuc. Mean  SE N=3 Biological Replicates. 
One-tailed Student’s t-test p<0.05 = * P<0.01 **. Level of SOX10 protein expression was 
measured using Western Blotting. Equal concentrations of extracted protein were confirmed 






The transcription factors MITF and SOX10 are important gene expression regulators 
of melanoma. While their protein-coding targets are well characterised, their non-
protein coding targets are not. Understanding the role of lncRNAs in regulating MITF 
and SOX10 transcriptional responses could reveal new pathways of regulation and so 
offer new therapeutic avenues for treating individuals with melanoma. Following the 
completion of a selection process, DIRC3 was chosen as a likely MITF-regulated 
intergenic lncRNA involved in melanoma. Further characterisation revealed this 
lncRNA to be a multi-exonic transcript regulated by both MITF and SOX10 that has 
features that suggest it may act as a tumour suppressor in melanoma.   
 
Using guilt-by-association, the genes neighbouring DIRC3 (IGFBP5 and TNS1) suggest 
its locus may be within a region with tumour suppressive activity. Tensin proteins are 
known to reside at focal adhesions where they interact with actin filaments and 
regulate actin polymerisation (Lo et al. 1994). Here, they regulate cell adhesion, 
migration and proliferation (Blangy 2017). TNS1 regulates proliferation and migration 
of endothelial cells through the TNS1-DLC1-RhoA signalling pathway (Shih et al. 
2015). It has also been proposed that the tumour suppressive activity of DLC1 is 
dependent on tensin activity (Blangy 2017). The protein-coding gene IGFBP5 
regulates cell proliferation, differentiation and metabolism via IGF1R-dependent and 
-independent methods (Tripathi et al. 2009, Wang et al. 2015, Clemmons 2016). 
IGFBP5 also acts as a tumour suppressor in several cancers, including melanoma, 
osteosarcoma, and breast cancer (Su et al. 2011, Ghoussaini et al. 2014, Wang et al. 
2015). Since functionally related genes are known to cluster together, DIRC3 could 
be predicted to also behave as a tumour suppressor (Thévenin et al. 2014). 
Furthermore, the identification of a strong positive correlation between IGFBP5 and 
DIRC3 could be the result of DIRC3 regulating IGFBP5 expression (or vice versa) or 
that both are regulated by the same factor, such as MITF or SOX10.   
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Genetic alteration of lncRNA loci can also indicate the likelihood of involvement in 
disease. Promoter or enhancer mutations may affect expression of lncRNAs 
(Camacho et al. 2018) whilst mutations within lincRNA exons may affect lncRNA 
structure and ability to bind with its targets (Sabarinathan et al. 2013, Leucci, Coe, et 
al. 2016). Such dysregulation of lncRNA activity can lead to disease-associated 
responses. The DIRC3 locus is deleted in a range of cancers (Table 3.3) and Bodmer 
(2003) also identified a t(2;3)(q35;q21)-associated 2q35 breakpoint that leads to 
disrupted DIRC3 expression in renal carcinoma. Depletion of DIRC3 was also observed 
in the majority of cancers analysed using GEPIA 2. Loss of function mutations leading 
to cancer could suggest tumour suppressive behaviour. The frequency with which 
DIRC3 is dysregulated could also indicate a more general role in cancer regulation. 
Although whether DIRC3 is functional is still to be explored for the majority of the 
cancers mentioned in Table 3.3, DIRC3 has already been proposed to behave as a 
tumour suppressor in renal carcinoma (Bodmer et al. 2003).  
 
Linking DIRC3 expression to clinical outcomes provides a clear positive correlation 
between DIRC3 expression and melanoma patient survival. DIRC3 appears to have a 
potential tumour suppressive effect due to the reduction in its expression correlating 
with reduced patient survival. If functional, DIRC3 could be acting as a tumour 
suppressor inhibiting melanoma progression. By preventing tumour progression to 
more lethal stages, such as metastasis, DIRC3 could increase patient survival. 
Consequently, DIRC3 could be a therapeutic target. By up-regulating expression of 
DIRC3 it may be possible to stop the disease progressing. If DIRC3 is not found to be 
functional, or is not easily targeted therapeutically, the lncRNA could be a biomarker. 
As a biomarker, DIRC3 could predict likelihood of survival or inform which therapeutic 
option is most suitable for a patient.  
 
Increasing numbers of oncogenic and tumour suppressive protein-coding genes are 
being identified that regulate expression of target lncRNAs. The tumour suppressor 
p53 can activate expression of hundreds of lncRNAs, including lincRNA-p21 which 
represses expression of anti-apoptotic genes (Huarte et al. 2010, Chaudhary and Lal 
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2017). The oncogene Myc also regulates numerous lncRNAs including H19 which is 
important in tumour cell transformation (Barsyte-Lovejoy et al. 2006, Iaccarino 
2017). Accordingly, it could be that MITF and SOX10 regulate expression of DIRC3 in 
order to enforce their own oncogenic activity. Their inhibition of DIRC3 is again 
suggestive of the lncRNA behaving as a tumour suppressor. The identification of MITF 
and SOX10 binding sites across the locus of DIRC3 also implies there may be 
regulatory elements present which DIRC3 could regulate MITF and SOX10 
accessibility to. MITF and SOX10 also co-occupy binding sites across a subset of the 
identified intergenic lncRNAs identified in this project. DIRC3 could consequently 
represent a mechanism for regulation of MITF and SOX10 activity via binding sites 
across an intergenic lncRNA locus. DIRC3, and other lncRNAs like it, could 
consequently play an important role in fine-tuning MITF and SOX10 transcriptional 
responses, and so could participate in the regulation of melanocyte and melanoma 
cell state.  
 
Although DIRC3 has features indicative of a tumour suppressor, it is not yet clear 
whether it is a functional lncRNA or not. If not found to be functional, the significant 
difference in melanoma patient survival based on DIRC3 expression suggests DIRC3 
could later be used to inform on melanoma aggressiveness or response to treatment. 
However, if a functional role is found for DIRC3, the lncRNA could be a potential 
therapeutic target for melanoma treatment. Also, DIRC3 could add to our expanding 
understanding of how lncRNA mechanistically work, as well as present an example 
mechanism for intergenic lncRNAs regulated by MITF and SOX10 but that also 
harbour MITF and SOX10 binding sites across their loci.  
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Chapter 4: DIRC3 is a nuclear lncRNA that 
regulates its neighbouring gene IGFBP5 and other 
genes important in melanoma 
 
4.1 Introduction  
 
4.1.1 LncRNA mechanisms of gene regulation.  
 
LncRNAs have been identified as novel regulators of gene expression. Whether they 
are localised to the nucleus or cytoplasm gives an initial insight into possible 
mechanisms a functional lncRNA may execute in gene regulation (Zhang et al. 2014). 
Compared to mRNAs which are predominantly trafficked to the cytoplasm where 
they undergo translation, lncRNAs show increased enrichment in the nucleus 
(Derrien et al. 2012). Within the nucleus, functional lncRNAs regulate expression of 
target genes either at sites local to or distant from their site of transcription (Vance 
et al. 2014). Regulation of targets close to a lncRNA’s locus may occur either through 
the act of lncRNA transcription alone or a functional transcript (Kaikkonen and 
Adelman 2018). LncRNAs may also regulate expression of genes at loci on different 
chromosomes or alleles. To do so, a functional transcript may be translocated to 
other sites or manipulations of chromatin structure may bring distal regions close to 
the lncRNA loci (Hacisuleyman et al. 2014, Vance and Ponting 2014). Numerous 
lncRNAs have also been identified that function in the cytoplasm. Here, functional 
lncRNA transcripts may participate in regulation of mRNA processing and protein 
activity (Tian et al. 2014, Leucci, Coe, et al. 2016).  
 
LncRNA functionality may be attributed to the lncRNA transcript, transcription, 
splicing and/or DNA elements within the lncRNA locus. (Marchese et al. 2017, Kopp 
and Mendell 2018). Functional transcripts can interact with DNA, RNA or proteins to 
confer their activity. In other cases, activities such as transcriptional interference and 
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splicing result in functional transcripts not being required for regulation of target 
genes, rendering the transcript a by-product of their activity (Latos et al. 2012, 
Engreitz et al. 2016). Additionally, when loci harbour regulatory elements, these 
regions may play a primary role in the regulation of target gene expression rather 
than expression of the lncRNA (Groff et al. 2016). However, lncRNAs are likely to be 
able to function using combinations of these methods. Some well-characterised 
examples of melanoma-expressed lncRNAs in the nucleus and cytoplasm, and how 
they function, are given in Table 4.1. 
 
Table 4.1 Selected examples of well-characterised melanoma-expressed lncRNAs present 
in the nucleus and cytoplasm.  
Nuclear SLNCR 
By recruiting the androgen receptor (AR) to EGR1-bound genomic 
loci, SLNCR1 switches transcription activation by EGR1 to repression, 
so that activity of tumour suppressor p21Waf1/Cip1 is repressed 
(Schmidt et al. 2019) 
Cytoplasmic 
SAMMSON 
Regulates mitochondrial homeostasis and metabolism through 
promoting activity of p32, a master regulator of mitochondrial 
metabolism. When expression was knocked down, cells were less 
viable were sensitised to MAPK- targeting therapeutics (Leucci, 
Vendramin, et al. 2016). 
UCA1 
By targeting miR-507, UCA1 prevents miR-507-mediated inhibition of 




4.1.2 Knockout/down methods to identify lncRNA function.  
 
LncRNA function can be studied using a range of methods involving deletion, 
suppression or overexpression of the target lncRNA. It is important to know whether 
the transcript is predominantly nuclear or cytoplasmic to assign the most suitable 
method for analysis of the effect of such lncRNA loss/gain of function. The resulting 
effect on expression of other genes or the cell’s phenotype can then be used to 
confirm functionality (Stojic et al. 2018). If a lncRNA is predominantly cytoplasmic, 
post-transcriptional knockdown methods such as shRNA knockdown may reduce 
expression of the target. However, those with expression restricted to the nucleus 
require methods that utilise cellular machinery within that compartment – such as 
CRISPRi and antisense oligonucleotides (ASOs). 
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The use of shRNAs and siRNAs to deplete lncRNA expression is based on their earlier 
success when knocking down protein-coding genes. Using these oligos, target RNA 
molecules are degraded using endogenous silencing machinery. Such techniques 
typically work more efficiently for targets expressed in the cytoplasm. However, in 
some cases it has been possible to knockdown nuclear-expressed lncRNAs, such as 
HOTTIP (Wang et al. 2011). This could be the consequence of some factors required 
for knockdown, such as Dicer and Argonaute, being identified in nuclei as well as the 
cytoplasm (Gagnon et al. 2014).  
 
Targeting lncRNA transcripts predominantly expressed in the nucleus using siRNAs 
can be challenging due to the required machinery being limited to the cytoplasm 
(Lennox and Behlke 2016). However, locked nucleic acid (LNA)-modified antisense 
oligonucleotides (ASOs) can be used to target nuclear-expressed lncRNAs. The single-
stranded DNA oligomers direct RNase H-mediated cleavage of target lncRNAs by 
forming chimeric RNA-DNA oligonucleotides (Ideue et al. 2009). By inducing RNase H 
activity, LNA-ASOs can target nuclear-expressed lncRNA transcripts for degradation. 
LNA-ASOs have been successfully used in the knockdown of lncRNAs including NEAT1 
and LincRNA-p21 (Dimitrova et al. 2014, Lennox and Behlke 2016).  
 
When designing experiments to investigate lncRNA function it is important to 
consider lncRNAs that work through the act of their transcription, as well as the 
transcript itself. The clustered regularly interspaced short palindromic repeats 
(CRISPR) system is now commonly used to generate lncRNA knockout models (Gilbert 
et al. 2014). Using a CRISPR-associated protein 9 (Cas9) endonuclease guided by a 
single-guide RNA (sgRNA), the target DNA region is removed following the creation 
of a double-strand break in the DNA and repair using endogenous machinery. 
Utilising the homologous recombination repair pathway, DNA modifications, such as 
single point mutations or new exogenous sequences, may be inserted (Hsu et al. 
2014). CRISPR has successfully been used for the knockout of lncRNAs including 
CCAT1 (Zare et al. 2018). It has also been used to modulate splicing of XIST in order 
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to identify the most active isoform in XCI (Yue and Ogawa 2017). However, deletion 
of a target site can unintentionally remove or disrupt regulatory elements within that 
region leading to a misinterpretation of how the targeted gene functions (Liu et al. 
2017).  
 
Preventing lncRNA activity by removing DNA can make it difficult to distinguish 
whether any observed effects are the result of the lncRNA or regulatory elements 
within the DNA sequence from which the lncRNA is transcribed. By preventing 
transcription of the target lncRNA, the DNA sequence is not affected so any 
observations are the result of lncRNA transcript-dependent or -independent activity. 
CRISPR inhibition (CRISPRi) can be used to do this. The catalytically inactive (dead) 
Cas9 (dCas9) blocks activity of RNAPII through steric hinderance (Gilbert et al. 2013, 
2014, Qi et al. 2013). dCas9 activity may also be enhanced by fusing repressor 
domains to the protein. Activator domains may also be used to up-regulate the 
expression of a target gene when performing CRISPR activation (CRISPRa). For gene 
knockdown, protein repressor domains such as Krüppel-associated box (KRAB) and 
MAX interactor 1 (Mxi1), fused to dCas9 increases the efficiency of silencing through 
recruiting chromatin-modifying proteins and inducing local chromatin compaction 
(Gilbert et al. 2013). The combined use of the dCas9 and KRAB proteins is more 
efficient at knocking down the expression of a target than the use of dCas9 alone 
(Goyal et al. 2017). Gilbert et al (2014) also identified a region -50 to +300 bp of the 
target’s TSS as the optimum area for targeting knockdown using the combined dCas9-
KRAB repression. This means the precise TSS of a target needs to be known in order 
to use dCas9-KRAB knockdown efficiently. CRISPRi also holds promise as it is a highly 
specific and reproducible method which causes undetectable intrinsic toxicity. This 
version of CRISPR has been tested to deplete expression of a range of lncRNAs, 
including GAS5, MALAT1, NEAT1, and XIST (Gilbert et al. 2014).  
 
Knock-in of the polyA cleavage signal is another commonly used method to block 
lncRNA function by inducing premature termination of lncRNA transcription (Liu and 
Lim 2018).  The transcript upstream to the signal is stabilised as it is protected by the 
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5’-cap structure, but transcript remaining downstream is rapidly degraded. 
Accordingly, the addition of polyA sequences is used for gene silencing of sequences 
downstream to where the signal is inserted. Poly(A) sequences from the bovine 
growth hormone (bGH) and the simian virus 40 (SV40) are commonly used 
(Gutschner et al. 2011). Sites typically targeted include the promoter, first exon or 
first intron. However, different portions of a lncRNA transcript can be targeted, 
allowing identification of the critical region of the lncRNA. CRISPR-Cas9-mediated 
homologous recombination can be used to insert a PolyA cassette into both alleles of 
a target gene (Liu and Lim 2018). As well as targeting singular regions, by using 
multiple sgRNAs an entire gene may be deleted. In the case of AIRN, gradual 
repositioning of the polyA signal across the lncRNA locus showed that the lncRNA 
regulated expression of IGF2R as its locus overlapped the promoter of this 
neighbouring gene (Latos et al. 2012). 
 
4.1.3 Chapter Summary.  
 
Although DIRC3 expression positively correlates with patient survival, suggesting a 
tumour suppressive role, this does not mean the lncRNA is functional. The observed 
changes in DIRC3 could be a bystander effect representing changes in other genes, 
rather than its altered expression producing a functional response. To begin to 
explore possible DIRC3 functionality, the lncRNA was targeted for knockdown. In 
order to decide on the most appropriate method, the cellular localisation of DIRC3 
was determined. Due to its predominantly nuclear location, DIRC3 was targeted using 
CRISPRi and LNA-ASOs. The effect of DIRC3 knockdown was first checked by 
measuring expression of its neighbouring cancer-causing genes IGFBP5 and TNS1. 
Combining the two knockdown methods revealed the ability of DIRC3 to regulate 
IGFBP5 through a functional transcript. The initial portion of the chapter also focuses 
on CASC11, another MITF-regulated lncRNA. CASC11 regulates its neighbouring gene 
MYC in colorectal cancer so was used to show that CASC11 activates MYC in 
melanoma and subsequently optimise the CRISPRi experimental method. The 
remainder of this chapter focuses on understanding the extent to which DIRC3 
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regulates targets across the genome. RNA-seq analysis of LNA-ASO and CRISPRi DIRC3 
knockdown revealed genes important in the regulation of cancer-associated 
processes. By including RNA-seq analysis of IGFBP5 ASO knockdown it also is 
apparent that DIRC3 may function through IGFBP5-independent and dependent 
methods. Consequently, DIRC3 is a functional lncRNA able to regulate expression of 





4.2.1 DIRC3 transcript is predominantly located in the nucleus 
 
In order to generate initial clues into DIRC3 and CASC11 function, as well as decide 
which method of knockdown was most appropriate, their location within SKmel28 
cell was identified.  
 
The cellular localisation of DIRC3 and CASC11 was determined in SKmel28 cells. 
Following separation of the cells into nuclear and cytoplasmic fractions, expression 
of target lncRNAs were quantified using RT-qPCR. The efficiency of fractionation was 
confirmed by checking expression of NEAT1 and DANCR in the nucleus and cytoplasm 
respectively (Lennox and Behlke 2016). DIRC3 is predominantly localised to the 
nucleus, with 70-80% of its transcript identified there (Figure 4.1). Expression of 
CASC11 is relatively evenly distributed between nucleus and cytoplasm.  
 
The predominantly nuclear localisation of DIRC3 suggests that it may directly regulate 
gene expression. CASC11 identification in both the nuclear and cytoplasmic fraction 
suggest the lncRNAs more likely acts distally from its locus. CRISPRi and ASOs were 
selected to generate loss of function models due to the nuclear localisation of both 






Figure 4.1 DIRC3 is enriched in the nuclear fraction of SKmel28 cells. Following biochemical 
nuclear-cytoplasmic fractionation of SKmel28 cells, expression of DIRC3 and CASC11 were 
measured using RT-qPCR. Positive controls DANCR (cytoplasmic) and NEAT1 (nuclear) were 
used to assess fractionation efficiency. Results are presented relative to expression of 
transcripts in the nucleus. N=2 Biological Replicates. 
 
4.2.2 DIRC3 is a functional transcript able to regulate expression of its neighbouring 
gene 
 
LncRNAs often control the expression of their adjacent protein-coding genes (Vance 
and Ponting 2014, Engreitz et al. 2016), so changes in expression of neighbouring 
genes with dCas9 alone (steric hindrance) and dCas9-KRAB were measured. 
Regulation of IGFBP5 and TNS1 could also more closely implicate DIRC3 in regulation 
of melanoma. CASC11 was also selected for knockdown because it has recently been 
found to regulate its upstream neighbouring gene MYC in colorectal cancer (Zhang et 
al. 2016) so could be used as a positive control for whether the CRISPRi knockdown 
method worked. 
 
CRISPRi knockdown of the lncRNAs was performed in SKmel28 cells. A single 
transfection was performed using a CRISPRi plasmid containing both the sgRNA and 
dCas9 either with or without KRAB (generated by Andrew Bassett, Sanger Institute, 
Cambridge). Two different sgRNAs (DIRC3sg1 and DIRC3sg2 / CASC11sg1 and 


























promoter to control for off-target effects. CRISPRi knockdown was performed both 
with and without the presence of the KRAB protein to control for possible chromatin-
mediated effects of the transcriptional repressor. Transfected cells were selected 
using puromycin for seven days. Expression of the lncRNAs and their neighbouring 
genes were measured using RT-qPCR relative to a scrambled control (NEGsg1). 
 
Knockdown of CASC11 using dCas9-KRAB resulted in a reproducible 45-52% 
knockdown of CASC11 which caused a 45-48% reduction in MYC (Figure 4.2a). Use of 
dCas9 alone to knockdown CASC11 produced a ~10% knockdown of CASC11 
expression, followed by a 15-30% reduction in MYC (Figure 4.2b). This confirmed the 
reduction of MYC observed when including the KRAB domain. The positive regulation 
of MYC by CASC11 suggests CASC11 activates MYC in melanoma, as was observed in 
colon cancer (Zhang et al. 2016) suggesting CASC11 regulation of MYC may be a more 
general mechanism.  
 
It is also unlikely that the CRISPRi method itself could have caused the reduction in 
MYC as the gene is present 2 kb downstream from CASC11, too far for the CRISPRi 
method to have caused an effect (Gilbert et al. 2013). The comparison between the 
use of dCas9 alone and in combination with KRAB also demonstrate the increased 
efficiency of knockdown when using the transcriptional repressor. Such increased 
efficiency of knockdown has previously been observed by Gilbert et al (2013) who 
observed a five-fold greater knockdown for the dCas9-KRAB fusion compared to the 
presence of dCas9 alone. 
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Figure 4.2 CASC11 activates that adjacent gene MYC in SKmel28 melanoma cells. CRISPRi 
knockdown of CASC11 was performed in SKmel28 cells using both dCas9-KRAB (A) and dCas9 
(B). Three days after transfection with vectors containing CASC11sg1, CASC11sg2 or NEGsg1, 
puromycin was added to the cells which were then left under selection for another seven 
days. RNA was then extracted, and RT-qPCR performed to measure knockdown of CASC11 
and effect on MYC expression. Results were normalised to POLII and presented relative to 
expression of NEGsg1. Mean  SE N=3 Biological Replicates. One-tailed Student’s t-test 
p<0.05 = * P<0.01 **  
 
Following confirmation of the efficiency of CRISPRi to silence lncRNA expression in 
melanoma cells when using a single transfection, DIRC3 knockdown was performed. 
sgRNAs were initially designed to target both the RefSeg gene NR_026597 and RACE-
identified isoforms (Figure 3.4a) to be confident that the most prevalent form is 
targeted during knockdown. The TSS of both isoforms are not within close enough 
proximity to that of their neighbouring genes that any changes to their expression 
could be a consequence of off-target CRISPRi effects. Changes in DIRC3 neighbouring 
genes IGFBP5 and TNS1 were measured following lncRNA knockdown. 
 
Targeting the TSS of the shorter SKmel28-RACE DIRC3 isoform using dCas9-KRAB gave 
more efficient knockdowns (~90%) than targeting the RefSeg gene NR_026597 (~30% 
max) (Figure 4.3a). This confirmed that the isoform identified using RACE is the more 
dominant isoform of DIRC3 in SKmel28. Subsequent CRISPRi knockdowns were 
performed using sgRNAs targeting this version of DIRC3. Inclusion of the KRAB 


















































resulted in a significant 35% and 37% decrease in IGFBP5 expression respectively. 
TNS1 showed a small but significant increase for DIRC3sg2 but not DIRC3sg1 (Figure 
4.3b). Use of dCas9 alone validated this finding as DIRC3sg1 resulted in a significant 
30% knockdown of DIRC3 and 32% reduction in IGFBP5 expression but no significant 
change in TNS1. DIRC3sg2 showed far greater variation for each gene, resulting in no 
significant changes in expression (Figure 4.3c).  
 
The initial knockdowns for both of the predicted DIRC3 isoforms demonstrate the 
importance of knowing the precise TSS of a target lncRNA when using CRISPRi. The 
variation in knockdown for DIRC3sg2, unlike DIRC3sg1, when using dCas9 alone was 
also likely the consequence of the precision required when targeting dCas9 to block 
RNAPII (steric hindrance). Additionally, the changes in IGFBP5 and TNS1 expression 
were similar both with a without the presence of KRAB, confirming such changes are 
the consequence of DIRC3 knockdown and not due to off-target effects induced by 
KRAB.  
 
No clear regulation of TNS1 by DIRC3 is apparent following DIRC3 knockdown. 
However, following significant knockdown of DIRC3, IGFBP5 is consistently reduced. 
Consequently, DIRC3 appears to positively regulate expression of the tumour 
suppressor IGFBP5. Such activity supports the proposal that DIRC3 may be a tumour 
suppressor in melanoma.  
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Figure 4.3 CRISPRi knockdown of DIRC3 causes reduced expression of IGFBP5. SKmel28 cells 
were transfected with CRISPRi vectors targeting DIRC3. (A) sgRNAs targeting the original 
(RefSeq gene NR_026597) and novel (RACE-SKmel28) isoforms were designed. CRISPRi 
vectors dCas9-KRAB (B) and dCas9 (C) targeted DIRC3 with the sgRNAs DIRC3sg1 and 
DIRC3sg2, as well as NEGsg1. Three days after transfection, puromycin was added to the cells 
which were then left under selection for another seven days. RNA was extracted from the 
cells and expression of DIRC3, IGFBP5, and TNS1 measured using RT-qPCR. Results were 
normalised to POLII and presented relative to expression of NEGsg1. Mean  SE, N=3 
Technical Replicates for (A), N=3 Biological Replicates for (B) and (C). One-tailed Student’s t-
test p<0.05 = * P<0.01 ** 
 
CRISPRi knockdown of DIRC3 reveals that it can regulate expression of its 
neighbouring gene IGFBP5. However, it is not clear whether this is the result of a 
transcript-independent or dependent mechanism. ASOs were therefore used to 
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(Ideue et al. 2009). Also, if DIRC3 positive regulation of IGFBP5 is observed, this would 
be a way to validate observations following CRISPRi knockdown.  
 
Knockdown of DIRC3 expression by around 50% using two different ASOs led to a 
reduction in IGFBP5 expression levels (44% and 34%), consistent with that identified 
using CRISPRi-KRAB (Figure 4.4a). However, there were not reproducible changes in 
TNS1 using both ASOs. Consistent with these results, DIRC3-IGFBP5 expression was 
shown to correlate in melanoma patients (Figure 4.4b) observed using RNA-seq data 
from TCGA for cutaneous melanoma patients (data generated by Pakavarin 
Louphrasitthiphol, Ludwig Institute Oxford). IGFBP5 was also amongst the top 10 
positively correlated genes with DIRC3 expression (Table 3.4). 
 
ASO-mediated knockdown of DIRC3 validates the identification of DIRC3 positively 
regulating the tumour suppressor IGFBP5 using CRISPRi knockdown. By finding the 
same effect using ASO knockdown, DIRC3 likely has a functional transcript, thus giving 
an initial insight into DIRC3 mode of action. The clear positive regulatory effect DIRC3 
has on IGFBP5 expression, and strong positive correlation in melanoma patients 
identified using TCGA, imply that this protein-coding gene is a key mediator of DIRC3 
function in melanoma. By positively regulating expression of IGFBP5, DIRC3 itself 
likely behaves as a tumour suppressor. DIRC3 also appears to have directional control 
of the genes it targets as the lncRNA does not regulate TNS1. This is demonstrated as 
for both CRISPRi and ASO knockdown, only one oligo each resulted in a significant 




Figure 4.4 DIRC3 expression positively correlates with IGFBP5. (A) SKmel28 cells were 
transfected with antisense oligos (ASOs) targeting DIRC3. RNA was extracted three days after 
transfection. Expression of DIRC3, IGFBP5 and TNS1 were measured using RT-qPCR. Results 
were normalised to POLII and presented relative to expression of ASO NEG. Mean  SE, N=3 
Biological Replicates. One-tailed Student’s t-test p<0.05 = * P<0.01 ** (B) TCGA RNA-seq data 
for 471 melanoma patients was ordered based on an increasing level of IGFBP5 expression 
against DIRC3. The bold lines represent the moving averages for 20 melanoma samples and 
vertical grey bars show absolute expression for each melanoma sample. TCGA data analysed 
by Pakavarin Louphrasitthiphol, Ludwig Institute Oxford. 
 
Taken together, these results provide strong evidence that DIRC3 is a novel functional 
nuclear-localised lncRNA able to activate expression of its neighbouring tumour 
suppressive gene IGFBP5. DIRC3 is likely to function in a transcript-dependent 
manner but it cannot yet be ruled out that DIRC3 could also have some transcript-
independent functions.   
 
4.2.3 DIRC3 regulates expression of genes distal to its locus  
 
LncRNAs have been identified that can function within close proximity to their locus, 
as well as target genes more distant on their own or other chromosomes (Vance and 
Ponting 2014). Although DIRC3 can regulate the melanoma tumour suppressor 
IGFBP5 (Wang et al. 2015), it may also influence the expression of other genes. The 
influence a lncRNA has on genes genome-wide can be explored using RNA-seq 



























Michael Shapero (University of Bath). As well as seeing which genes are affected, 
gene grouping by GO analysis allows identification of biological pathways influenced 
by DIRC3 expression. The identification of programmes important to cancer could 
help predict how a lncRNA influences key hallmarks of cancer. 
 
In this study, the influence of DIRC3 on genes distal to its locus was explored using 
RNA-seq analysis of DIRC3 ASO knockdown (DIRC3 ASO-1) in SKmel28 cells compared 
against a scrambled control (NegA). Since IGFBP5 is known to play an important role 
in regulating melanoma cellular processes, the number of genes influenced by both 
IGFBP5 (using IGFBP5 ASO-1) and DIRC3 were identified to see whether DIRC3 gene 
regulatory activity is dependent on or independent of IGFBP5. For IGFBP5 
knockdown, the gene was again targeted in SKmel28 cells using ASOs.  
 
Knockdown of DIRC3 resulted in a ~63% reduction and subsequent decrease in 
IGFBP5 (Figure 4.5a). This reduced expression led to a significant change in 1886 
genes (at a 5% false discovery rate (FDR)) compared to a non-targeting control. Of 
those, 1015 (54%) showed increased expression while 871 (46%) decreased (Figure 
4.6a). For the IGFBP5 knockdown, a ~79% reduction in expression (Figure 4.5b) 
resulted in 557 genes (5% FDR) showing altered expression. Of those, 360 were up-
regulated and 197 down-regulated (Figure 4.6b). When comparing the DIRC3 and 
IGFBP5 ASO knockdowns, 240 common targets were identified (Figure 4.6c). 
Compared to random sampling of all expressed genes, there is a significant 22.8-fold 
enrichment (p<1e-6), indicating the overlap is a result of a direct relationship rather 
than through chance. Also, the majority of shared genes showed changes in 
expression in the same direction, supporting the discovery that DIRC3 positively 
regulates expression of IGFBP5 (Figure 4.6d).  
 
Of the shared DIRC3-IGFBP5 targets, GO enrichment analysis identified genes 
involved in cell migration, proliferation, differentiation and metabolism (Figure 4.6e). 
Such cancer-associated regulatory pathways could participate in controlling 
melanoma. In addition to acting through IGFBP5, DIRC3 can regulate melanoma-
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associated gene categories such as angiogenesis, ERK signalling, and apoptotic 
signalling, independently of IGFBP5 (Figure 4.6f). 
 
RNA-seq analysis of the DIRC3 knockdown using ASOs demonstrates that DIRC3 has 
more widespread activity and can regulate gene pathways important in cancer 
development and progression. However, regulation of these pathways is at least 
partially dependent upon IGFBP5. Consequently, DIRC3 regulation of IGFBP5 could 
be an important determinant of the predicted tumour suppressive activity of DIRC3 
in melanoma. Also, the number of co-regulated genes between DIRC3 and IGFBP5 
make up almost half (43%) of those identified for IGFBP5 suggesting DIRC3 could play 
an important role in the regulation of IGFBP5 activity. With two very differently 
designed oligos (DIRC3 ASO-1 and IGFBP5 ASO-1) identifying the same candidates, it 
is far less likely that these expression changes are the result of off-target effects and 
so are more likely to play a role as mediators of DIRC3 functional activity. RNA-seq 
analysis of DIRC3 and IGFBP5 ASO knockdowns demonstrate that the DIRC3 
transcriptional response is via IGFBP5-dependent and -independent activities.  
 
Figure 4.5 Generation of DIRC3 and IGFBP5 knockdown for RNA-seq analysis. DIRC3 (A) and 
(B) IGFBP5 expression were depleted in SKmel28 cells using ASOs. Three days after 
transfection the level of knockdown was measured using RT-qPCR. Results were normalised 
to POLII and presented relative to expression in the siCtrl. Mean  SE N=3 Biological 














































Figure 4.6 RNA-seq analysis of ASO DIRC3 and IGFBP5 knockdown show joint and 
independent gene regulation. Volcano plots show significantly up- and down-regulated 
genes following DIRC3 (A) and IGFBP5 (B) knockdown. (C) Venn diagram presenting the 
intersection for DIRC3 and IGFBP5 independent shared genes (D) Plot generated showing an 
increase or decrease in expression of common targets. Gene Ontology (GO) enrichment 
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analysis was examined for both IGFBP5 and DIRC3 common targets (E) and DIRC3 gene 
targets alone (F). GO enrichment analysis was performed using GOstats and FDR correction 
was applied. All bioinformatic analyses were generated by Michael Shapiro (University of 
Bath).  
 
RNA-seq analysis of genes following DIRC3 depletion was also performed in SKmel28 
cells containing DIRC3 dCas9-KRAB knockdown. Bioinformatic analysis was 
performed by Yihong Jennifer Tan (University of Lausanne). By using CRISPRi 
knockdown, genes affected by transcript-independent DIRC3 function can also be 
identified. In addition, different knockdown methods have previously been found to 
identify different genes and gene pathways affected following target gene 
knockdown (Stojic et al. 2016). By combining ASO and CRISPRi knockdowns of DIRC3 
it may be possible to identify which genes or gene pathways consistently overlap. 
Also, the comparison may help identify which technique is more efficient at 
generating a list of potential DIRC3 targets.   
 
The dCas9-KRAB was targeted to DIRC3 using sgRNA DIRC3sg2 to deplete DIRC3 levels 
in SKmel28 cells. After transfection, the cells were selected under puromycin for 10 
days. Once the level of DIRC3 knockdown and corresponding reduction in IGFBP5 was 
confirmed using RT-qPCR, the samples were analysed using RNA-seq, and gene 
expression changes identified compared to cells transfected with a scrambled control 
(NEGsg1).  
 
Following a 50% reduction in DIRC3 and 61% reduction in IGFBP5 expression (Figure 
4.7a), 422 genes (5% FDR) significantly changed expression. Of those, 259 were up-
regulated and 163 down-regulated (Figure 4.7b). Gene ontology (GO) enrichment 
analysis found DIRC3-regulated genes were particularly enriched in cancer- and 
melanoma-associated pathways regulating activities including apoptosis, cell cycle 
control, neural crest cell migration, and mitochondrial activity (Figure 4.7c). When 
comparing the genes in common following DIRC3 ASO and CRISPRi knockdown, 35 
were found in both (Figure 4.7d). Of those, 21 showed expression changes in the 
same direction (Table 4.2). These genes include those which participate in the 
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regulation of melanoma-associated processes including apoptosis (CFLAR), cell 
adhesion (KAZN), mitochondrial activity (MT-ND4), and activation of MAPK signalling 
(SEMA4C) (Zeng et al. 2011, O’Leary et al. 2015). 
 
Analysis of genes affected by DIRC3 depletion following CRISPRi knockdown confirms 
DIRC3 expression can influence the activity of genes across the genome. 
Identification of 35 genes using both CRISPRi and ASO knockdown techniques 
suggests they are more likely to be DIRC3 targets.  
 
ASO knockdown produced a significant change in almost four times more genes than 
identified using CRISPRi, the genes also showed a greater fold change in expression, 
suggesting ASO knockdown could be a more effective method for RNA-seq analysis. 
Of the 35 genes, 21 showed expression changes in the same direction of which 
several were related to key cancer-associated processes. With the remaining genes 
changing expression in different directions, they could still be a consequence of off-
target effects. Consequently, ASOs could be more effective for detecting gene 
changes due to differences in their experimental design. One example is the 
harvesting of the cells three days post-transfection rather than 10, so that the cells 
have less time to respond to the knockdown and induction of rescue pathways is 
limited. However, due to the introduction of oligos, ASOs may induce more off-target 
effects (Stojic 2018). 
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Figure 4.7 DIRC3 regulates expression of genes in trans. (A) DIRC3 was depleted in SKmel28 
cells using CRISPRi-KRAB. The level of knockdown was measured using RT-qPCR 10 days after 
transfection. Results were normalised to POLII and presented relative to expression in the 
siCtrl. Mean  SE N=3 Biological Replicates. One-tailed Student’s t-test p<0.05 = * P<0.01 ** 
(B) A volcano plot was generated showing significantly upregulated (red) and downregulated 
(blue) genes following DIRC3 knockdown (C) Gene Ontology (GO) enrichment analysis for 
genes showing a significant change in expression. (D) A Venn diagram demonstrating the 
overlap of significantly altered genes using either ASOs or CRISPRi. Bioinformatic analysis was 
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Table 4.2 A list of 35 significantly changed genes identified following RNA-seq analysis of 
DIRC3 ASO and CRISPRi knockdown in SKmel28 cells. An increase or decrease in expression 





Gene ASO CRISPRi 
AC004447.2 ↑ ↑ 
AC009237.8 ↓ ↑ 
ACOT2 ↑ ↓ 
ANKRD34A ↑ ↑ 
ARL10 ↓ ↓ 
CFLAR ↓ ↓ 
CHL1 ↑ ↑ 
CNP ↓ ↓ 
CTC-296K1.3 ↓ ↓ 
CTD-2336O2.1 ↑ ↓ 
DAK ↑ ↓ 
FARP1 ↑ ↓ 
FBXO2 ↑ ↑ 
GPR55 ↑ ↓ 
KAZN ↑ ↑ 
LYPD1 ↓ ↓ 
MALSU1 ↑ ↓ 
MT-ND4 ↓ ↓ 
NPR2 ↑ ↑ 
POM121 ↑ ↑ 
PSMC3IP ↓ ↓ 
RP11-203J24.8 ↓ ↓ 
RP11-400F19.6 ↑ ↓ 
RP11-817O13.8 ↑ ↑ 
RP4-751H13.7 ↓ ↑ 
SEMA4C ↑ ↑ 
SGPP2 ↓ ↓ 
SLC25A26 ↓ ↑ 
SLC9A5 ↑ ↓ 
SNX32 ↓ ↓ 
STK25 ↑ ↑ 
TMEM160 ↑ ↓ 
TOR3A ↓ ↓ 





Regulation of neighbouring genes is common for both non-coding and protein-coding 
genes. A large proportion of lncRNA loci have been identified that regulate the 
expression of their neighbouring genes (Ørom et al. 2010, Engreitz et al. 2016). 
However, the likelihood of lncRNAs regulating their neighbouring gene decreases 
with increasing distance apart. Derrien et al (2012) found that while 2.95% of 
identified lncRNA positively correlated with expression of their neighbouring genes 
when within 20 kb of one another, this dropped to 0.44% when the distance 
increased to 80-100 kb. However, DIRC3 positively regulates expression of IGFBP5 
despite it being 600 kb downstream. LncRNAs may regulate their neighbouring genes 
through actions such as recruiting regulatory complexes, altering RNAPII occupancy, 
or DNA looping (Wang et al. 2011, Kornienko et al. 2013, Hacisuleyman et al. 2014). 
If a functional transcript is important for DIRC3 to regulate IGFBP5 expression it could 
be that DIRC3 guides transcription factors to, or sequesters proteins away from, the 
IGFBP5 locus (Deniz and Erman 2016). It should also be noted that while DIRC3 
appears to act using a functional transcript, the presence of potential regulatory 
elements across the DIRC3 locus, such as enhancers, could also play a part in IGFBP5 
regulation.  
 
A recent study suggested that ASOs can prevent transcription of a target gene by 
blocking RNAPII elongation. Greer et al (2019) found that when they targeted Hdac2 
with two different ASOs, transcription towards the 3’ end of the gene was 
consistently impeded while transcription at the 5’ end was not. Consequently, while 
initiation of transcription is still possible, elongation is prevented. If this is the case, 
ASO knockdown of DIRC3 may not be representative of a functional transcript and 
instead only act to validate findings using CRISPRi. Presence of the nascent DIRC3 
transcript could be confirmed using nuclear run-on (NRO) (Greer et al. 2019). siRNAs 
have also previously been used to knockdown activity of lncRNA transcripts, such as 
MALAT1, within the nucleus despite its use of cellular machinery within the 
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cytoplasm (Tripathi et al. 2010). Consequently, if possible to knockdown DIRC3 using 
siRNAs, any effects on expression of IGFBP5 and genes identified using RNA-seq, 
could indicate whether the DIRC3 transcript is functional.  
 
As DIRC3 activation of IGFBP5 was demonstrated using both CRISPRi and ASO 
mediated knockdown, this strongly indicates that DIRC3 is a functional lncRNA. 
IGFBP5 itself could, therefore, play an important part in DIRC3 function in melanoma.  
IGFBP5 is expressed in both normal and cancer tissues where it regulates cell 
adhesion, differentiation, migration, and apoptosis (Su et al. 2011, Sureshbabu et al. 
2012). Dysregulation of IGFBP5 has been found to drive cancer growth and 
metastasis in breast cancer, osteosarcoma, and melanoma (Su et al. 2011, 
Sureshbabu et al. 2012, Wang et al. 2015). In addition, its increased expression is 
associated with increased patient survival in breast cancer (Ahn et al. 2010). IGFBP5 
may also play an important role in inhibiting both tumour growth and metastasis in 
melanoma as suggested by its lower expression in metastatic tissue compared to 
primary melanoma samples (Wang et al. 2015). Consequently, IGFBP5 is likely to 
function as a tumour suppressor in a range of cancer types, including melanoma. As 
DIRC3 positively regulates expression of IGFBP5, this suggests DIRC3 may function as 
a tumour suppressor via its regulation of IGFBP5.  
 
The identification that DIRC3 regulates genes involved in multiple cancer-associated 
processes, support the hypothesis that DIRC3 participates in regulating cancer 
progression. In order to regulate expression of genes distant from the DIRC3 locus, a 
range of transcript-dependent and -independent methods may be executed. If there 
is sufficient quantity of the molecule, the lncRNA transcript may translocate from its 
site of synthesis to distal genes. This may be achieved through direct RNA-DNA based 
targeting to genomic sites, or through being guided by proteins. For example,  
HOTAIR can interact with loci genome-wide through directly interacting with the DNA 
itself (Gupta et al. 2010). In the case of Paupar, the transcript is guided to distant 
sites, including those on multiple chromosomes other than its own, by the DNA-
binding protein PAX6 which it complexes with (Vance et al. 2014). Another proposed 
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mechanism is that distal regions, either on the same or different chromosomes, may 
be brought into closer proximity with the lncRNA loci through chromosomal looping 
such as has been proposed for the lncRNA Firre (Hacisuleyman et al. 2014).   
  
In some cases, wide-spread expression changes may be observed as a result of 
downstream effects due to the lncRNA’s local activity (Engreitz et al. 2016). This was 
the case for Linc-p21. Originally the nuclear-localised lncRNA was thought to directly 
repress distal genes as part of the p53 response to DNA damage (Huarte et al. 2010). 
However, it has since been recognised that such effects are due to its positive 
regulation of the protein-coding gene Cdkn1a via regulatory elements within the Linc-
p21 locus (Groff et al. 2016). The lncRNA ncRNA-a7 has also been recognised for 
having an enhancer-like function as it positively regulates expression of Snai1, 
through which it affects processes including cell migration. In this case, additional 
distal genes were also identified that mediate ncRNA-a7 effects independent of Snai1 
(Ørom et al. 2010). Due to the overlapping regulated genes identified following DIRC3 
and IGFBP5 ASO knockdown, a large proportion of genome-wide activity may be 
through its regulation of IGFBP5. Many of those shared genes are involved in cancer-
associated processes. However, DIRC3 also appears to regulate the expression of a 
range of cancer-causing gene programmes independent of IGFBP5. 
 
 Using GO analysis of RNA-seq data from ASO and CRISPRi knockdowns of DIRC3 it 
was possible to observe similarities in their target gene pathways. Both knockdown 
techniques highlighted gene expression programmes important to cancer. However, 
only 35 overlapping genes were identified and ASO knockdown showed almost five-
fold more genes with significant changes. Previous studies have also found 
discrepancies between observed molecular changes when using different methods 
to knockdown gene expression, including for ASOs and CRISPRi. Some differences can 
be down to the design of the method used. With CRISPRi preventing transcription of 
its target, local activities caused by the act of DIRC3 transcription could influence 
expression of genes downstream, and so such targets may not be affected by 
transcript knockdown alone (Stojic et al. 2018). It could also be the case that the 
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CRISPRi method is able to repress expression of regulatory elements, such as 
enhancers, present locally to the lncRNA TSS, and so effect alternative genes this way 
(Liu and Lim 2018). Also, although CRISPRi has been found to induce very few off-
target effects (Gilbert et al. 2014, Stojic et al. 2018), the longer period of time 
between transfection and harvesting the cells (10 days rather than three as for ASOs) 
could allow transcriptional programmes to be altered within the cell resulting in 
discrepancies between the methods. Some genes typically altered during DIRC3 
knockdown may have their expression rescued via an alternative method within that 
time frame. In the case of ASOs, off-target effects are more of a concern as the 
oligonucleotides may contain sufficient complementarity to transcripts that are not 
their target, causing these genes to also become repressed (Watts and Corey 2012). 
Such off-target effects may also be executed by negative controls resulting in it 
becoming difficult to differentiate which genes changed due to non-specific effects 
of the negative control oligos (Stojic et al. 2018). However, it should be noted that 
due to the DIRC3 and IGFBP5 ASOs targeting such different sequences and still 
showing overlap, it is highly likely that the 240 overlapping genes are targets of 
DIRC3, likely through its regulation of IGFBP5 expression. These factors could have 
contributed to the large discrepancy in the number of DIRC3 targets identified using 
by CRISPRi and ASO knockdown in the RNA-seq experiment. Variations in the genes 
identified following knockdown allow different conclusions to be made about 
possible functions of the target based on the knockdown method used. However, as 
genes related to cancer pathways are consistently altered using different DIRC3 
knockdown methods, this suggests DIRC3 participates in the regulation of cancer 
initiation and/or progression. 
 
The ability of lncRNAs to translocate from their site of synthesis to distal locations 
can be investigated using rescue experiments. Following knockdown of DIRC3 
expression, heterologous expression of DIRC3 from a plasmid can be used to attempt 
to rescue the lncRNA’s activity. If the lncRNA is able to translocate from its locus, 
functionality should be restored following this ectopic expression. However, care 
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must be taken to restore expression to physiologic levels in the correct subcellular 
location (Ransohoff et al. 2017, Kopp and Mendell 2018).  
 
Capture hybridisation of RNA targets (CHART)-seq could also be used to map sites of 
DIRC3 chromatin occupancy genome-wide and identify genes that are directly bound 
and regulated by DIRC3 (Simon et al. 2011). De novo motif discovery may also be 
performed to identify possible proteins involved in targeting DIRC3 to chromatin. In 
the case of the CNS-expressed lncRNAs Paupar and Dali, no enrichment in sequence 
complementarity was identified between the lncRNAs and their identified binding 
sites. Instead, the proteins PAX6 and Pouf3 were found to be enriched at Paupar and 
Dali sites respectively, suggesting that they target the lncRNAs to distant sites in the 
genome (Vance et al. 2014). Consequently, lncRNAs may not only regulate their 
adjacent protein-coding genes in cis but may also bind the proteins that are 
produced. Tests such as this and RNA immunoprecipitation (RIP) could be performed 
to identify whether DIRC3 binds and regulates the IGFBP5 protein. 
 
Together the data collected show DIRC3 is a functional nuclear-expressed lncRNA 
able to regulate its neighbouring gene, IGFBP5, in a transcript-dependent manner. 
DIRC3 is also able to regulate genes distal from its locus at least partly via its 
regulation of IGFBP5.  
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5.1.1 LncRNAs and melanoma 
 
Cancer cells acquire a number of biological characteristics that distinguish them from 
normal cells, including increased cell survival, proliferation, and invasion. These are 
known as the hallmarks of cancer (Hanahan and Weinberg 2011, Elia et al. 2018). One 
key hallmark is metastasis. Metastasis enables primary neoplasms to migrate to 
distant locations in the body and so plays a major role in the lethality of cancer (Steeg 
2006, Menyhárt et al. 2016). Prior to metastasising, cells lose cell adherence proteins 
and increase in motility. These cells undergo epithelial-to-mesenchymal-transition 
(EMT) in which epithelial cells acquire more mesenchymal features so that their 
migratory and invasive potential increase (Nieto et al. 2016). Expression of matrix-
degrading proteinases enables them to invade through the extracellular matrix (ECM) 
and enter blood vessels or the lymphatic system, leading to their dissemination 
around the body. In order to migrate through the blood to distant sites, the cells must 
be able to survive in an anchorage-independent manner. The metastatic cells may 
then extravasate from the vessels and form new colonies (Guadamillas et al. 2011, 
Lambert et al. 2017). In the case of melanomas, tumours detected early on that are 
still benign may be excised surgically and have a high survival rate. However, 
metastatic melanoma is less treatable and so very lethal. Consequently, while only 
accounting for a small proportion of skin cancer cases, metastatic melanoma makes 
up the majority of skin cancer deaths (Siegel et al. 2019).  
 
MITF and SOX10 are key factors in regulating the switching of melanoma cells 
between proliferative and invasive states (Hoek et al. 2008, Verfaillie et al. 2015). 
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Proliferative cells in primary tumours have previously been found to express high 
levels of MITF and SOX10. Subpopulations of cells on the edge of primary lesions 
express low MITF, allowing acquisition of invasive properties which eventually lead 
to their metastasis. Metastatic sites have also been found to contain MITF-positive 
cells, supporting the ability of melanoma cells to switch between proliferative and 
invasive (Verfaillie et al. 2015).  
 
A number of lncRNAs participate in regulating a range of cellular activities in 
melanoma. BANCR, an oncogenic lncRNA upregulated in primary melanomas 
containing the BRAFV600E mutation, regulates genes involved in melanoma cell 
proliferation and migration (Li et al. 2014). CASC15 (Cancer susceptibility candidate 
15), which is amplified in some metastatic melanoma cases, participates in regulating 
of cell invasiveness (Lessard et al. 2015). SLNCR1 promotes melanoma cell invasion 
by promoting MMP9, AR and Brn3a expression (Schmidt et al. 2016). These represent 
a handful of lncRNAs that have been identified with functional roles in melanoma. By 
accumulating information about the functional roles of lncRNAs in melanoma, it 
becomes increasingly clear that they are a crucial layer of regulation in cancer 
prevention or induction. This makes them promising targets in the development of 
therapeutics that could be used alongside current methods.  
 
5.1.2 Assays for measuring proliferation, invasion, and anchorage-independent 
growth 
 
Using transcriptomic profiling, changes in lncRNA expression may be associated with 
genes important to the hallmarks of cancer. Such associations may be used to predict 
likely cellular activities a lncRNA influences. Cellular assays offer a method to directly 
identify changes in cellular behaviour following knockdown or activation of a gene of 
interest. 
 
Dysregulated expression of oncogenes or tumour suppressors can enable 
uncontrolled proliferation of cancer cells, allowing the formation of tumours 
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(Hanahan and Weinberg 2011, Borowicz et al. 2014). As the cells continue to divide, 
there are more opportunities for additional mutations to arise. Of these, some may 
offer a growth selective advantage, enhancing survival and allowing the cancer to 
progress towards a more metastatic state (Evan and Vousden 2001). The influence 
DIRC3 has on proliferation may be assessed by quantifying growth of the cells with 
reduced DIRC3 compared to a negative control.   
 
In the early stages, tumours are benign, constrained to a region surrounded by 
healthy tissue. However, when cells develop more invasive properties, they no longer 
adhere to their neighbouring cells and penetrate through the barrier of healthy tissue 
using proteolytic degradation (Steeg 2006, Elia et al. 2018). Such behaviour is the 
beginning of tumours becoming metastatic. Cancer cell invasiveness may be 
measured using a Matrigel invasion assay. The porous filter of the migration chamber 
is coated with components reminiscent of the ECM. The presence of a 
chemoattractant (such as FBS) in the lower well triggers chemotaxis and encourages 
cells to move through the membrane, degrading the matrix-like components in order 
to pass through. The number of cells that invade through the matrix may then be 
quantified (Menyhárt et al. 2016, Schmidt et al. 2016, Elia et al. 2018). 
 
Once cells enter the vascular system, they must survive their journey without being 
attached to the ECM. Typically, cells undergo anoikis upon detachment (Taddei et al. 
2012). However, if they are able to avoid this process, cells can travel to sites distant 
from where they initially formed. A key assay for determining the ability of cells to 
proliferate in an anchorage-independent manner is the soft-agar assay. Using this 
assay, cells are grown in a semi-soft agar-based media on top of a slightly denser 
media, preventing cells from adhering to the plate. The ability of a target gene to 
influence anchorage-independent growth is revealed by the number and/or size of 
colonies formed in the absence of an adhesive surface (Borowicz et al. 2014). Since 
cancer cells become more metastatic through EMT, anchorage-independent growth 
is a hallmark of cellular transformation. Measurement of anchorage-independent 
growth is also commonly used to assess metastatic potential. When observed in vitro, 
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this phenotype has been found to reflect the metastatic potential of a range of 
tumour types, including breast, lung, and ovarian cancers (Mori et al. 2009). Mori et 
al also found that lung cancer patients with tumours expressing a strong genetic 
signature for anchorage-independent growth had a worse overall outcome, likely due 
to the tumours metastasising.  
 
5.1.3 Chapter Summary 
 
DIRC3 regulates IGFBP5 as well as other cancer-regulating genes through IGFPB5-
dependent and -independent methods, however, this does not conclusively mean 
DIRC3 disruption alters any of the hallmarks of cancer. Clonal cells containing 
depleted DIRC3 were used to measure the effect of reduced DIRC3 expression on 
proliferation, invasion, and anchorage-independent growth. DIRC3 does not 
influence melanoma cell proliferation or invasion under normal growth conditions. 
However, reduced DIRC3 induces a strong increase in anchorage-independent 
growth, which is a central assay used to indicate the ability of cells to metastasise. 
This is likely to be via its interaction with IGFBP5 as knockdown of IGFBP5 also led to 
an increase in anchorage-independent growth. The proposed DIRC3 repression of 
anchorage-independent growth, likely via regulation of IGFBP5, supports a tumour 
suppressive behaviour of DIRC3. Consequently, DIRC3 may also inhibit melanoma 
metastatic capability by regulating this activity and so represent a good candidate 




5.2.1 DIRC3 does not regulate proliferation or invasion of SKmel28 cells under 
normal growth conditions 
 
MITF, SOX10, and IGFBP5 have each been implicated in regulating melanoma cell 
proliferation and invasion (Verfaillie et al. 2015, Wang et al. 2015). By regulating and 
being regulated by DIRC3, respectively, DIRC3 could also participate in mediating 
these cellular activities. RNA-seq analysis of the DIRC3 genome wide transcriptional 
response (Chapter 4) also suggests a role for DIRC3 in the regulation of proliferative 
and invasive phenotypes. Consequently, it was hypothesised that DIRC3 may have a 
role in regulating melanoma cell proliferation and invasion.  
 
Initially, expression of DIRC3 was measured in known proliferative and invasive 
melanoma cells using RT-qPCR. RNA from short-passage melanoma cultures was 
donated by Eleonora Leucci (KU Leuven). The MM047 and MM099 cultures have 
previously been identified as expressing an invasive transcriptional state, while the 
remainder expressed a more proliferative (Verfaillie et al. 2015). DIRC3 expression 
was typically higher in the proliferative cells, with four out of six proliferative cell 
types showing greater DIRC3 expression. These ranged from six- to 68-fold greater 
than the invasive cell types (Figure 5.2).  
 
The altered DIRC3 expression between the proliferative and invasive cell types 
suggest DIRC3 expression participates in at least one of these states. It could be the 
case that changes in cell gene expression which occur during the switch between 
proliferative and invasive states promote changes in DIRC3 so that its tumour 






Figure 5.1 DIRC3 shows increased expression in proliferative melanoma cells. Expression of 
DIRC3 was measured in short-term cultures of proliferative and invasive melanoma cells 
(Verfaillie et al. 2015). Expression was analysed using RT-qPCR with results normalised to 
POLII. Mean  SE N=3 Technical Replicates. One-tailed Student’s t-test p<0.05 = * 
 
Changes in DIRC3 expression between cell types recognised for regulating different 
cellular activities could be indicative of a role for DIRC3 in such processes. However, 
they do not give a definitive answer of whether the lncRNA affects cellular activity. 
By performing cellular proliferation and invasion assays it is possible to investigate 
whether DIRC3 has a direct role in these cellular processes.  
 
The effect of DIRC3 knockdown on melanoma cell proliferation was explored in 
SKmel28 CRISPRi knockdown cells grown under normal cell culture conditions. Over 
four days there was no significant difference between proliferation of the control 
cells (NEGsg1) and DIRC3 knockdown (DIRC3sg1, sg2) (Figure 5.3a). Consequently, 
DIRC3 does not appear to participate in regulating proliferation in melanoma cells 
under normal growth conditions.  
 
The effect of DIRC3 knockdown on melanoma cell invasion was also explored in 
SKmel28 cells containing the CRISPRi DIRC3 knockdown. Invasion was assessed using 
a Matrigel invasion chamber. To encourage invasion, cells were starved of FBS 24 
hours before being seeded in an FBS-depleted chamber with an FBS-rich chamber 
























invaded through the membrane. There was no significant difference in invasion 
between DIRC3 depleted cells (DIRC3sg1, DIRC3sg2) and the controls (NEGsg1) 
(Figure 5.3b). DIRC3 consequently appears to not have a role in regulating SKmel28 
melanoma invasion in nutrient rich conditions. 
 
 
Figure 5.2 DIRC3 does not regulate SKmel28 cell proliferation or invasion. (A) DIRC3 CRISPRi 
clonal knockdown SKmel28 were seeded at a density of 1500 cells/well in a 12-well plate. 
The number of cells were counted at 0, 2, and 4 days. (B) Following FBS starvation DIRC3 
clonal knockdown SKmel28 were seeded in Matrigel chambers with 20 % FBS in the lower 
well. The number of cells that passed through the membrane were quantified after 48 hours. 
Mean  SE N=3 Technical Replicates. One-tailed Student’s t-test p<0.05 = * 
 
Although the proliferation and invasion assays suggest DIRC3 does not participate in 
regulating these cellular processes, the conditions that the cells are grown under may 
have influenced the results. Although the invasion assay included FBS-depletion, 
neither assay was performed under conditions representative of the tumour 
microenvironment. Conditions such as glutamine starvation or hypoxia, which are 
commonly observed in tumours, may trigger expression of other genes (Feige et al. 
2011, Xue et al. 2014). Such changes could then induce or suppress expression of 
DIRC3, meaning involvement of the lncRNA is only initiated in proliferation or 
invasion when under such stressful conditions. This is consistent with melanoma 
patient RNA-seq data from TCGA (data generated by Pakavarin Louphrasitthiphol, 
Ludwig Institute Oxford) which demonstrates a strong positive correlation between 







































it is not yet possible to confidently say whether DIRC3 regulates proliferation and 
invasion in melanoma cells. However, it has conclusively shown DIRC3 does not to 
participate in regulating proliferation or invasion under normal growth conditions.  
 
Figure 5.3 DIRC3 expression correlates with glutamine starvation. TCGA RNA-seq data for 
471 melanoma patients was ordered based on increasing levels of expression of the 
glutamine starvation signature. The bold lines represent the moving averages and vertical 
grey bars show absolute DIRC3 expression for each melanoma sample. (Data generated by 
Pakavarin Louphrasitthiphol, Ludwig Institute Oxford). 
 
5.2.2 Generation of clonal DIRC3 knockdown SKmel28, 501mel, and A375 
melanoma cells  
 
To further investigate the involvement of DIRC3 in regulating melanoma, its 
expression was depleted before performing anchorage-independent growth assays. 
Using the CRISPRi method, clonal cell lines were generated so that a stable DIRC3 
knockdown could be maintained for long periods. This was necessary as the 
anchorage-independent growth assay require several weeks before results can be 
obtained.  
 
Clonal cell lines were generated following stable transfection of dCas9-KRAB and 
sgRNAs (DIRC3sg1, DIRC3sg2, or NEGsg1). Clones were isolated and expanded 
following puromycin selection. DIRC3 and IGFBP5 expression were determined in 
each cell line using RT-qPCR so that those with the greatest knockdown were selected 
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for use in the cellular assays. As well as using two sgRNAs to account for off-target 
effects, two clones were used to control for effects caused by vector integration at 
different points in the genome. Expression of IGFPB5 was also measured in case any 
variations in the cellular assays could be linked to changes in its expression. DIRC3 
loss of function was performed in SKmel28, 501mel and A375 cell lines. By using 
several melanoma cells lines, general functions of DIRC3 in melanoma could be 
identified. 
 
For the SKmel28 clonal loss of function cells, DIRC3 was significantly knocked down 
which also led to a significant reduction in IGFBP5 (Figure 5.1a).  DIRC3 and IGFBP5 
were also significantly reduced following DIRC3 knockdown in A375 (Figure 5.1c).  
In the case of 501mel, significant knockdown of DIRC3 only led to a significant 
reduction of IGFBP5 in DIRC3sg1-targeted cells, with DIRC3sg2 showing no significant 
change from the NEGsg1 control cells (Figure 5.1b).  
 
As well as measuring and confirming DIRC3 knockdown in each of the clonal cells, 
analysis of IGFBP5 expression supports the positive regulation of IGFBP5 identified in 
Chapter 4. The reproducibility of this positive regulation in different cell lines 
supports the positive regulation being a general feature in melanoma cells. The 
varied expression of IGFBP5 in 501mel cells DIRC3sg2, could be a consequence of the 
prolonged selection allowing amplification of its expression or an off-target effect 
caused by the sgRNA.  
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Figure 5.4 DIRC3 knockdown cells were generated using CRISPRi with dCas9-KRAB. Clonal 
(A) SKmel28 (B) 501mel and (C) A375 cell lines containing the DIRC3 CRISPRi knockdown were 
generated following strong puromycin selection and growth from single cells. The levels of 
DIRC3 and IGFBP5 expression were measured using RT-qPCR. Results were normalised to 
















































































































































5.2.3 DIRC3 inhibits anchorage-independent growth of melanoma cells through 
positive regulation of IGFBP5 
 
The anchorage-independent growth assay more accurately represents the tumour 
phenotype due to cells being assessed in 3D growth conditions rather than 2D 
monolayers adhered to a plate. By measuring the ability of cancer cells to survive and 
proliferate without attaching to a substrate the assay can detect malignant 
transformation of cells and is predictive of the ability of cells to metastasise. The 
effect of DIRC3 depletion on anchorage-independent growth was determined in 
clonal melanoma cell lines SKmel28, 501mel, and A375. The three cell types were 
used to identify whether any changes are common amongst melanoma cell lines and 
not restricted to one cell type. The dCas9-KRAB DIRC3 knockdown cells were 
suspended in noble agar for three weeks before the number and size of the colonies 
formed were semi-quantitatively measured using ImageJ. 
 
Anchorage-independent growth was initially studied in DIRC3 depleted SKmel28 
cells. These showed a significant 2.5-7-fold increase in the number of colonies when 
there was reduced DIRC3 (Figure 5.5a). There was no consistent change in the size of 
colonies (Figure 5.5d). For 501mel cells there was a ~2-fold increase in number of 
colonies for DIRC3sg1, but no great change for DIRC3sg2 (Figure 5.5b) as well as a 
slight reduction in the size of colonies (Figure 5.5e). The A375 cells also showed a 
significant ~5-8-fold increase in number of colonies (Figure 5.5c) and no significant 
change in sizes of colonies following DIRC3 depletion (Figure 5.5f). Representative 
figures for the anchorage-independent growth assays are given in Figure 5.5g.  
 
The 501mel DIRC3sg2 knockdown cells that did not show a significant increase in 
number of colonies following DIRC3 depletion (Figure 5.5b) express higher IGFBP5 
than the scrambled controls and DIRC3sg1 knockdowns (Figure 5.1b). The reduced 
anchorage-independent growth only occurring in cells with such high IGFPB5 suggest 




















   
Figure 5.5 DIRC3 has a tumour suppressive effect on anchorage independent growth. Clonal 
DIRC3 loss of function SKmel28 (i) 501mel (ii) and A375 (iii) cells containing the DIRC3 
CRISPRi-KRAB knockdown were grown in soft agar for three weeks. The number (A) and size 
(B) of colonies formed were semi-quantified using ImageJ. Representative figures for 
DIRC3sg1, DIRC3 sg2 and NEGsg1 are given (C). Mean  SE N=3 Biological Replicates. One-














































































































































SKmel28 501mel A375 
A B C 
















To investigate whether DIRC3 activation of IGFBP5 is needed for its tumour 
suppressive function, the anchorage independent growth assay was repeated in 
clonal SKmel28 cells containing a CRISPRi knockdown of IGFBP5 and compared 
against a scrambled control (NEGsg1). Each knockdown of IGFBP5 was greater than 
90% (Figure 5.6a). Following three weeks of growth, there were significantly more 
colonies in the IGFBP5 knockdown cells. In addition, IGFBP5sg1(2) and IGFBP5sg2(2) 
both showed a significant increase in the average size of colonies that formed (Figure 
5.6b,c). Representative figures for the anchorage-independent growth assays are 
given in Figure 5.6d. The effect of IGFBP5 knockdown on anchorage-independent 
growth support the postulation that DIRC3 regulation of anchorage-independent 
growth is through its positive regulation of IGFBP5. 
 














Figure 5.6 IGFBP5 suppresses anchorage-independent growth in SKmel28 melanoma cells. 
(A) The level of IGFBP5 in CRISPRi dCas9-KRAB SKmel28 clonal knockdown cells. IGFBP5 
expression was measured using RT-qPCR. Results were normalised to POLII and presented 
relative to expression of an average of NEGsg1. (B,C,D) Clonal SKmel28 cells containing the 
IGFBP5 CRISPRi-KRAB knockdown were grown in soft agar for three weeks. The number (B) 
and size (C) of colonies formed were semi-quantified using ImageJ. Representative figures 
for DIRC3sg1, DIRC3 sg2 and NEGsg1 are given (D). Mean  SE N=3 Biological Replicates. One-
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Overall this data provides strong evidence that DIRC3 functions as a tumour 
suppressor by blocking anchorage-independent growth in melanoma cells through 
its positive regulation of IGFBP5. Such an interaction is supported by the 
identification of numerous cancer-associated genes that are regulated by DIRC3 in an 
IGFBP5-dependent manner in Chapter 4.  As anchorage-independent growth is an 
indicator of cancer cell ability to metastasise (Mori et al. 2009), DIRC3 may 
consequently be able to suppress melanoma metastasis. Due to the worse prognosis 
of patients following cancer metastasis, this would correlate with the earlier finding 






DIRC3 suppresses anchorage-independent growth in several melanoma cell lines, 
suggesting DIRC3 could play a role in suppressing metastasis of melanoma in patients. 
IGFBP5 knockdown phenocopying the suppressed anchorage independent growth 
seen following DIRC3 depletion supports the proposal that DIRC3 positively regulates 
and works through IGFBP5 to exert its tumour suppressive function. In addition, it 
cannot yet be ruled out that DIRC3 may participate in regulating melanoma cell 
proliferation and invasion due to the assays used not being representative of the 
tumour microenvironment.  
 
MITF and SOX10 expression levels regulate the ability of melanoma cells to switch 
between proliferative and invasive states. Proliferative cells express high levels of 
MITF and SOX10 while they are reduced in invasive (Hoek and Goding 2010, Verfaillie 
et al. 2015). The negative regulation of DIRC3 expression by MITF and SOX10 
(identified in Chapter 3) means lower expression of DIRC3 would be expected in 
proliferative cells and higher in invasive. However, higher DIRC3 expression was 
detected in proliferative than invasive cells. In this case, it could be hypothesised that 
downregulation of DIRC3 in invasive cells, may allow melanoma progression as cells 
become metastatic more easily. This would be consistent with the earlier observation 
that patients expressing lower DIRC3 have reduced survival compared to those with 
higher. Individuals expressing higher DIRC3, may accordingly find that reduced MITF 
expression in invasive cells triggers an increase in DIRC3 leading to reduced ability of 
cells to metastasise. 
 
The proliferation and invasion assays demonstrated no significant change in SKmel28 
following DIRC3 knockdown under normal cell growth conditions. Despite it being 
possible to identify alterations in anchorage-independent growth without observing 
any changes in proliferation and invasion, it is plausible that the assays used do not 
closely enough represent the tumour environment to elicit an effect by DIRC3. Assays 
that attempt to replicate the in vivo environment may alter a cancer cell’s 
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transcriptional state, allowing different genes to be induced or suppressed. LncRNAs 
may respond to the stressful conditions found in the tumour environment such as 
hypoxia, immunity evasion, ECM turnover, and angiogenesis. Hypoxia is the result of 
abnormal vascularisation following growth of tumours (Ackerman and Simon 2014). 
It has been linked to EMT which allows cells to become more motile before 
metastasising (Nobre et al. 2018). For example, hypoxic conditions stimulate UCA1 
(urothelial carcinoma-associated 1) through inducing hypoxia-inducible factor 1a 
(HIF-1a) which leads to the promotion of tumour invasion of bladder cancer cell lines 
in vitro (Xue et al. 2014). Hypoxia also has an inhibitory effect on MITF expression in 
vitro and in vivo, leading to growth arrest of the cells (Feige et al. 2011). Another 
feature that may be copied in vitro is glutamine starvation. High rates of proliferation 
mean the nutrient may become depleted in the surrounding tumour environment 
(Zhang 2017). BRAF inhibitor-resistant melanoma cells can express strong addictions 
for glutamine (Hernandez-Davies et al. 2015). By limiting supplies of glutamine to 
melanoma cells over prolonged periods, Falletta et al (2017) found that MITF 
expression was supressed. This repression of MITF was thought to promote cancer 
cell survival by limiting MITF-induced proliferation which would otherwise have a 
high-nutrient demand on a glutamine supply that was no longer available. The 
inhibitory effect hypoxia and glutamine starvation have on MITF expression could 
result in DIRC3 activation. It should be noted that RNA-seq analysis of genes 
influenced by hypoxic conditions have identified an increase in DIRC3 expression 
(Colin Goding, University of Oxford – personal communication). Consequently, 
adjusting proliferation and invasion assays through methods such as using a hypoxic 
chamber, generating an oxygen gradient, or inflicting glutamine starvation, could 
trigger a response in DIRC3 that would otherwise go unrecognised. 
 
Depletion of DIRC3 followed by reduced IGFBP5 in 10 out of the 12 SKmel28, 501mel, 
and A375 clonal melanoma cells strongly supports the positive regulation of IGFPB5 
by DIRC3 identified in Chapter 4. The remaining two knockdown cells (501mel) where 
IGFBP5 is restored showed the smallest change in anchorage-independent growth 
compared to scrambled control. Taken together with the finding that IGFBP5 
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knockdown in SKmel28 cells increases anchorage-independent growth, this suggests 
that DIRC3 activation of IGFBP5 mediates its tumour suppressive function. IGFBP5 
has also previously been found to inhibit anchorage-independent growth in A375 
melanoma cells (Wang et al. 2015) as well as inhibits metastasis in breast cancer and 
osteosarcoma (Su et al. 2011, Sureshbabu et al. 2012, Wang et al. 2015).  It was 
proposed that IGFBP5 prevents metastasis by inducing cell adhesion when epithelial 
cells are exposed to a mesenchymal environment, such as when epithelial–
mesenchymal boundaries become compromised during metastasis (Sureshbabu et 
al. 2012). Consequently, DIRC3 may inhibit melanoma metastasis by promoting 
expression of IGFBP5. In addition, Wang et al (2015) found IGFBP5 expression also 
inhibits proliferation and invasion in the A375 melanoma cell line, supporting the 
proposal that DIRC3 could participate in regulating melanoma cell proliferation and 
invasion in addition to anchorage-independent growth. 
 
Rescue experiments could also be performed to validate the proposed DIRC3 tumour 
suppressive function (Stojic et al. 2018). For the soft-agar assays described earlier, re-
introduction or overexpression of DIRC3 should inhibit anchorage-independent 
growth. CRISPRa can be performed in which a single sgRNA activates transcription of 
endogenous DIRC3 through targeting the dCas9 fused to an activating effector 
domain to the DIRC3 promoter (Gilbert et al. 2014). Also, ectopic expression of DIRC3 
would inform whether the lncRNA is able to execute this function via its transcript 
targeting locations distal to its locus. However, in either case overexpression requires 
particular care as low levels of lncRNA expression make it possible to increase 
expression levels far beyond those biologically possible. Also, intracellular 
localisation should be preserved (Stojic et al. 2018); in this case DIRC3 expression 
should predominantly be kept to the nucleus. As well as rescuing DIRC3 expression, 
the importance of DIRC3 regulation of IGFBP5 for regulation of anchorage-
independent growth requires further analysis.  To confirm DIRC3 is working through 
IGFBP5, reintroduction of IGFBP5 following DIRC3 knockdown should reduce the level 
of anchorage-independent growth observed. 
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Earlier studies have found anchorage-independent growth to indicate cellular 
transformation in vitro as well as predict likelihood of metastasis in patients in a range 
of cancer types. Mori et al (2009) found patients with lung, ovarian, or breast cancer 
exhibiting anchorage-independent growth signatures displayed worse survival rates. 
If DIRC3 is able to repress such metastatic capability by reducing anchorage-
independent growth, this could lead to melanoma patients expressing high levels of 
DIRC3 displaying significantly increased survival as identified using TCGA clinical data 
(Figure 3.5). Consequently, DIRC3 could be a candidate biomarker or therapeutic 
target. It would also be of interest to determine the level of DIRC3 expression in 
patients whose tumours are benign compared to those with highly metastatic in case 
DIRC3 is an indicator of tumour stage. Also, its ability to regulate such a key hallmark 
of cancer means DIRC3 could potentially be therapeutically targeted so that its 




Chapter 6: DIRC3 regulates accessibility of SOX10 





Gene expression patterns are precisely regulated through an interplay of 
transcription- and chromatin modifying- factors at DNA regulatory elements. The act 
of lncRNA transcription, or lncRNA transcripts, may participate in this process of 
promoting or repressing expression of target genes (Ernst and Kellis 2010, García-
González et al. 2016). They can do this by shaping chromosome conformation, 
regulating ability of regulatory factors to bind to target sites, or allosterically 
regulating protein functional activity, amongst a range of other activities that may 
require or be independent of a functional transcript (Briggs et al. 2015, Kaikkonen 
and Adelman 2018, Sun et al. 2018).  
 
LncRNAs that have a functional transcript may interact with a multitude of partners 
to regulate expression of target genes. This includes transcription factors, chromatin-
modifying complexes, mRNAs, miRNAs, and DNA (Dykes and Emanueli 2017). 
LncRNAs can bring proteins together so that they form a functional complex as well 
as direct them to target genes (Tsai et al. 2010, Dykes and Emanueli 2017, Balas and 
Johnson 2018). In other cases, lncRNAs sequester proteins away from their targets; 
for example PANDA which prevents cell apoptosis by sequestering NF-YA from its 
targets (Hung et al. 2011). A range of lncRNAs have been identified that target 
modifying complexes to chromatin to either promote or inhibit access to their target 
sites. This includes KCNQ1OT1 which represses expression of its targets by recruiting 
PRC2 and G9a to induce the repressive H3K27me3 and H3K9me3 modifications 
(Pandey et al. 2008). In the case of SCHLAP1, the lncRNA impairs function of the 
SWI/SNF chromatin remodelling complex by preventing SNF5 binding to the genome 
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(Prensner et al. 2013). Another lncRNA, Evf2, inhibits ATPase activity and chromatin-
remodelling activity of the BRG1 component of the SWI/SNF complex, resulting in 
reduced chromatin accessibility at target gene enhancers (Cajigas et al. 2015). 
LncRNAs may also participate in regulation of target gene expression by regulating 
chromatin looping. This activity is commonly induced between promoters and 
enhancers. LncRNAs may regulate loop formation by associating with the mediator 
complex, cohesion, or CTCF (CCCTC-binding factor) (Dykes and Emanueli 2017, 
Kaikkonen and Adelman 2018). In the case of CCAT1-L (colon cancer associated 
transcript 1), the lncRNA interacts with CTCF in order to promote chromatin looping 
between the MYC promoter and its enhancers (Xiang et al. 2014).  
 
In other cases, nascent RNA may interact with factors, such as transcription factors 
and epigenetic regulators, so that they are targeted to actively transcribed regions. 
Consequently, transcription of the lncRNA can result in increased local concentration 
of transcription factors as well as encourage activities such as deposition of activating 
histone marks (Kaneko et al. 2014, Kaikkonen and Adelman 2018).  
 
In some instances, the process of lncRNA transcription is sufficient for control of 
target gene expression without any involvement of the transcript. Numerous lncRNAs 
harbour DNA regulatory elements within their promoter or gene body, so that the 
act of lncRNA transcription can be sufficient to regulate target gene expression 
(Anderson et al. 2016, Engreitz et al. 2016, Groff et al. 2016). In the case of Uph, 
transcription of the lncRNA across an enhancer for its neighbouring gene Hand2 led 
to increased Hand2 expression independent of the lncRNA transcript (Anderson et al. 
2016). In addition, the presence of RNAPII may prevent or promote transcription 
factor binding or nucleosome repositioning during transcription and can also make 
regulatory elements more, or less, accessible (Kornienko et al. 2013, Kaikkonen and 
Adelman 2018, Kopp and Mendell 2018). For SRG1, transcription of the lncRNA 
results in repression of its neighbouring gene SER3 as it promotes a high density of 
nucleosomes over its promoter (Hainer et al. 2011). Histone modifying enzymes have 
also been identified that interact with elongating RNAPII (Ng et al. 2003, Kaikkonen 
 139 
and Adelman 2018). Other activities, such as splicing can regulate target gene 
expression, such as was found for BLUSTR which requires lncRNA transcription or 
splicing, but not transcript, to induce changes in chromatin state and neighbouring 
gene expression (Engreitz et al. 2016). 
 
Information is still limited on how lncRNAs function, so understanding DIRC3 
mechanism of action would build on these general mechanisms currently known for 
lncRNAs. This would add to the diverse range of activities lncRNAs use in the 
regulation of gene expression. Understanding the mechanism behind lncRNA 
functional activity also opens new avenues for more targeted therapeutic 
intervention to treat disease.  
 
6.1.1 Chapter Summary 
 
DIRC3 is a nuclear lncRNA that activates expression of its adjacent gene IGFBP5 and 
induces genome-wide expression programmes involved in cancer. It is not yet clear 
how DIRC3 mechanistically regulates expression of IGFBP5. Predicted co-occupied 
binding sites for MITF and SOX10 across the DIRC3 locus suggest regulatory elements 
may be present at these locations. Binding of SOX10 is confirmed in SKmel28 cells for 
three out of its four binding sites previously identified using ChIP-seq in 501mel cells. 
DIRC3 depletion leads to increased SOX10 binding and a more open chromatin state 
(indicated by an increased presence of H3K27ac). This suggests DIRC3 controls 
accessibility of SOX10 to binding sites across its locus. Chromosomal looping may also 
occur between the proposed regulatory elements within the DIRC3 locus and the 
IGFBP5 promoter, and reduced SOX10 and MITF induces an increase in IGFBP5, 
suggesting SOX10 and MITF may participate in regulation of IGFBP5 expression. If 
DIRC3 is able to regulate MITF and SOX10 transcriptional response, it could represent 
a mechanistic model for the 245 melanoma-expressed lncRNAs identified containing 
the putative MITF-SOX10 co-bound sites as well as other lncRNAs that overlap 





6.2.1 SOX10 binding across the DIRC3 locus is repressed by DIRC3 expression. 
 
DIRC3 expression is negatively regulated by MITF and SOX10. However, the presence 
of MITF-SOX10 co-occupied binding sites across the DIRC3 locus suggest DIRC3 may 
regulate their ability to bind at these sites. The binding sites of MITF and SOX10 were 
originally identified using ChIP-seq of 501mel melanoma cells (Figure 6.1a)(Laurette 
et al. 2015). To confirm whether SOX10 binds to these sites in SKmel28 cells, ChIP-
qPCR using an anti-SOX10 antibody was performed. DIRC3 regulation of transcription 
factor binding was focussed on SOX10 as there were no antibodies that could 
efficiently immunoprecipitate endogenous MITF using ChIP. DIRC3 was also knocked 
down using dCas9-KRAB to observe whether a reduction in DIRC3 transcription and 
transcript influenced the ability of SOX10 to bind. The level of SOX10 binding in DIRC3 
depleted cells (DIRC3sg1, DIRC3sg2) was compared against those transfected with a 
scrambled control (NEGsg1). To ensure detected proteins were above background, 
the level of immunoprecipitation was compared against control regions not known 
to be targeted by SOX10. Immunoglobin G (IgG) was used as an isotype control to 
account for non-specific binding of proteins to the antibodies. In addition, clonal 
populations of SKmel28 containing the DIRC3 knockdown were used due to the large 
number of cells required to perform ChIP-qPCR.  
 
The results showed high levels of SOX10 binding at the predicted binding sites 1-3 
compared to control regions. DIRC3 depletion also led to an increase in SOX10 
chromatin binding (Figure 6.1b). The presence of SOX10 at binding sites 1-3 in 
SKmel28 verifies their identification by ChIP-seq in 501mel cells. The reduction in 
SOX10 binding following depletion of DIRC3 using CRISPRi could be the result of a 
functional DIRC3 transcript targeting SOX10 activity directly. Alternatively, the DIRC3 
transcription and/or transcript could induce a more closed chromatin state which 
prevents SOX10 binding. Ultimately, the increased binding of SOX10 following 
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Figure 6.1 DIRC3 suppresses SOX10 binding across its locus. (A) UCSC Genome Browser 
(GRCh37/hg19) view of predicted binding sites across the DIRC3 locus in 501mel cells 
(Laurette et al. 2015). BS – binding site. The blue bands indicate regions where there are sites 
of MITF-SOX10 co-occupancy. (Figure generated from http://genome.ucsc.edu) (B) Levels of 
SOX10 binding in SKmel28 clonal CRISPRi-KRAB DIRC3sg1, DIRC3sg2, and NEGsg1 cells were 
identified using ChIP-qPCR. An IgG antibody was used as an isotype control for non-specific 
binding of proteins. The indicated SOX10 binding sites were analysed by qPCR. Percent input 
was calculated as 100*2^(Ct Input-Ct IP). Data presented relative to NEGsg1 BS3. Mean  SE 
N=3 Biological Replicates. One-tailed Student’s t-test p<0.05 = * P<0.01 ** 
 
To confirm the changes in SOX10 binding were not a result of changes in expression 
following DIRC3 knockdown using dCas9-KRAB, SOX10 protein levels were checked. 
Following confirmation of DIRC3 knockdown using RT-qPCR (Figure 6.2a), level of 
SOX10 expression was measured using Western blotting. Level of SOX10 protein 
remained consistent between knockdowns and scrambled controls (Figure 6.2b). 
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Consequently, changes in SOX10 binding observed were the result of DIRC3 
regulating its accessibility to the binding sites.  
  
 
Figure 6.2 SKmel28 clonal CRISPRi knockdown cells contained reduced DIRC3 but no 
significant change in SOX10. (A) Clonal SKmel28 containing DIRC3 CRISPRi knockdown had 
their level of DIRC3 expression confirmed using RT-qPCR. Results were normalised to POLII 
and presented relative to expression of NEGsg1. Mean  SE N=3 Biological Replicates. One-
tailed Student’s t-test p<0.05 = * P<0.01 **. (B) Level of SOX10 expression was confirmed 
using Western blotting. Equal concentrations of extracted protein were confirmed using 
ACTIN as a control.  
 
6.2.2 Reduced DIRC3 expression induces a histone modification signature 
suggestive of an active chromatin state. 
 
The ability of DIRC3 to block SOX10 binding to sites across its locus suggest DIRC3 is 
able to modulate chromatin accessibility. Histone modifications are a key regulator 
of chromatin accessibility, so can be used to identify transcriptional regulatory 
regions of DNA. Commonly recognised modifications include histone H3 lysine 27 
acetylation (H3K27ac), and histone H3 lysine 27 methylation/trimethylation 
(H3K4me1/3). These signatures can be used to identify positions of regulatory 
sequences, such as enhancers, in the genome. Different combinations of acetylation 
and methylation inform whether sequences are active (H3K27ac and H3K4me1 
positive), or poised (H3K27ac negative, H3K4me1 positive). In the case of H3K4me1 
























suggests the presence of promoters (Creyghton et al. 2010, Spicuglia and Vanhille 
2012, Fufa et al. 2015).  
 
Histone modifications H3K27ac, H3K4me1 and H3K4me3 were explored across the 
DIRC3 locus using ChIP-seq data from (Fiziev et al. 2017)(Figure 6.3a). The local peaks 
of increased H3K27ac and H3K4me1, and low H3K4me3 across the locus suggest 
there are active enhancer-like regions within the DIRC3 locus. To determine whether 
DIRC3 regulates chromatin accessibility within its locus, the H3K27ac signature was 
measured at SOX10-bound sequences in cells containing a DIRC3 dCas9-KRAB 
knockdown compared against a scrambled control. Consistent with the predicted 
open chromatin signature and binding identified for SOX10 across the DIRC3 locus, 
binding sites 1-3 were found to be most enriched for H3K27ac (Figure 6.3b). Following 
DIRC3 knockdown there was typically an increase in the presence H3K27ac – this is 
significant for DIRC3sg2 cells at binding sites 1 and 2. The prediction of chromatin 
signatures indicate there could be active enhancer-like regulatory elements within 
the DIRC3 locus. The confirmation of H3K27ac binding at sites 1-3 is consistent with 
the pattern for SOX10 binding and reveal a more accessible region to SOX10. The 
increase in H3K27ac following DIRC3 depletion also suggest there is a more closed 
chromatin state when the lncRNA is present. Consequently, DIRC3 may be able to act 
locally at its site of expression to modulate chromatin conformation and so control 





Figure 6.3 Reduced DIRC3 expression induces an open chromatin state. (A) Predicted H3K27 
acetylation and H3K4 methylation/trimethylation across the DIRC3 locus (Fiziev et al. 2017). 
The blue bands indicate regions where there are sites of MITF-SOX10 co-occupancy. (Figure 
generated from UCSC Genome Browser (GRCh37/hg19) http://genome.ucsc.edu) (B) ChIP-
qPCR for H3K27ac show the level of binding across SOX10 binding sites at binding sites 1-4. 
An IgG antibody was used as an isoform control for non-specific binding of proteins. The 
indicated binding sites were analysed by qPCR. Percent input was calculated as 100*2^(Ct 
Input-Ct IP). Data presented relative to NEGsg1 Peak 3 Mean  SE N=3 Biological Replicates. 
One-tailed Student’s t-test p<0.05 = * P<0.01 ** 
 
The identification of SOX10 binding and active histone modifications at several sites 
across the DIRC3 locus suggest there are regulatory elements, such as enhancers, 
present that DIRC3 is able to regulate SOX10 accessibility to. The interplay of DIRC3 
regulating SOX10 binding, and SOX10 repressing DIRC3 expression in SKmel28 cells 



































































across the DIRC3 locus. Consequently, DIRC3 may participate in the SOX10 
transcriptional response.  
 
6.2.3 DNA looping may occur between SOX10 binding sites across the DIRC3 locus 
and IGFBP5 
 
Due to DIRC3 being able to act locally to regulate expression of its neighbouring gene, 
the chromatin structure of the IGFPB5-DIRC3-TNS1 gene territory was mapped using 
Hi-C data from normal human epidermal keratinocytes (NHEK) (Rao et al., 2014). A 
HiC heatmap was generated by Yihong Jennifer Tan (University of Lausanne) using 
JuiceBox (Durand et al. 2016). By revealing the presence of topologically associated 
domains (TADs) and DNA looping, the mechanism by which DIRC3 regulates IGFBP5 
may be better understood.  
 
A TAD was identified that contains both DIRC3 and IGFBP5, but not TNS1 (Figure 6.4). 
Within this TAD, two potential DNA looping interactions were identified between the 
promoter of IGFBP5 and the MITF-SOX10 bound sequences within the DIRC3 locus. 
The presence of a TAD region surrounding DIRC3 and IGFBP5 but not TNS1 supports 
the earlier finding that DIRC3 does not regulate TNS1 despite it being closer in the 
linear sequence. The identification of potential looping interactions between MITF-
SOX10 binding sites and the IGFBP5 promoter region also suggest that the two 
oncogenes regulate IGFBP5 expression by interacting with regulatory elements for 
the tumour suppressor within the DIRC3 locus. Regulatory elements, such as 
promoters and enhancers, preferentially form contacts with each other when found 
within the same TAD (Dixon et al. 2012, Hansen et al. 2018). Although the TADs and 
looping regions were identified in NHEK cells, such domains are highly conserved 
across different cell types, so such sites are likely to be present in the melanoma cells 



















Figure 6.4 IGFBP5 may directly interact with the DIRC3 locus via chromosomal looping. 
Chromosomal interactions identified using Hi-C presented as a heatmap for the regions 
surrounding DIRC3 (red), IGFBP5 (green) and TSN1 (purple) (Rao et al. 2014, Durand et al. 
2016). Gene browser view given for NHEK (chr2: 217,500,000-219,000,000). The TAD is 
represented by the dotted black square box and encompasses both DIRC3 and IGFBP5. 
Chromosomal loops are identified by black arrows. The MITF and SOX10 binding sites are 
presented as blue boxes. Analysis performed by Yihong Jennifer Tan (University of Lausanne). 
 
6.2.4 SOX10 and MITF negatively regulate expression of IGFBP5 
 
The presence of DNA looping between the IGFPB5 promoter and sequences close to 
MITF-SOX10 binding sites within the DIRC3 locus suggest MITF and SOX10 participate 
in regulation of IGFBP5 expression. The effect of MITF and SOX10 knockdown on 
IGFBP5 expression was tested in melanoma cell lines. MITF and SOX10 siRNA and 
esiRNA knockdowns, respectively, were performed in SKmel28 cells and changes in 
IGFBP5 expression were measured using RT-qPCR.  
 
Following reduced MITF expression there was a 41-70% increase in IGFBP5 
expression in (Figure 6.5a). Reduced SOX10 expression also resulted in an increase in 
IGFBP5 (Figure 6.5b). This suggests expression of MITF and SOX10 is important in the 
regulation of IGFBP5 expression. However, it does not reveal whether the negative 
regulation is through MITF and SOX10 interacting with the binding sites across the 
DIRC3 locus or is through their negative regulation of DIRC3.  
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Figure 6.5 Decreased MITF and SOX10 expression leads to an increase in IGFBP5. SKmel28 
cells were transfected with siRNA/esiRNA targeting MITF and SOX10 respectively and non-
targeting controls (siCtrl/esiLuc). Three days following transfection, the efficiency of 
knockdown for (A) MITF and (B) SOX10 and corresponding level of IGFBP5 expression were 
measured using RT-qPCR. Results were normalised to POLII and presented relative to 
expression in the siCtrl. Mean  SE N=3 Biological Replicates. One-tailed Student’s t-test 
p<0.05 = * P<0.01 **  
 
The predicted interaction between MITF-SOX10 and IGFBP5 suggests the oncogenes 
bind to IGFBP5 regulatory elements within the DIRC3 locus to negatively regulate 
expression of IGFBP5. It could also be that DIRC3 acts to suppress their inhibition of 
IGFBP5 by blocking accessibility to regulatory elements across its locus in a feedback 





















































6.3 Discussion  
 
The ability of DIRC3 to block SOX10 binding across its locus is demonstrated by 
increased SOX10 binding at sites 1-3 following DIRC3 depletion in SKmel28 cells. This 
inhibition may be through DIRC3 inducing a more closed chromatin state, as 
suggested by the increased H3K27ac identified in DIRC3 depleted cells. Inhibition of 
SOX10 binding may prevent the transcription factor from inhibiting expression of the 
tumour suppressor IGFBP5 via regulatory elements within the DIRC3 locus. Based on 
the reduced H3K4me3 modification predicted to be present, the regulatory elements 
may be enhancers for IGFBP5. Consequently, DIRC3 may permit precise control of 
IGFBP5 expression via feedback control of SOX10.  
 
Regulation of enhancers by lncRNAs has been described for other lncRNAs. In the 
case of Uph, the lncRNA contains a super-enhancer for Hand2 within its locus. 
Transcription of Uph promotes the presence of H3K4me1 and H3K27ac epigenetic 
marks across this enhancer, leading to increased expression of Hand2. However, for 
Uph, knockdown using ASOs, and overexpression of the transcript, did not alter 
expression of Hand2 mRNA, suggesting the transcript itself is non-functional 
(Anderson et al. 2016). Also, in the case of DIRC3, access to the enhancer-like 
regulatory elements appears to be blocked following the induction of a closed 
chromatin state.  
 
The prediction that SOX10 binds to regulatory elements within the DIRC3 locus could 
be checked by investigating the presence of additional chromatin modifications using 
ChIP-qPCR. The level of H3 lysine for monomethylation and trimethylation 
(H3K4me1/3) can be used to assess presence of promoters or enhancers. The 
signature H3 lysine 27 trimethylation (H3K27me3) is also indicative of the condensed 
chromatin state so could be used to confirm whether there is a less repressive 
chromatin state following decreased DIRC3 expression (García-González et al. 2016). 
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Using CRISPRi for lncRNA knockdown means it is yet to be revealed whether DIRC3 
regulation of SOX10 binding is through a transcript-dependent or -independent 
method. To see whether the transcript is involved in these local changes, ASO 
knockdown of DIRC3 could be performed prior to ChIP analysis. If the same patterns 
of expression are observed, it is likely the transcript is involved in regulating 
accessibility of SOX10 to the proposed binding sites across the DIRC3 locus.  
 
The presence of MITF-SOX10 binding sites, H3K27ac, and predicted chromosomal 
looping using Hi-C are all suggestive of the presence of DNA elements important for 
the regulation of IGFBP5 expression. It could be the case that DIRC3 transcription 
across these regulatory elements is what controls IGFBP5 expression. Using CRISPR, 
each predicted regulatory element may be removed and the effect on IGFBP5 
expression measured by RT-qPCR (Gilbert et al. 2013). Since the majority of the 
binding sites are within intronic regions of DIRC3, it should not perturb activity of the 
lncRNA transcript. If removal of the sequences alters IGFBP5 expression, it would also 
be possible to identify whether they have a typically inhibitory or promoting effect 
on expression of the tumour suppressor.  
 
The Hi-C data combined with knockdown of MITF and SOX10 suggest these key 
melanoma regulators may repress IGFBP5 expression by binding likely regulatory 
elements for IGFBP5 within the DIRC3 locus. During chromosomal looping, target 
sequences are brought into closer proximity with a high concentration of 
transcription factors and cofactors important for regulation of transcription (García-
González et al. 2016). Chromosomal looping is typically restricted to TADs which 
regulate the spread of interactions between DNA elements (Dixon et al. 2012, 
Rodríguez-Carballo et al. 2017), and frequently occurs between enhancers and their 
target promoters (Hansen et al. 2018). Chromosome conformation capture (3C) may 
be performed to verify whether chromosomal looping occurs between the putative 
regulatory elements within the DIRC3 locus and IGFBP5 (Han et al. 2018). Predicted 
interactions between the DNA regions, as well as lncRNA, may also be confirmed 
using a combination of RNA- and DNA-fluorescent in situ hybridisation (FISH) to 
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visualise spatial distributions of the targets. To see whether DIRC3 is important for 
looping formation, 3C or FISH could be repeated following DIRC3 knockdown. Again, 
using a mixture of transcription- and transcript-targeting knockdown methods, it 
would be possible to identify whether processes dependent or independent of a 
functional transcript are required.   
 
Together these data give an insight into how DIRC3 may act locally to activate IGFBP5 
expression by blocking binding of SOX10 (and possibly MITF) to putative regulatory 
elements across its locus. Such a mechanism may be representative of MITF-SOX10 
bound intergenic lncRNAs ability to control MITF-SOX10 transcriptional response in 
melanoma by modifying chromatin and blocking their binding at regulatory elements. 
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Chapter 7: General Discussion 
 
7.1 DIRC3 is a functional tumour suppressive lncRNA in melanoma 
 
It is now clear that DIRC3 is a tumour suppressive intergenic lncRNA that blocks 
anchorage-independent growth in melanoma cells, likely through its positive 
regulation of IGFBP5. IGFBP5 has already been identified as an important tumour 
suppressor in a range of cancers including melanoma, regulating proliferation, 
invasion, and anchorage-independent growth, as well as being indicative of patient 
survival (Su et al. 2011, Sureshbabu et al. 2012, Wang et al. 2015). DIRC3 regulation 
of IGFBP5 may also play an important role in its manipulation of genes distal to its 
locus. As well as having its expression regulated by MITF and SOX10, DIRC3 is able to 
control SOX10 (and so inferably MITF) binding across its locus through modulating 
chromatin accessibility. Thus, DIRC3 has the potential to modify the MITF-SOX10 
transcriptional response in melanoma. These findings demonstrate that DIRC3 is not 
simply a downstream mediator of MITF-SOX10 activity, but also a feedback regulator. 
As numerous other intergenic lncRNAs have been identified with MITF-SOX10 co-
bound sites, DIRC3 regulation of SOX10 (and MITF) may be representative of a 
general activity amongst intergenic lncRNAs which could form part of a new class of 
melanoma regulator.  
 
7.2 DIRC3 mechanism of action   
 
By combining knockdown and ChIP-qPCR data a picture of the likely mechanism of 
action for DIRC3 has begun to form. With a focus on local activity, expression of DIRC3 
promotes transcription of IGFBP5 as well as blocks binding of SOX10 to putative 
regulatory elements across its locus by inducing a repressive chromatin state. The 
presence of MITF-SOX10 co-occupancy and H3K27ac signature at sites across the 
DIRC3 locus suggest these sequences are important in transcriptional regulation, 
likely behaving as enhancers or silencers of IGFBP5. It is also well recognised that 
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chromatin looping commonly occurs between enhancers and promoters (Mora et al. 
2015) so the proposed regulatory elements within these regions may also interact 
with IGFBP5 through chromosomal looping. In addition, SOX10 (and MITF) inhibition 
of DIRC3 expression may allow them to access binding sites across the DIRC3 locus. 
 
Accordingly, it could be the case that when DIRC3 is repressed, regulatory elements 
within its locus are targeted by SOX10 (and MITF), possibly promoting or inhibiting 
looping between them and the promoter of IGFBP5, leading to inhibition of its 
expression (Figure 7.1a). However, increased DIRC3 expression reduces acetylation 
and prevents binding of SOX10 (and MITF) to the regulatory elements so that IGFBP5 
may then be expressed (Figure 7.1b). 
 
 
Figure 7.1 Proposed model of DIRC3 mechanism of action. The model illustrates how DIRC3 
could function at its locus. (A) SOX10 suppresses DIRC3 activity allowing increased SOX10 
binding and deposition of H3K27ac. This results in repression of IGFBP5 expression. (B) When 
DIRC3 is expressed, there is reduced SOX10 binding and reduced H3K27ac, resulting in 
IGFBP5 activation. Orange hexagon – SOX10; Blue circle – H3K27ac mark; Green line – DIRC3; 














7.2.1 Proposed activities of a functional DIRC3 transcript 
 
If confident that the transcript plays a key role mediating DIRC3’s regulation of MITF-
SOX10 and IGFBP5 activity, the identification of factors it interacts with is key to 
understanding further its mechanism of action. LncRNA transcripts can interact with 
proteins or RNAs to modulate their function or binding.  
 
Functional lncRNA transcripts may regulate gene expression by sequestering RNA-
binding proteins and transcription factors away from their targets (Morriss and 
Cooper 2017), such as in the cases of GAS5 and PANDA (Kino et al. 2010, Hung et al. 
2011). Consequently, the reduced SOX10 binding with greater levels of DIRC3 could 
suggest that the lncRNA transcript sequesters SOX10 away from the binding sites 
across the DIRC3 locus. It could also be the case that DIRC3 sequesters BRG1, the 
binding partner of MITF and SOX10 also found at active melanoma regulatory 
elements (Laurette et al. 2015). In the case of SLNCR it has been recognised that the 
lncRNA could switch the activity of a target protein from activating to repressing. 
SLNCR changed EGR1-mediated transcriptional activation of p21Waf1/Cip1 to a 
repressive activity by recruiting AR to chromatin-bound EGR1 (Schmidt et al. 2019). 
This could also be the case for DIRC3, with it altering the activity of its associated 
protein factors, such as SOX10 or BRG1.  
 
A functional DIRC3 transcript could also guide chromatin modifiers to its locus or 
sequester them from their sites. Such proteins are typically not able to directly 
interact with DNA and so require the binding site specificity of factors such as 
transcription factors and lncRNAs to guide them to desired locations. DIRC3 could 
consequently recruit repressive chromatin modifiers to its locus. For example, 
PARTICLE, a shown for functional transcript, interacts with the silencing complexes 
G9A and PRC2 leading to repression of the tumour suppressors MAT2A and WWOX 
through inducing the histone H3K27me3 modification (O’Leary et al. 2015, 2017). 
DIRC3 could also inhibit the activity of chromatin-modifying factors in a manner 
similar to Evf2 which inhibits ATPase activity of the chromatin re-modeller BRG1 so 
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that it is unable to create a more open (activating) environment for target enhancers 
(Cajigas et al. 2015).  
 
In some cases, lncRNAs can interact with proteins such as Mediator, cohesion and 
CCCTC-binding factor (CTCF) to promote the looping of DNA sequences (e.g. 
promoters and enhancers) together. For example, Wrap53 has been proposed to 
induce chromatin looping by interacting with CTCF during regulation of p53 
expression (Saldaña-Meyer et al. 2014). Consequently, chromosomal looping could 
be regulated by DIRC3. If DIRC3 interacts with one of the aforementioned proteins, it 
could promote or inhibit chromosomal looping between the regulatory elements 
present within its locus and the IGFBP5 promoter. 
 
It is not yet clear which proteins DIRC3 interacts with, if any. For predicted protein 
targets such as MITF and SOX10, RIP coupled with RT-qPCR may be performed to 
confirm whether the lncRNA transcript interacts with them. When identifying 
unknown interacting protein partners care must be taken if native methods are used. 
Techniques that do not involve crosslinking frequently pick up false-positive 
interactions. One chromatin modifier frequently found to bind non-specifically in 
vitro is PRC2 (Davidovich et al. 2015).  Consequently, CHART and RNA-antisense 
purification (RAP) could be used to detect endogenous RNA interactions with 
proteins (or DNA) in a crosslinked chromatin extract. By combining these RNA-pull 
down methods with mass-spectrometry, it is possible to identify novel proteins the 
DIRC3 transcript interacts with.  
 
Once likely interacting protein targets are identified, confirmation of functional 
activity could be studied by sterically blocking their interaction with DIRC3. This could 
be performed using LNAs in a manner similar to antagomirs - targeting the DIRC3 
sequence so that they block proteins from interacting (Tsai et al. 2011). By measuring 
features such as expression of IGFBP5, binding of SOX10, or the level of anchorage-




7.2.2 Proposed activities of DIRC3 function independent of transcript 
 
The results do not rule out the possibility that DIRC3 is able to function independently 
of its transcript. Accordingly, activities such as the act of DIRC3 transcription or 
splicing could recruit factors key for the regulation of IGFBP5 expression without the 
need of a functional transcript.  
 
The process of intergenic lncRNA transcription across a DNA regulatory sequence can 
regulate target gene expression. Such as in the cases of Uph, Airn, and Blustr (Latos 
et al. 2012, Anderson et al. 2016, Engreitz et al. 2016). Using CRISPR the predicted 
regulatory elements could be removed or mutated so that the effects of their 
absence on IGFBP5 expression can be observed. The sites that would be targeted do 
not lie within exons of DIRC3 so their removal should not influence DIRC3 transcript-
dependent activity.  
 
Splicing has also been found to regulate expression of target genes. In the case of 
BLUSTR, splicing at its 5’ splice site is important for activating transcription of Sfmbt2 
through the interaction between the spliceosome and nascent transcript. Splicing can 
also influence methylation patterns (H3K4me3 and H3K27me3) and RNAPII 
occupancy (Engreitz et al. 2016). Whether DIRC3 regulates IGFBP5 through splicing 
could be identified by knocking out predicted splice sites using CRISPR.  
 
The process of transcription can also alter nucleosome density (Valouev et al. 2011). 
It has been proposed that transcription can induce rearrangement of nucleosomes 
into positions that either promote or inhibit accessibility to regulatory elements 
within the lncRNA loci. Re-deposition of nucleosomes can alter their density so that 
conditions are favourable or unfavourable for transcription factors to bind target 
regulatory elements (Kornienko et al. 2013, Kaikkonen and Adelman 2018). Changes 
to nucleosome density may be measured using nucleosome density ChIP-seq 
(ndChIP-seq) and measuring MNase accessibility to open regions of chromatin 
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(Lorzadeh et al. 2016). Nucleosome density could be measured following blocking 
DIRC3 transcription using methods such as CRISPRi or insertion of PolyA signals to see 
whether it increases or decreases following reduced DIRC3 transcription.  
 
7.3 Understanding the tumour suppressive role of DIRC3 in melanoma in vivo 
 
DIRC3 suppression of anchorage-independent growth in vitro combined with the 
increased survival identified in melanoma patients with greater DIRC3 expression 
make this lncRNA a candidate for further study in vivo.  
 
Xenografting cultured human cells into immunocompromised mice (Mus musculus) 
is commonly used for testing disease mechanisms and model therapies in vivo. The 
implanted cells can adhere, grow and eventually metastasise. By injecting cells 
containing stable DIRC3 knockdown into mice, it would be possible to observe the 
cellular response within a model organism (Kuzu et al. 2015, Aktary et al. 2018). Using 
this model, the effect of DIRC3 knockdown on primary tumour growth and its ability 
to metastasise can be observed, although this is limited by the lack of immune 
response in the mice (Aktary et al. 2018). Since anchorage-independent growth in 
vitro has previously been indicative of metastatic ability in vivo, it could be predicted 
that DIRC3 expression negatively regulates metastasis in vivo (Mori et al. 2009).  
 
While immortalised cancer cell lines are useful for performing mouse xenograft 
experiments, there is still the issue that the longer these cells are maintained in 
culture, the more they will differ from the original tumour. Instead, analysis of DIRC3 
knockdown in patient derived xenografts (PDXs) may be performed. In this case cells 
directly from human tumours are obtained from patients following surgery or biopsy 
and transplanted into mice. This can be under the skin, in the same organ as the 
sample was obtained, or in the renal capsule of immunocompromised mice (Yada et 
al. 2017). To analyse gene depletion, transplanted tumours are removed from the 
mice and the target gene knocked down before being re-transplanted into mice to 
see whether tumour growth is affected (Aktary et al. 2018). PDXs are proposed to 
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better model human disease. Morphological cellular and structural characteristics 
are well preserved in PDXs for numerous cancers (Ben-David et al. 2017, Yada et al. 
2017). PDXs also have greater heterogeneity, so are more representative of tumours 
than immortalised cell lines. In addition, when PDXs were used from a breast cancer 
patient, although poorly metastatic, those metastases observed were predominantly 
the same as those in the patient’s original cancer (Derose et al. 2011). 
 
A small number of lncRNAs have been studied using PDXs in mouse models. The 
therapeutic potential of targeting SAMMSON using LNA GapmeRs in combination 
with the BRAFV600E inhibitor dabrafenib was assessed in two PDX melanoma models. 
The work demonstrated the efficiency of combining treatments and that targeting 
lncRNAs can enhance response to current therapies (Leucci, Vendramin, et al. 2016). 
Using either xenograft model, it would be possible to explore DIRC3 participation in 
primary tumour growth, metastases, as well as possible responses to therapies. This 
would highlight the clinical importance of DIRC3 and is necessary for the design of 
DIRC3 targeting therapies for melanoma.  
 
An orthologous DIRC3 gene is present in mice in a syntenic location (Figure 3.4b). 
Consequently, it would be possible to knockout DIRC3 expression in the embryo to 
determine whether its locus directly contributes to a genetic susceptibility to 
melanoma by observing changes in the animals’ susceptibility to and development of 
cancer. Using such models mean that the effect of knockout on tumour growth can 
be explored without the need for the organism to be immunocompromised. 
Knockout mice have previously been used for the study of NEAT1 in skin cancer. 
Silencing the lncRNA impaired growth of skin tumours as preneoplastic cell became 
more sensitised to DNA-damage-induced cell death (Adriaens et al. 2016). 
 
By exploring DIRC3 in mouse models, using xenografts or knockouts, the role of DIRC3 
in development as well as disease can be investigated. If found to be functional in 
such models, DIRC3 would be more likely to play an important role in equivalent 
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human processes due to the genetic and physiological similarities between the two 
(Köhler et al. 2017).  
 
7.3.1 Exploring MITF-SOX10 regulated lncRNA as potential biomarkers and 
therapeutic targets 
 
7.3.1.1 LncRNAs as biomarkers in cancer 
 
LncRNA expression signatures have potential to be used as biomarkers which utilise 
changes in expression as an informative tool for a presence or progression of a 
cancer. Variations in expression of groups, or in some cases individual, genes may be 
used to define tumour progression, or provide an indication of the likelihood of 
disease lethality. LncRNAs are particularly promising candidates as biomarkers due 
to their specificity of expression across specific lineages and tumours, as well as 
tumour stage (Yan et al. 2015, Grimaldi et al. 2017). The proportion of lncRNAs with 
cancer type specific dysregulation has been found to be higher than that for protein 
coding genes (Yan et al. 2015). As well as identifying the presence of cancer, 
alterations to lncRNA expression have potential to help inform decisions on most 
suitable treatment options, likelihood of survival, and likelihood of recurrence. Also, 
with 3-5% of tumours being of unknown primary origin, lncRNA expression signatures 
could also be used to determine where they originated (Yan et al. 2015).  
 
The current method for diagnosing melanoma is assessment of morphology. 
However, lesions containing overlapping benign and malignant histopathological 
features can make such diagnosis difficult (Hu et al. 2014, Shain and Bastian 2016). 
Consequently, biomarkers suggestive of malignant behaviour would be useful for 
identifying patients with the metastatic form of the disease that may go unrecognised 
or prevent patients with benign cells undergoing unnecessary treatment. In addition, 
early-stage melanomas have limited starting material, making sub-sampling difficult. 
Instead, information based on morphology and histology of the tissue sample may be 
combined with detection of lncRNA localisation and expression levels using 
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fluorescent in situ hybridisation (FISH). These can then give a prediction of likelihood 
of tumour metastasis (Leucci, Coe, et al. 2016).  
 
Non-invasive methods can be used to profile lncRNA expression in cancers including 
metastatic melanoma. Free nucleic acids, including lncRNAs, are released from 
cancer cells and can be detected in body fluid, such as blood, urine, and sputum, 
allowing non-invasive assessment (Grimaldi et al. 2017, Thomas and Marcato 2018). 
LncRNA secondary structures can also make the transcripts relatively stable, allowing 
for easier detection (Yan et al. 2015). LncRNAs may be detected using techniques 
such as RT-qPCR, next generation sequencing, and microarrays (Bolha et al. 2017). 
This non-invasive use of biomarkers allows responses to therapies or patient progress 
to be regularly monitored. In one study, expression of HOTAIR in ovarian cancer 
patients following treatment using carboplatin, indicated likely poor survival, while 
those who were HOTAIR-negative tended to have better responses (Teschendorff et 
al. 2015). A key requirement for lncRNA biomarkers is that they are easily detected 
during early stages of the disease, as earlier detection significantly increases patient 
prognosis. One of the most well-known lncRNA biomarkers is PCA3 (prostate cancer 
antigen 3). PCA3 has already been approved for use as a diagnostic marker for 
prostate cancer through detection in urine samples (Groskopf et al. 2006). The 
lncRNA was found to outperform the prostate-specific antigen (PSA) blood test in 
sensitivity and specificity (Haese et al. 2008, Bolha et al. 2017). 
 
The identification of increased DIRC3 expression in melanoma patients with greater 
survival (Figure 3.10), and participation in regulating the metastatic activity of 
anchorage-independent growth (Figure 5.5), suggest that the level of DIRC3 could be 
used to predict likelihood of a patient survival, and possibly melanoma metastasis. 
However, the low expression of DIRC3 (Figure 3.2) mean it could be challenging to 
collect enough tissue to detect expression. However, the association of MITF-SOX10 
expression with melanoma cell proliferation and invasion, as well as resistance to 
drugs, (Konieczkowski et al. 2014, Sun et al. 2014, Verfaillie et al. 2015) mean lncRNAs 
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associated with the transcription factors could be used to generate a signature to 
predict likelihood of metastasis or survival. 
  
7.3.1.2 Detection of MITF-SOX10 associated lncRNAs, including DIRC3, in melanoma 
patient tumours 
 
Expression of DIRC3 and other MITF-SOX10-regulated lncRNAs in melanoma has been 
determined primarily using RNA-seq data from TCGA and data from immortalised 
melanocyte and melanoma cell lines. By using melanoma samples from patients with 
benign and metastatic forms of the disease it would be possible to identify levels of 
lncRNA expression at different stages of melanoma. For example, it may be the case 
that DIRC3 is initiated or repressed at certain stages or that patients prone to more 
aggressive forms of melanoma have reduced DIRC3 expression overall.  
 
Expression of DIRC3 and other lncRNAs could be measured using a NanoString 
nCounter which quantifies RNA using fluorescently tagged probes. Although 
expensive, such sensitive technology would be favoured over RT-qPCR due to the 
poor preservation of RNA in patient samples available which are typically 
formaldehyde fixed paraffin embedded (FFPE). The requirement of only a single cell 
and no reverse transcription of samples mean less material is needed. This is 
advantageous due to the typically small size of samples available, particularly for 
benign tumours (Geiss et al. 2008, Mohankumar and Patel 2016). FISH could also be 
used to determine the level of lncRNA expression in FFPE or fresh tissue samples. The 
heterogenous nature of tumour cells means FISH can be useful for detecting 
expression of a target gene in single cells or subpopulations of tumour cells (Hu et al. 
2014).  
 
Following transformation of melanocytes into benign naevi, cells undergo a number 
of events which eventually can lead to metastasis. Initially, cells rapidly proliferate 
and spread horizontally through the epidermis in a premalignant radial growth phase 
(RGP). As the tumour evolves, it may become metastatic following its transition to a 
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vertical growth phase (VGP). During VGP, an increase in ECM-degrading enzymes and 
reduced adhesion allow the tumour to start growing vertically into the dermis, 
eventually allowing cells to enter into the lymphatic and vascular systems so they 
may metastasise (Braeuer et al. 2011, Mobley et al. 2012). The melanoma-expressed 
lncRNA SAMMSON was easily detected in VGP samples while not in normal human 
melanocyte or RGP samples (Leucci, Vendramin, et al. 2016). This demonstrated 
induction of SAMMSON when melanoma cells transition between the growth phases. 
In the case of SLNCR, expression was found to be significantly higher in melanomas 
that were at least 1 mm thick. When in the VGP, tumours greater than 1 mm thick 
are more likely to metastasise due to increased likelihood of reaching blood vessels. 
Consequently, expression of SLNCR was also found to correlate with melanoma 
severity (Schmidt et al. 2016). Expression of DIRC3 and other MITF-SOX10-associated 
lncRNAs could also be measured to see whether they show any significant changes 
between RGP and VGP suggestive of tumour development.  
 
If DIRC3 or other MITF-SOX10-associated lncRNAs show consistent distinct changes 
between stages of melanoma progression, they could be promising biomarkers 
predictive of patient prognosis. Also, if sufficient quantities of the lncRNAs can be 
extracted from patients’ blood samples who have metastatic melanoma, monitoring 
the level of expression against response to therapies could indicate which treatments 
work most efficiently for patients based on higher or lower levels of the lncRNA 
detected.  
 
7.3.2 DIRC3 potential as a therapeutic target 
 
LncRNAs also offer another avenue for developing novel therapeutics for cancer 
treatment. While melanoma is highly treatable if identified in the very early stages, 
it is incredibly lethal when they metastasise. Current BRAFV600E inhibitors and immune 
checkpoint inhibitors are initially very effective for some patients with metastatic 
melanoma. However, a considerable proportion either do not respond or develop 
resistance to the therapy (Chapman et al. 2011, Villanueva et al. 2013). Due to the 
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rapid evolution of cancers caused by their genetic instability, single-agent therapies 
for advanced cancers rarely cure patients. Consequently, combination therapies are 
likely to be advantageous for targeting such diseases by blocking the development of 
drug resistance. 
 
Two methods currently being explored to target oncogenic lncRNAs are siRNAs and 
ASOs (Leucci, Coe, et al. 2016). ASOs against MALAT1 have been tested in nude mice 
intravenously injected with human lung cancer cells. They were able to both reduce 
tumour growth and metastases (Gutschner et al. 2013). In other cases, lncRNA-
targeting ASOs combined with current therapies have been explored. For example, 
knockdown of NEAT1 sensitised cancer cell lines to chemotherapy and p53 
reactivation therapy (Adriaens et al. 2016). ASOs targeting SAMMSON have also been 
shown to improve the effectiveness of the BRAF-inhibitor dabrafenib in mice. While 
use of dabrafenib alone inhibited tumour growth, when combined with SAMMSON 
depletion, both tumour repression and increased apoptosis were observed. The 
group also identified no adverse effects to the mice undergoing the combination 
therapy (Leucci, Vendramin, et al. 2016).  
 
Another avenue is to exploit the precise expression of lncRNAs to selectively deliver 
drugs to the cancers and limit off-target effects. The vector DTA-H19 plasmid carrying 
the gene for the alpha subunit of diphtheria toxin which was regulated by the H19 
promoter was successfully used in mice with bladder cancer. The vector was only 
activated in cells containing the lncRNA H19 and protein-coding gene IGF2-P4 (Amit 
and Hochberg 2013).  
 
The development of therapeutic strategies targeting tumour suppressor genes has 
had less focus. However, restoration of tumour suppressor gene function has been 
explored for a number of protein-coding genes by re-introducing their expression 
using viral and non-viral vectors (Atkinson and Chalmers 2010). While methods are 
being explored, there is still limited data on their use for lncRNAs. However, in the 
case of GAS5, LNAs that mimic the lncRNA’s hormone response element mimic 
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(HREM) binding sequence to its target hormone receptors have been found to be 
capable of restoring cancer cell apoptosis when GAS5 expression is depleted (Pickard 
and Williams 2016). Such induction of tumour suppressive function could have future 
therapeutic potential. Accordingly, by reactivating expression of DIRC3, or mimicking 




The majority of previous cancer research has focused on protein-coding genes and 
their involvement in cancer development and progression. In the case of melanoma, 
the function of protein-coding genes within key MITF-SOX10 transcription networks 
is also well defined. This study reveals that lncRNAs play an important role in 
regulation of MITF-SOX10 transcriptional responses. These new insights into the roles 
of lncRNAs in melanoma stimulate ideas for new biomarkers and therapeutics  
 
DIRC3 represents a promising regulator of melanoma progression. DIRC3 is a tumour 
suppressive intergenic lncRNA able to inhibit anchorage-independent growth likely 
through regulation of IGFBP5 expression in a transcript-dependent manner. DIRC3 
also demonstrates the capability of a lncRNA target of MITF and SOX10 to act as a 
feedback regulator or regulate the activities of these two key melanoma transcription 
factors, rather than being purely a downstream mediator of their activity. 
 
While development of therapeutics is an exciting prospect for new candidate 
lncRNAs, more detailed studies on the mechanism of action of DIRC3 and its 
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Figure 8.1 Circular map of pxdCas9Krab plasmid. The vector contains both the sgRNA and 
dCas9-KRAB fusion. The plasmid is driven by a CBh promoter. Increased binding to a dCas9 is 
allowed following small modifications to the sgRNA backbone. Presence of ampicillin and 
puromycin resistance allow for selection following transformation and transfection 
respectively. The px5gRNAsCas9Puro vector has the same structure and features but lacks 
the KRAB protein. 
 
